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A B S T R A C T
Background
Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for people with worsening symptoms of chronic
obstructive pulmonary disease (COPD) and repeated exacerbations. They are commonly used as combination inhalers with long-acting
beta2-agonists (LABA) to reduce exacerbation rates and all-cause mortality, and to improve lung function and quality of life. The most
common combinations of ICS and LABA used in combination inhalers are fluticasone and salmeterol, budesonide and formoterol
and a new formulation of fluticasone in combination with vilanterol, which is now available. ICS have been associated with increased
risk of pneumonia, but the magnitude of risk and how this compares with different ICS remain unclear. Recent reviews conducted to
address their safety have not compared the relative safety of these two drugs when used alone or in combination with LABA.
Objectives
To assess the risk of pneumonia associated with the use of fluticasone and budesonide for COPD.
Search methods
We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), clinicaltrials.gov, reference lists of existing
systematic reviews and manufacturer websites. The most recent searches were conducted in September 2013.
Selection criteria
We included parallel-group randomised controlled trials (RCTs) of at least 12 weeks’ duration. Studies were included if they compared
the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy
for people with COPD.
Data collection and analysis
Two review authors independently extracted study characteristics, numerical data and risk of bias information for each included study.
We looked at direct comparisons of ICS versus placebo separately from comparisons of ICS/LABA versus LABA for all outcomes,
and we combined these with subgroups when no important heterogeneity was noted. After assessing for transitivity, we conducted
an indirect comparison to compare budesonide versus fluticasone monotherapy, but we could not do the same for the combination
therapies because of systematic differences between the budesonide and fluticasone combination data sets.
When appropriate, we explored the effects of ICS dose, duration of ICS therapy and baseline severity on the primary outcome. Findings
of all outcomes are presented in ’Summary of findings’ tables using GRADEPro.
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Main results
We found 43 studies that met the inclusion criteria, and more evidence was provided for fluticasone (26 studies; n = 21,247) than for
budesonide (17 studies; n = 10,150). Evidence from the budesonide studies was more inconsistent and less precise, and the studies
were shorter. The populations within studies were more often male with a mean age of around 63, mean pack-years smoked over 40
and mean predicted forced expiratory volume of one second (FEV1) less than 50%.
High or uneven dropout was considered a high risk of bias in almost 40% of the trials, but conclusions for the primary outcome did
not change when the trials at high risk of bias were removed in a sensitivity analysis.
Fluticasone increased non-fatal serious adverse pneumonia events (requiring hospital admission) (odds ratio (OR) 1.78, 95% confidence
interval (CI) 1.50 to 2.12; 18 more per 1000 treated over 18 months; high quality), and no evidence suggested that this outcome
was reduced by delivering it in combination with salmeterol or vilanterol (subgroup differences: I2 = 0%, P value 0.51), or that
different doses, trial duration or baseline severity significantly affected the estimate. Budesonide also increased non-fatal serious adverse
pneumonia events compared with placebo, but the effect was less precise and was based on shorter trials (OR 1.62, 95% CI 1.00 to
2.62; six more per 1000 treated over nine months; moderate quality). Some of the variation in the budesonide data could be explained
by a significant difference between the two commonly used doses: 640 mcg was associated with a larger effect than 320 mcg relative to
placebo (subgroup differences: I2 = 74%, P value 0.05).
An indirect comparison of budesonide versus fluticasone monotherapy revealed no significant differences with respect to serious adverse
events (pneumonia-related or all-cause) or mortality. The risk of any pneumonia event (i.e. less serious cases treated in the community)
was higher with fluticasone than with budesonide (OR 1.86, 95% CI 1.04 to 3.34); this was the only significant difference reported
between the two drugs. However, this finding should be interpreted with caution because of possible differences in the assignment of
pneumonia diagnosis, and because no trials directly compared the two drugs.
No significant difference in overall mortality rates was observed between either of the inhaled steroids and the control interventions
(both high-quality evidence), and pneumonia-related deaths were too rare to permit conclusions to be drawn.
Authors’ conclusions
Budesonide and fluticasone, delivered alone or in combination with a LABA, are associated with increased risk of serious adverse
pneumonia events, but neither significantly affected mortality compared with controls. The safety concerns highlighted in this review
should be balanced with recent cohort data and established randomised evidence of efficacy regarding exacerbations and quality of life.
Comparison of the two drugs revealed no statistically significant difference in serious pneumonias, mortality or serious adverse events.
Fluticasone was associated with higher risk of any pneumonia when compared with budesonide (i.e. less serious cases dealt with in the
community), but variation in the definitions used by the respective manufacturers is a potential confounding factor in their comparison.
Primary research should accurately measure pneumonia outcomes and should clarify both the definition and the method of diagnosis
used, especially for new formulations and combinations for which little evidence of the associated pneumonia risk is currently available.
Similarly, systematic reviews and cohorts should address the reliability of assigning ’pneumonia’ as an adverse event or cause of death
and should determine how this affects the applicability of findings.
P L A I N L A N G U A G E S U M M A R Y
Do inhaled steroids increase the risk of pneumonia in people with chronic obstructive pulmonary disease (COPD)?
Why is this question important?
Inhaled corticosteroids (ICS) are drugs that can reduce the occurrence of COPD flare-ups and improve quality of life. In COPD, ICS
are commonly used alongside long-acting beta2-agonists (LABA). The most common combinations of ICS and LABA inhalers are
fluticasone and salmeterol, and budesonide and formoterol, but fluticasone furoate is also used once daily with a new LABA called
vilanterol. Lots of studies have shown benefits of ICS, but they can also increase the risk of pneumonia. Added to this concern,
pneumonia can be difficult to diagnose, and the severity of pneumonia can be poorly reported in trials. Therefore even though we
have reviews on inhaled steroids for COPD, we wanted to do a review exclusively on pneumonia, so we could take a closer look at the
evidence.
The overall aim of this review is to assess the risk of pneumonia for people with COPD taking fluticasone or budesonide.
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How did we answer the question?
We looked for all studies comparing budesonide or fluticasone versus a dummy inhaler (placebo), and all studies comparing their use
in combination with a LABA (i.e. budesonide/formoterol, fluticasone propionate/salmeterol, and fluticasone furoate/vilanterol) versus
the same dose of LABA alone. This allowed us to assess the risk of ICS used alone or in combination with LABA.
What did we find?
We found 43 studies including more than 30,000 people with COPD. More studies used fluticasone (26 studies; 21,247 people) than
budesonide (17 studies; 10,150 people). A higher proportion of people in the studies were male (around 70%), and their COPD was
generally classed as severe. The last search for studies to include in the review was done in September 2013.
We compared each drug against controls and assessed separately the results of studies that compared ICS versus placebo, and an ICS/
LABA combination versus LABA alone. We also conducted an indirect comparison of budesonide and fluticasone based on their effects
against placebo, to explore whether one drug was safer than the other.
Fluticasone increased ’serious’ pneumonias (requiring hospital admission). Over 18 months, 18 more people of every 1000 treated with
fluticasone were admitted to hospital for pneumonia.
Budesonide also increased pneumonias that were classed as ’serious’. Over nine months, six more hospital admissions were reported for
every 1000 individuals treated with budesonide. A lower dose of budesonide (320 mcg) was associated with fewer serious pneumonias
than a higher dose (640 mcg).
No more deaths overall were reported in the ICS groups compared with controls, and deaths related to pneumonia were too rare to tell
either way.
When we compared fluticasone and budesonide versus each other, the difference between them was not clear enough to tell whether
one was safer (for pneumonia, requiring a hospital stay, general adverse events and death). The risk of any pneumonia event (i.e. less
serious cases that could be treated without going to hospital) was higher with fluticasone than with budesonide.
Evidence was rated to be of high or moderate quality for most outcomes. When an outcome is rated of high quality, further research is
very unlikely to change our confidence in the estimate of effect, but moderate ratings reflect some uncertainty in the findings. Results
from the budesonide studies were generally less clear because they were based on fewer people, and the studies were shorter.
Conclusion
Budesonide and fluticasone, delivered alone or in combinationwith LABA, can increase serious pneumonias that result in hospitalisation
of people. Neither has been shown to affect the chance of dying compared with not taking ICS. Comparison of the two drugs revealed
no difference in serious pneumonias or risk of death. Fluticasone was associated with a higher risk of any pneumonia (i.e. cases that could
be treated in the community) than budesonide, but potential differences in the definition used by the respective drug manufacturers
reduced our confidence in this finding. These concerns need to be balanced with the known benefits of ICS (e.g. fewer exacerbations,
improved lung function and quality of life).
Researchers should remain aware of the risks associated with ICS and should make sure that pneumonia is properly diagnosed in studies.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fluticasone for chronic obstructive pulmonary disease
Patient or population: patients with chronic obstructive pulmonary disease
Intervention: fluticasone (alone or with LABA co-intervention)
Comparison: placebo or LABA monotherapy (dependent upon whether fluticasone was given with LABA in the intervention group)
Setting: community
Outcomes
Follow-ups presented as
weighted means
Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Fluticasone
Non-fatal, serious adverse
pneumonia events (requiring
hospital admission)
Follow-up: 18 months
25 per 1000 43 per 1000
(37 to 51)
OR 1.78
(1.50 to 2.12)
19,504
(17 studies)
⊕⊕⊕⊕
high
Mortality, all-cause
Follow-up: 19 months
58 per 1000 58 per 1000
(51 to 65)
OR 0.99
(0.87 to 1.13)
20,861
(22 studies)
⊕⊕⊕⊕
high
Mortality, due to pneumonia
Follow-up: 18 months
2 per 1000 3 per 1000
(2 to 5)
OR 1.23
(0.70 to 2.15)
19,532
(18 studies)
⊕⊕⊕©
moderate1
Non-fatal, serious adverse
events (all)
Follow-up: 19 months
227 per 1000 237 per 1000
(225 to 251)
OR 1.06
(0.99 to 1.14)
20,381
(19 studies)
⊕⊕⊕⊕
high
All pneumonia events
Follow-up: 22 months
72 per 1000 116 per 1000
(104 to 129)
OR 1.68
(1.49 to 1.90)
15,377
(11 studies)
⊕⊕⊕©
moderate2
Withdrawals
Follow-up: 18 months
343 per 1000 297 per 1000
(286 to 310)
OR 0.81
(0.77 to 0.86)
21,243
(26 studies)
⊕⊕⊕⊕
high
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
Unless otherwise stated, subgroup differences between monotherapy studies (fluticasone versus placebo) and combination therapy studies (fluticasone/LABA versus LABA) were not
significant
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Wide confidence intervals include significant benefit and harm, based on very few events (-1 for imprecision).
2More than half the studies did not report the outcome (-1 for publication bias).
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B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a respiratory
disease characterised by chronic and progressive breathlessness,
cough, sputum production and airflow obstruction, which leads
to restricted activity and poor quality of life (GOLD 2013). The
World Health Organization (WHO 2012) has estimated that
COPD is the fourth or fifth most common single cause of death
worldwide, and that the treatment and management costs present
a significant burden to public health. In the UK the annual cost
of COPD to the National Health Service (NHS) is estimated to
be GBP 1.3 million per 100,000 people (NICE 2011). Further-
more, because of its slow onset and under-recognition of the dis-
ease by patients and healthcare professionals, COPD is heavily
under diagnosed (GOLD 2013). COPD comprises a combina-
tion of bronchitis and emphysema and involves chronic inflam-
mation and structural changes in the lung. Cigarette smoking is
the most important risk factor, but air pollution and occupational
dust and chemicals are also recognised risk factors. COPD is a
progressive disease that leads to decreased lung function over time,
even with the best available care. Currently no cure is known for
COPD, although the condition is both preventable and treatable.
As yet, apart from smoking cessation and non-pharmacological
treatments such as long-term oxygen therapy in hypoxic patients
and pulmonary rehabilitation, no intervention has been shown to
reduce mortality (GOLD 2013; Puhan 2011). Management of
the disease is multi-faceted and includes interventions for smok-
ing cessation (Van der Meer 2001), pharmacological treatments
(GOLD 2013), education (Effing 2007) and pulmonary rehabil-
itation (Lacasse 2006; Puhan 2011). Pharmacological therapy is
aimed at relieving symptoms, improving exercise tolerance and
quality of life, improving lung function and preventing and treat-
ing exacerbations.
Description of the intervention
Pharmacological management for COPD is generally a stepwise
process, commencing with therapy for symptoms, which is fol-
lowed by introduction of additional therapeutic agents as needed
to achieve control and to reduce the frequency and severity of ex-
acerbations (GOLD 2013). Often the first step is to use a short-
acting bronchodilator for control of breathlessness when needed: a
short-acting beta2-agonist (SABA) (e.g. salbutamol) or the short-
acting muscarinic antagonist (SAMA) ipratropium. For persistent
or worsening breathlessness associated with lung function decline,
long-acting bronchodilators may be introduced (GOLD 2013).
These comprise twice-daily long-acting beta2-agonists (LABA),
such as salmeterol or formoterol; once-daily beta2-agonists, such as
indacaterol; and the long-acting anticholinergic agent tiotropium.
For patients with severe or very severe COPD (forced expiratory
volume in one second (FEV1) < 50% predicted) and with repeated
exacerbations, the Global initiative for chronic Obstructive Lung
Disease (GOLD 2013) recommends the addition of inhaled cor-
ticosteroids (ICS) to bronchodilator treatment. ICS are anti-in-
flammatory drugs that are licensed as combination inhalers for use
with LABA. The most common ICS and LABA components in
combination inhalers are fluticasone propionate and salmeterol,
budesonide and formoterol and a new formulation of fluticasone
furoate in combination with vilanterol, which is now available for
once-daily use. Patients with severe COPD may also be treated
with the phosphodiesterase 4 (PDE4) inhibitor roflumilast, which
may reduce the risk of exacerbations (GOLD).
How the intervention might work
ICS are anti-inflammatory drugs. They reduce the rate of exacer-
bation and improve quality of life, but they have not been found
to have an effect on overall mortality or on the long-term de-
cline in FEV1 (Agarwal 2010; GOLD 2013; Yang 2009). ICS
and LABA combination inhalers reduce exacerbation rates and
all-cause mortality and improve lung function and quality of life
(Nannini 2013). These effects are thought to be greater for com-
bination inhalers than for the component preparations (GOLD
2013; Nannini 2013). ICS, alone or in combination with LABA,
however, have been associated with increased risk of pneumonia
(GOLD 2013; Singh 2009). Several mechanisms have been pro-
posed by which ICS could increase the risk of pneumonia; these
mechanisms are principally related to the immunosuppressive ef-
fects of ICS and include ICS reaching the lung in high concen-
trations. Particularly, inhibition of nuclear factor kappa B (NF-
κB) by ICS in COPD, one of the proposed mechanisms for their
therapeutic effect, could lead to the suppression of normal host
responses to bacterial infection (Singanayagam 2010).
Why it is important to do this review
Use of ICS for treatment of COPD may be beneficial, at least
for some COPD patients. But the role of ICS therapy in patients
with stable COPD is controversial, especially as an elevated risk
of pneumonia has been found in studies of ICS use. Pneumonia
in COPD is associated with high morbidity and mortality (Ernst
2007) and worsening quality of life and pulmonary function, so
it is important to understand the strength and nature of the asso-
ciation between ICS use and this adverse event.
Several systematic reviews published in the last few years have
looked at the risk of pneumonia with ICS use (Drummond 2008;
Halpin 2011; Sin 2009; Singh 2009). Of these, only one com-
pared different ICS versus each other and as combination inhaler
therapy together with a LABA (Halpin 2011). Although ICS are
usually administered in a combination inhaler in clinical practice,
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we are interested in the most comprehensive evidence on the risk
of pneumonia with ICS. Differences in themolecular structures of
ICS formulations are known to alter their relative potency ratios
and durations of action (Johnson 1998; Rossios 2011), but poten-
tial differences between formulations in the magnitude of pneu-
monia risk remains unclear. It is also uncertain whether the associ-
ationwith pneumonia is altered by LABA in combination inhalers.
We therefore included studies that examined ICS treatment both
alone and in combination with a LABA. We focused on the risk
of pneumonia with the two most frequently prescribed ICS-fluti-
casone and budesonide-compared with control, and on the differ-
ence in risk of pneumonia between these ICS. When there was a
paucity of head-to-head trials directly comparing fluticasone and
budesonide, we planned to complement the direct comparisons
with an adjusted indirect comparison of budesonide and flutica-
sone using placebo as a common comparator (Figure 1). Indirect
comparisons are considered valid if ’clinical and methodological
homogeneity’ is present between the budesonide and fluticasone
studies (Cipriani 2013). The indirect comparison of budesonide
and fluticasone when taken in a combination inhaler with differ-
ent LABA assumes that the LABA salmeterol, formoterol and vi-
lanterol do not have an important effect on the risk of pneumonia.
Figure 1. Direct and indirect comparisons of fluticasone and budesonide covered in the review.
O B J E C T I V E S
To assess the risk of pneumonia associated with the use of flutica-
sone and budesonide for COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with a paral-
lel-group design of at least 12 weeks’ duration. We did not ex-
clude studies on the basis of blinding. Cross-over trials were not
included, as ICS can have long-acting effects, and because the pri-
mary outcome is an adverse event.
Types of participants
We included RCTs that recruited participants with a diagnosis
of COPD (e.g. based on criteria recommended by the American
Thoracic Society and the European Respiratory Society) (ATS/
ERS 2004).
1. Forced expiratory volume after one second (FEV1)/forced
vital capacity (FVC) ratio < 0.7, which confirms the presence of
persistent airflow limitation.
2. One or more of the following key indicators.
i) Progressive and/or persistent dyspnoea.
ii) Chronic cough.
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iii) Chronic sputum production.
iv) History of exposure to risk factors (tobacco smoke,
smoke from home cooking and heating fuels, occupational dusts
and chemicals).
Types of interventions
We included studies that performed any of the following compar-
isons.
1. Fluticasone versus placebo.
2. Budesonide versus placebo.
3. Fluticasone/salmeterol versus salmeterol.
4. Fluticasone/vilanterol versus vilanterol.
5. Budesonide/formoterol versus formoterol.
6. Fluticasone versus budesonide.
7. Fluticasone/salmeterol versus budesonide/formoterol.
8. Fluticasone/vilanterol versus budesonide/formoterol.
We allowed ICS/LABA combination treatment in a single inhaler
and in separate inhalers. Participants were allowed to take other
concomitant COPD medications as prescribed by their health-
care practitioner provided they were not part of the trial treat-
ment under study. For example, we excluded studies that com-
pared triple therapy of budesonide/formoterol combination in-
haler plus tiotropium versus formoterol plus tiotropium.
Types of outcome measures
We were interested in events of pneumonia. Pneumonia is usually
defined as an acute lower respiratory tract infection that generally
includes symptoms and signs from the respiratory tract and noted
in the general health of the patient, but the specific definition/
diagnosis varies. We recorded the basis of diagnosis, specifically,
radiological confirmation, and planned to conduct a subgroup
analysis. One example of the definition of diagnostic criteria for
pneumonia is found in BTS 2009.
1. Symptoms of an acute lower respiratory tract illness (cough
and at least one other lower respiratory tract symptom).
2. New focal chest signs on examination.
3. At least one systemic feature (either a symptom complex of
sweating, fevers, shivers, aches and pains and/or temperature of
38°C or higher).
4. No other explanation for the illness.
We primarily looked at pneumonia events leading to hospital ad-
missions (i.e. serious adverse pneumonia events), which usually are
better documented and diagnosed by imaging studies and labora-
tory investigations than pneumonia events of any severity, and are
associated with substantial morbidity and mortality. One example
of the definition of diagnostic criteria for pneumonia in hospital
is found in BTS 2009.
1. Symptoms and signs consistent with an acute lower
respiratory tract infection associated with new radiographic
shadowing for which no other explanation is known (e.g. not
pulmonary oedema or infarction).
2. The illness is the primary reason for hospital admission and
is managed as pneumonia.
We used end of study as the time of analysis for all studies, which
ranged from three to 36 months in duration.
Primary outcomes
1. Non-fatal, serious adverse pneumonia events (requiring
hospital admission).
We chose serious adverse pneumonia events as the primary out-
come because of the increased burden these events have on the
individual and on healthcare systems.
Secondary outcomes
1. Mortality: all-cause and due to pneumonia.
2. Non-fatal serious adverse events: all-cause.
3. All pneumonia events.
4. Withdrawals.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Specialised
Register of trials (CAGR), which is maintained by the Trials
Search Co-ordinator for the Group. The Register contains trial
reports identified by systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and
PsycINFO, and conference abstracts found through handsearch-
ing (see Appendix 1 for further details). We searched all records in
the CAGR coded ’COPD’ using the following terms.
((steroid* or corticosteroid*) and inhal*) or ICS or budesonide
or fluticasone or pulmicort or flovent or flixotide or symbicort or
viani or seretide or advair.
We also searched ClinicalTrials.gov using search terms provided
in Appendix 2. We searched all databases with no restriction on
date or language of publication up to September 2013.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references.We searched the manufacturers’ websites
(AstraZeneca and GlaxoSmithKline) for additional information
on studies identified through the electronic searches.
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Data collection and analysis
Selection of studies
Two review authors (AS and CK) independently screened the titles
and abstracts of citations retrieved through literature searches and
obtained those deemed to be potentially relevant. We assigned
all references to a study identifier and assessed them against the
inclusion criteria of this protocol. We resolved disagreements by
consensus. Subsequent search updates were screened by AS and
KMK.
Data extraction and management
Two review authors (KMKandASorCK) independently extracted
information from each included study (recording the data source)
for the following characteristics.
1. Design (study design, total duration of study, number of
study centres and locations).
2. Participants (number randomly assigned to each treatment,
mean age, gender, baseline lung function, smoking history,
inclusion criteria, exclusion criteria).
3. Interventions (run-in, intervention and control treatment
including concentration and formulation).
4. Outcomes (definitions of pneumonia events and data on
the numbers of participants with one or more events with onset
during the treatment period).
We resolved discrepancies in the data by discussion, or by consul-
tation with a third party when necessary.
Assessment of risk of bias in included studies
We assessed the risk of bias according to recommendations out-
lined in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011) for the following items.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
We graded each potential source of bias as high, low or unclear ac-
cording to recommendations outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
Measures of treatment effect
Direct comparisons (fluticasone vs placebo; budesonide vs
placebo; fluticasone/LABA vs LABA; budesonide/LABA vs
LABA)
We analysed direct pair-wise comparisons using Mantel-Haenszel
odds ratios (ORs) with 95% confidence intervals (CIs). When
events were rare, we employed the Peto odds ratio. When count
data were available as rate ratios, we transformed them into log rate
ratios and analysed themusing generic inverse variance (GIV). For
the primary outcome, the number needed to treat for an additional
harmful outcome was calculated from the pooled odds ratio and
its confidence interval and was applied to appropriate levels of
baseline risk.
Indirect comparisons (monotherapy: fluticasone vs
budesonide; combination therapy: fluticasone/LABA vs
budesonide/LABA)
We also conducted indirect comparisons of fluticasone and budes-
onide treatments using odds ratios with a 95% CI (Bucher 1997).
When available, we planned to combine the indirect evidence with
randomly assigned head-to-head comparisons of fluticasone and
budesonide.
Assessing transitivity and similarity
To permit valid indirect comparisons of fluticasone and budes-
onide, the sets of trials for each drugmust be similar in their distri-
bution of effect modifiers (Cipriani 2013). Before conducting in-
direct comparisons, we constructed summary tables formonother-
apy and combination therapy separately to compare the following
characteristics between budesonide and fluticasone trials.
1. Inclusion and exclusion criteria (including allowed co-
medications).
2. Baseline characteristics (smoking history, % predicted
FEV1, age, percentage male).
3. Intervention characteristics (dose distribution, inhaler
device).
4. Methodology (risk of bias, study duration, sample size,
funding).
5. Control group event rates.
Unit of analysis issues
The unit of analysis was the individual participant for dichoto-
mous outcomes, but events were used to compare rates of exacer-
bation.
Dealing with missing data
When pneumonia data or key study characteristics were not re-
ported in the primary publication, we searched clinical trial reports
and contacted study authors and sponsors for additional informa-
tion. We used intention-to-treat (ITT) analysis on outcomes of all
randomly assigned participants when possible. We considered the
impact of the unknown status of participants who withdrew from
the trials as part of the sensitivity analysis.
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Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by record-
ing differences in study design, participant characteristics, study
sponsorship and pneumonia definition between individual stud-
ies. We assessed the extent of statistical variation among study re-
sults by using the I2 measurement. We tested for inconsistency
between direct and indirect data by calculating the log ratio of
direct and indirect odds ratios (ROR) (Song 2008).
Assessment of reporting biases
We tried tominimise reporting bias fromnon-publication of stud-
ies or selective outcome reporting by using a broad search strategy,
checking references of included studies and relevant systematic re-
views and contacting study authors for additional outcome data.
We visually inspected funnel plots when 10 or more studies were
included.
Data synthesis
We looked at direct comparisons of ICS versus placebo separately
from comparisons of ICS/LABA versus LABA for all outcomes
(Figure 1). When no important discrepancy was noted between
the analyses with and without LABA, we combined the results.
When a study comparing ICS/LABA versus LABA included arms
for both a single inhaler (ICS/LABA) and separate inhalers (ICS +
LABA), we split the control group (LABA) in half to avoid double-
counting.
The decision whether to perform indirect comparisons of studies
was based on our assessment of their clinical and methodological
differences.
If both direct and indirect comparison data were available, we
planned to combine the estimates using a fixed-effect model, but
when statistical heterogeneity was evident (I2 > 30%), we used a
random-effects model to analyse the data and explore the hetero-
geneity (see below). When no important discrepancy was noted
between direct and indirect estimates, we combined the resulting
odds ratio and 95% CI from the indirect comparison with any di-
rect pair-wise data for the same comparison using inverse variance
weighting (Glenny 2005).
Wepresented the findings of all outcomes in ’Summary of findings’
tables using GRADEPro software and recommendations provided
in the Cochrane Handbook for Systematic Reviews of Interventions.
Subgroup analysis and investigation of heterogeneity
When appropriate, we explored heterogeneity between studies by
analysing data for the primary outcome by looking at the following
subgroups.
1. ICS dose (separate subgroups for each of the following
drugs and doses: fluticasone 500 and 1000 mcg; budesonide
320, 640 and 1280 mcg).
2. Duration of ICS therapy (≤ one year; > one year).
3. Diagnostic criteria of pneumonia.
4. Disease severity at baseline (FEV1 < 50% predicted; FEV1
≥ 50% predicted).
Sensitivity analysis
We assessed the robustness of our analyses by performing sensitiv-
ity analyses, while systematically excluding studies from the overall
analysis:
1. of high risk of bias; or
2. with high and or uneven withdrawal rates.
R E S U L T S
Description of studies
Results of the search
Two thousand forty-seven citations were identified by searching
electronic databases. Twenty-seven additional citationswere found
by searching reference lists, clinicaltrials.gov and drug company
websites. Forty-two duplicates were removed, and the remaining
2032 titles and abstracts were sifted. Two review authors excluded
1806 references that did not meet the inclusion criteria. Full texts
were obtained and scrutinised for the final 226 references, and 195
(representing 43 studies) met all of the inclusion criteria. Figure
2 shows this information as a flow diagram and gives reasons for
exclusion of the 31 references that were excluded after the full text
was reviewed.
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Figure 2. Study flow diagram.
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Included studies
Forty-three studies met all of the inclusion criteria and were in-
cluded in the review: 26 using fluticasone and 17 using budesonide
as the inhaled steroid. The fluticasone studies included more than
twice as many people, with 21,247 people randomly assigned to
the treatments of interest compared with 10,067 in the budes-
onide studies. Two of the included budesonide studies reported
no data that could be used in the analyses and are not included in
these numbers (Laptseva 2002; Senderovitz 1999).
No studies directly comparingfluticasonewith budesonidemet the
inclusion criteria (either as monotherapy or in their combination
preparations), so only indirect evidence was available for these
comparisons.
Design and duration
All studies were randomised, double-blind, parallel-group trials of
at least 12 weeks’ duration. Most were funded by pharmaceuti-
cal companies, predominantly GlaxoSmithKline for the fluticas-
one studies and AstraZeneca for the budesonide studies. Duration
ranged from three to 36 months for both drugs, but mean dura-
tion weighted by sample size was longer for the fluticasone studies
(fluticasone, 18 months; budesonide, 14 months). A summary of
each study and baseline characteristics can be found in Table 1
and Table 2.
Participant inclusion and exclusion criteria
Full details of the inclusion and exclusion criteria for each trial
can be found in Characteristics of included studies. Inclusion and
exclusion criteria were largely similar across trials, with the excep-
tion of which medications participants were allowed to continue
taking during the study period. In most studies, participants were
required to be over the age of 40 and to have a smoking history
of at least 10 pack-years. In terms of lung function, most stud-
ies required values consistent with a GOLD diagnosis of COPD.
Studies excluded participants if they had asthma or any other res-
piratory disorder. Other common exclusion criteria included re-
cent lower respiratory tract infection, the need for long-term or
nocturnal oxygen therapy and recent use of antibiotics or oral cor-
ticosteroids (usually within four to six weeks of screening).
Baseline characteristics of participants
Baseline data are given for individual trial arms in Characteristics
of included studies tables and are summarised across fluticasone
and budesonide studies in Table 1 and Table 2, respectively. All of
the trials recruited more men than women, with a mean of around
70% and 75% in the fluticasone and budesonide studies, respec-
tively (range 52% to 100%). Mean age within the trials ranged
from 47 to 67 years, and the overall mean was similar in the flu-
ticasone and budesonide studies (~63 years). Smoking history as
measured by overall pack-years (one pack-year = one pack of 20
cigarettes per day for one year) was reported in three-quarters of
the studies, and the mean was higher in the fluticasone combina-
tion therapy studies (53 pack-years) than in the other sets of trials;
all were between 41 and 43 pack-years overall. The range across all
trials was 27 to 63 pack-years. Percentage predicted FEV1, an indi-
cator of disease severity, was reported in most trials. Overall means
for fluticasone and budesonide were very similar (47% and 48%,
respectively). One outlier in the fluticasone monotherapy studies
recruited a much less severe population (those showing early signs
and symptoms of COPD; van Grunsven 2003), with nine mean
pack-years and percentage predicted FEV1 of 97. Two budesonide
monotherapy studies also recruited less severe populations, with
percentage predicted FEV1 of 77 and 87 (Pauwels 1999; Vestbo
1999). None of these three studies reported the primary outcome.
Characteristics of the interventions
Of the 26 fluticasone studies, 18 compared fluticasone monother-
apy versus placebo, and 15 compared fluticasone/LABA combi-
nation versus LABA monotherapy (12 using salmeterol and three
using the new LABA, vilanterol). Seven trials used multi-arm dou-
ble-dummy designs that performed both comparisons of inter-
est (Calverley 2003 TRISTAN; Calverley 2007 TORCH; GSK
SCO104925 2008; Hanania 2003; Mahler 2002), including two
newly published trials using vilanterol and fluticasone furoate
(Kerwin 2013; Martinez 2013). Fifteen fluticasone studies used
fluticasone propionate at a total daily dose of 1000 mcg, and seven
used 500mcg.One further study,GSK FLTA3025 2005, included
both doses. The three vilanterol studies used fluticasone furoate at
total daily doses of 50, 100 and 200mcg, and 25mcg of vilanterol.
Of the 17 budesonide studies, 13 compared budesonide
monotherapy versus placebo, and seven compared budesonide/
formoterol combination versus formoterol monotherapy. Three
studies had four or more arms and performed both compar-
isons of interest (Calverley 2003b; Szafranski 2003; Tashkin 2008
SHINE). Twelve studies used a total daily budesonide dose of 640
mcg, and two studies used a daily dose of 1280 mcg (Renkema
1996; Yildiz 2004). Three studies used more than one dose
(Rennard 2009; Sharafkhaneh 2012), including one that had a
total of six arms (Tashkin 2008 SHINE): three combination arms,
budesonide 640 mcg, formoterol 18 mcg and placebo. Formoterol
as monotherapy control or in combination with budesonide was
given at a total daily dose of 18 mcg in all studies.
Table 3 presents the beclomethasone dipropionate (BDP) equiv-
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alent doses for the included treatments. As shown, higher-dose
budesonide (1280mcg/d = 1280BDP) ismore similar to the lower
dose of fluticasone (500 mcg/d = 1000 BDP). Fluticasone furoate
doses of 100 mcg and 200 mcg daily are equivalent to fluticasone
propionate 250 mcg twice daily (1000 BDP) and 500 mcg twice
daily (2000 BDP) respectively, and the lowest dose of fluticasone
furoate is equivalent to 500 BDP. Only the 100 mcg dose of flu-
ticasone furoate is currently licensed for use in COPD
In most studies, participants were allowed short-acting bron-
chodilators and treatment for acute exacerbations. Most studies
also allowed people to continue on some long-acting treatments
that were not the treatments under study (usually theophylline,
mucolytics, anticholinergics). Run-in periods varied somewhat in
length and nature. Most ranged from two to eight weeks; some re-
quired all bronchodilator treatment, ICS alone or ICS and LABA
treatment to be tapered off; others used placebo and oral corticos-
teroids; and a subset did not describe the procedures used.
Transitivity and similarity
1. Inclusion and exclusion criteria: Inclusion and exclusion
criteria, as described above, were considered comparable between
the two sets of trials; although variation was noted in the allowed
co-medications between individual trials, this was not
systematically different between the fluticasone and budesonide
studies.
2. Baseline characteristics: Although variation between trials
was seen, we did not consider that baseline characteristics
systematically differed between budesonide monotherapy and
fluticasone monotherapy trials, or between budesonide
combination therapy and fluticasone combination therapy trials
(see above and Table 1; Table 2).
3. Intervention characteristics: Budesonide and fluticasone
studies most often used the respective commonly used twice-
daily dose, although the once-daily fluticasone furoate studies
introduced a potential source of heterogeneity. More important,
the fluticasone studies generally used the Diskus or Accuhaler,
and the budesonide studies used the Turbuhaler device; this may
have confounded the common placebo comparator.
4. Methodology: We were concerned that funding for the
fluticasone and budesonide trials was systematically different, but
in light of similar inclusion criteria, baseline characteristics and
study designs, we believed that funding alone was not a reason to
believe that the transitivity assumption did not hold. However,
although the monotherapy trials were of a comparable duration
(weighted means of 22 and 23 months), the fluticasone
combination therapy trials were a lot longer than the budesonide
combination therapy trials (16 and nine months, respectively).
Risk of bias was similar across all studies and did not differ
systematically between those funded by the two main drug
companies. Similarly, although fluticasone monotherapy trials
had somewhat larger sample sizes than budesonide monotherapy
trials, this finding was not deemed significant. The two sets of
combination therapy trials had very similar mean sample sizes.
5. Control group event rates: Event rates for placebo
monotherapy comparisons and for LABA combination therapy
comparisons are presented in Table 4. Differences were noted
between fluticasone and placebo for both monotherapy and
combination therapy comparisons, with fluticasone studies
consistently showing higher control group event rates. Inspection
of control events showed that Calverley 2007 TORCH, which
observed a large population over a longer time scale than most
other studies (three years), was skewing the event rates. Although
four other long-term fluticasone monotherapy studies (two to
three years) were identified, they had smaller populations, did
not contribute to all of the outcomes and did not observe the
same magnitude of event rates. With this study removed, control
group events were much more similar between the two drugs
(presented in brackets). Overall, considered in light of similar
baselines and inclusion criteria, it is unlikely that the figures
represent true differences in baseline event rates of the two
populations.
In light of all of the information collected, we decided to calculate
the indirect comparison of fluticasone and budesonide monother-
apy via placebo because the only potential confound was the in-
haler device used, and all other moderating factors were consid-
ered comparable. For the reasons outlined regarding control group
event rates, we conducted a sensitivity analysis excluding Calverley
2007 TORCH.
For the combination therapy comparison, we considered the com-
mon LABA comparison to systematically differ between the two
sets of combination studies; fluticasone studies used either sal-
meterol or vilanterol, which differed in their delivery and dosing
schedules, and budesonide was always compared with formoterol.
In addition, the fluticasone studies were much longer, and the
same funding and device issues existed as for the monotherapy
studies. As such, we did not perform an indirect comparison to
compare fluticasone/LABA versus budesonide/LABA.
Outcomes and analysis structure
Unless otherwise stated, all of the analyses were conducted as
proposed with fixed-effect models using Mantel-Haenszel meth-
ods. Several outcomes included some zero cells, but estimates
were barely affected in sensitivity analyses using the Peto method.
Therefore, Peto odds ratios were used only for ’mortality due to
pneumonia’, because events for this outcome were very rare. The
quality of evidence for each outcome was rated using GRADE-
Pro software, and this information is presented in Summary of
findings for the main comparison (fluticasone) and Summary of
findings 2 (budesonide).
Indirect comparisons performed to compare fluticasone with
budesonide monotherapy are presented for the primary outcome
and for three secondary outcomes (all-cause mortality, all non-fa-
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tal serious adverse events and all pneumonia events). Although we
did not foresee the inclusion of fluticasone furoate when we con-
ceived of the protocol, we decided to combine these data with the
fluticasone propionate data on the basis of consistency observed in
the monotherapy subgroup of each of the relevant direct analyses
(Analysis 1.1; Analysis 1.2; Analysis 1.4).
For the primary outcome, ’non-fatal serious adverse pneumonia
events’, data were organised into three sets of subgroups to explore
the effects of three prespecified potential moderators. Subgroup
analyses for daily dose, duration of ICS therapy (≤ one year and
> one year) and baseline severity (< 50% FEV1 predicted and ≥
50% FEV1 predicted) are presented separately for fluticasone and
budesonide in comparisons three and four, respectively.
We also conducted a sensitivity analysis while removing stud-
ies judged to be at high risk of bias because of high or uneven
levels of dropout. Of the 17 studies that fell into this category,
eight reported the primary outcome and were removed from the
analysis (fluticasone: Calverley 2003 TRISTAN; Ferguson 2008;
GSKSCO40041 2008; Lapperre 2009;Mahler2002; budesonide:
Rennard 2009; Shaker 2009; Sharafkhaneh 2012).
Excluded studies
Thirty-one references were excluded after full texts were consulted.
Reasons for exclusion were ’wrong comparison’ (n = 19), discon-
tinuation of study (n = 6), ’asthma diagnosis’ (n = 2) and ’treatment
period less than 12 weeks (n = 2). One study is awaiting classifica-
tion (only abstract is available), and recruitment for one study was
ongoing in March 2014. Full details are listed in Characteristics
of excluded studies.
Risk of bias in included studies
Studies generally were well conducted and were rated as low or
unclear risk of bias for all four of the allocation and blinding
parameters. However, in almost half of the studies, potential for
bias was due to attrition and selective outcome reporting. Full
details of our judgements for each study, as well as supporting
information for each judgement, can be found in Characteristics
of included studies. A summary of risk of bias across all studies is
shown in Figure 3.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Studies were rated for potential biases introduced by the method
of sequence generation (e.g. computerised random number gener-
ator) and by the methods used to conceal the allocation sequence
from those recruiting people into the studies.
Most studies were judged to be at low risk of bias for sequence
generation (n = 39). Although not all of these studies adequately
described sequence generation methods, all were funded by phar-
maceutical companies that had previously confirmed their meth-
ods. The remaining four studies were rated ’unclear’ because they
did not describe their methods in detail and did not appear
to be funded by a pharmaceutical company (Dal Negro 2003;
Senderovitz 1999; Yildiz 2004).
Allocation concealment was not well reported, and only 17 studies
were given a rating of low risk of bias because they adequately
described the methods used. However, no studies were considered
to be at high risk of bias, and the remaining 26 studies were given
an ’unclear’ rating.
Blinding
The risk of bias introduced by methods of blinding was rated sep-
arately for blinding of participants and personnel and for blinding
of the people assessing outcomes.
Most studies stated that double-blind procedures were used, and
trial reports or registrations usually confirmed that this approach
included both participants and investigators. For this reason, most
studies were rated as low risk of bias (n = 39), and the remaining
four were rated as ’unclear’. No studies were open-label or used
inadequate blinding procedures, so none were judged to be at high
risk of bias.
Quite often, it was difficult to ascertain from the study reports who
the outcome assessors were and for which outcomes the blind-
ing applied. Only 10 studies gave enough information to allow a
judgement of low risk of bias to be made, and the remaining 33
were rated as ’unclear’.
Incomplete outcome data
Around half of the studies were rated as low risk of bias because
of incomplete outcome data (n = 21), either because the number
of dropouts per group was low and even, or because the quantity
and distribution of missing data were deemed acceptable given
the method of imputation (e.g. intention-to-treat analysis using
last observation carried forward). Sixteen studies were rated as
high risk of bias, usually because dropout was very high in both
groups, or because dropout was much higher in one group than
in another. In the remaining six studies, authors considered that
the information regarding attrition was not sufficient to permit
judgement of whether dropout and methods of data imputation
were likely to have affected the results.
Selective reporting
More than half of the studies were rated as low risk of bias for selec-
tive outcome reporting (n = 24), either because reported outcomes
could be checked against the outcomes stated in a prospectively
registered protocol, or because study authors provided additional
data through personal communication. Five studies were rated as
unclear, usually because no clear evidence on missing outcomes
was available, but no trial registration could be found to confirm
that all prespecified outcomes were properly reported. In all cases,
attempts were made to contact trial authors for clarification; this
is detailed in each study’s risk of bias table in Characteristics of
included studies. The remaining 14 studies were judged to be at
high risk of bias, either because outcomes stated in the trial reg-
istration were missing or poorly reported in the published report,
or because several key outcomes analysed in this review were not
reported.
Other potential sources of bias
No additional sources of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison Fluticasone
for chronic obstructive pulmonary disease; Summary of findings
2 Budesonide for chronic obstructive pulmonary disease
In comparisons one and three, studies are pooled for fluticasone
and budesonide, respectively, and are subgrouped in each case in
terms of whether each randomly assigned group also received a
long-acting beta-agonist. Comparisons two and four show addi-
tional subgroup analyses for the primary outcome of non-fatal se-
rious adverse events for fluticasone and budesonide, respectively.
Comparison five presents results for the indirect comparison of
fluticasone and budesonide via the common placebo comparator
(Figure 1). Comparison six refers to the equivalent comparison of
fluticasone with budesonide given as combination therapy with a
long-acting beta-agonist. As described above, no indirect compari-
son was undertaken for combination therapy because of violations
of transitivity and similarity.
For illustration and visual comparison of the two drugs, effects of
all fluticasone studies (comparison one) and all budesonide stud-
ies (comparison three) are presented together for each outcome
in Figure 4. No statistical heterogeneity was noted between the
pooled effect for budesonide and that of fluticasone for all out-
comes except ’all pneumonia events’; for this reason the effects are
not pooled for this outcome.
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Figure 4. Summary of pooled effects of trials comparing ICS versus placebo and combination versus
LABA.Non-fatal serious adverse pneumonia events were those requiring hospital admission. Data for all
pneumonia events were not pooled because of heterogeneity.
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Comparison one: fluticasone versus controls (all
outcomes subgrouped to compare ICS vs placebo
with ICS/LABA vs LABA)
1.1 Primary outcome: non-fatal, serious adverse pneumonia
events (requiring hospital admission)
Twenty-four comparisons in 17 studieswere analysed (n=19,504),
with seven studies contributing data to both the ’fluticasone versus
placebo’ and ’fluticasone/LABA versus LABA’ subgroups. Fluti-
casone increased the incidence of non-fatal serious adverse pneu-
monia events (OR 1.78, 95% CI 1.50 to 2.12; I2 = 0%, P value
0.65), with no significant heterogeneity noted between studies.
No significant evidence indicated that the odds of having a seri-
ous adverse pneumonia event were differentially affected by fluti-
casone alone (against placebo) compared with fluticasone/LABA
combination (against LABA alone) (I2 = 0%, P value 0.77). The
outcome was rated of high quality.
1.2 Mortality, all-cause
Twenty-nine comparisons in 22 fluticasone studies were included
in the analysis (n = 20,861), although seven comparisons did not
contribute to the pooled estimate because no events were reported
in either group. No evidence suggested a difference between flu-
ticasone and controls (OR 0.99, 95% CI 0.87 to 1.13; I2 = 0%,
P value 0.73), and a test for subgroup differences between ’fluti-
casone versus placebo’ and ’fluticasone/LABA versus LABA’ com-
parisons was not significant (I2 = 0%, P value 0.39). Evidence was
rated of high quality.
1.3 Mortality, due to pneumonia
Data for pneumonia-related deaths were available for 25 compar-
isons in 18 studies (n = 19,532). However, all but five compar-
isons observed no events, and Calverley 2007 TORCH accounted
for 80% of the analysis weight across its two comparisons. No
difference was detected between fluticasone and control overall
(Peto OR 1.23, 95% CI 0.70 to 2.15; I2 = 0%, P value 0.95),
and no observable subgroup differences were reported between
themonotherapy and combination therapy subgroups (I2 = 0%, P
value 0.44). Evidence was rated of moderate quality, being down-
graded once for imprecision because so few events were reported.
1.4. Non-fatal serious adverse events, all-cause
Nineteen studies across 26 comparisons reported all-cause serious
adverse events (n = 20,381). The odds of a serious adverse event
were higher with fluticasone than with control (OR 1.06, 95%
CI 0.99 to 1.16; I2 = 0%, P value 0.66). The lower confidence
just crossed the line of no effect, but no significant heterogeneity
was noted between studies. No evidence suggested a difference
between monotherapy and combination therapy subgroups (I2 =
0%, P value 0.58). Evidence was rated of high quality.
1.5. All pneumonia events
Fifteen studies making 11 comparisons reported the outcome (n =
15,377), and Calverley 2007 TORCH carried almost 80% of the
weight across the analysis. The odds of any pneumonia event were
significantly greater with fluticasone than with control (OR 1.68,
95% CI 1.49 to 1.90), with no important heterogeneity observed
between studies (I2 = 0%, P value 0.76) or subgroups (I2 = 0%,
P value 0.64). The outcome was underreported across the studies,
so evidence was downgraded for publication bias, and was rated
of moderate quality.
1.6. Withdrawals
Data from 26 studies (33 comparisons, n = 21,243) show that
withdrawals were much less common on fluticasone than on con-
trol, with no significant heterogeneity noted (OR 0.81, 95% CI
0.77 to 0.86; I2 = 3%, P value 0.43). The effect was larger for flu-
ticasone monotherapy, but the difference between subgroups was
not statistically significant (I2 = 66%, P value 0.09). No reasons
suggested the need to downgrade the evidence from high quality.
Comparison two: subgroup analyses-fluticasone
versus controls
Dose: Combining all studies and organising by fluticasone dose
did not reveal significant subgroup differences between doses (I
2 = 0%, P value 0.90; Analysis 2.1). Pooled effects for the three
furoate dose subgroups (50mcg, 100mcg and 200mcg once a day)
contained fewer data and therefore had much wider confidence
intervals than the more widely used propionate preparation doses.
Higher-dose fluticasone propionate was the most widely studied
and hence has the most precise estimate, but the pooled effect was
not statistically different from the other dose subgroups.
Trial duration:No evidence shows significant differences between
the trials with duration of one year or less and the three trials (four
comparisons) that followed participants for three years (I2 = 0%,
P value 0.61; Analysis 2.2). No significant heterogeneity between
individual studies was noted within either subgroup (I2 = 0% in
both cases).
Baseline percentage predicted FEV1 : Studies with a mean baseline
percentage predicted FEV1 of less than 50% accounted for 99%
of the analysis weight (Analysis 2.3), so no conclusions could be
drawn regarding the moderating effect of baseline severity.
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Comparison three: budesonide versus controls (all
outcomes subgrouped to compare ICS vs placebo
with ICS/LABA vs LABA)
3.1 Primary outcome: non-fatal, serious adverse pneumonia
events (requiring hospital admission)
Data for eight comparisons in seven studies were analysed (n
= 6472), with Tashkin 2008 SHINE contributing data to both
’budesonide versus placebo’ and ’budesonide/LABA versus LABA’
subgroups. Budesonide increased non-fatal serious adverse pneu-
monia events (OR 1.62, 95% CI 1.00 to 2.62), and, although a
degree of variation was noted between study results, it was not
significant (I2 = 28%, P value 0.21). Heterogeneity was evident
between the monotherapy and combination subgroups, but the
test for differences was not statistically significant (I2 = 55%, P
value 0.14). The confidence intervals around the pooled estimate
were quite wide but were not considered serious enough to war-
rant downgrading.However, because two-thirds of the budesonide
studies did not appear in the analysis, the outcome was down-
graded once for publication bias and was rated of moderate qual-
ity.
3.2. Mortality, all-cause
Budesonide did not significantly affect all-cause mortality relative
to control interventions (OR 0.90, 95% CI 0.65 to 1.24), based
on 15 comparisons in 12 studies (n = 10,009). Heterogeneity was
not significant across studies (I2 = 0%, P value 0.76), and no statis-
tically significant difference was noted between the monotherapy
and combination therapy subgroups (I2 = 0%, P value 0.75). Evi-
dence was rated of moderate quality after being downgraded once
for imprecision because the confidence intervals included signifi-
cant benefit and harm.
3.3. Mortality, due to pneumonia
Only three budesonide studies reported the outcome (n = 1511),
of which two studies observed no events in either group. No con-
clusions could be made from Sharafkhaneh 2012, which observed
one event in the budesonide/LABA group. Evidence was rated
of very low quality, being downgraded twice for imprecision and
once for publication bias.
3.4. Non-fatal serious adverse events, all-cause
Fifteen comparisons in 12 studies were analysed (n = 10,009).
Budesonide was not found to increase the odds of a serious adverse
event (OR 1.01, 95% CI 0.83 to 1.22), although significant het-
erogeneity was noted between studies (I2 = 59%, P value 0.002),
so a random-effects analysis was used and the outcome was down-
graded for inconsistency to moderate quality. No heterogeneity
was observed between the subgroups (I2 = 0%, P value 0.68).
Anoutlier in the budesonide versus placebo subgroupwas removed
in a post hoc sensitivity analysis (Vestbo 1999), which changed the
effect for the subgroup to favour the control (OR 1.27, 95% CI
1.04 to 1.55) with no within-subgroup heterogeneity (previously
I2 = 72%). The study recruited a less severe population, which
might explain the difference in effect.
3.5. All pneumonia events
Not enough evidence was obtained to rule out a significant in-
crease or a potential reduction in pneumonia events on budesonide
compared with controls (OR 1.12, 95% CI 0.83 to 1.51; eight
comparisons in six studies; n = 7011). A degree of unexplained
heterogeneity was observed between studies (I2 = 13%, P value
0.33) and between treatment subgroups (I2 = 14%, P value 0.28),
neither of which was significant. Although confidence intervals
were quite wide, findings were not deemed serious enough to war-
rant downgrading of the evidence. However, because most of the
budesonide studies did not appear in the analysis, the outcome
was downgraded for publication bias and was rated of moderate
quality.
3.6. Withdrawals
When 18 comparisons in 15 studies were combined (n = 10,150),
withdrawalswere seen to be less common in the budesonide groups
than in the control groups (OR 0.78, 95% CI 0.71 to 0.85). No
important heterogeneity was noted between individual studies (I2
= 12%, P value 0.31) or between monotherapy and combination
therapy subgroups (I2 = 0%, P value 0.57). Evidence was rated of
high quality.
Comparison four: subgroup analyses-budesonide
versus controls
Dose: When all budesonide studies were subgrouped according
to daily dose, the difference between 320 mcg and 640 mcg was
significant (I2 = 74%, P value 0.05; Analysis 4.1); the higher dose
increased non-fatal serious adverse pneumonia events (OR 2.02,
95% CI 1.15 to 3.57), and no significant difference was observed
for the lower dose (OR 0.68, 95% CI 0.27 to 1.71). The only
study using the highest dose of 1280 mcg, Yildiz 2004, did not
contribute data to the analysis because no events occurred in either
group.
Trial duration:The difference between five studies lasting a year or
less and Shaker 2009 (which followed participants for a minimum
of two years) was not significant (I2 = 39%, P value 0.20; Analysis
4.2).
Baseline percentage predicted FEV1:When studies were subgrouped
according to baseline severity, differences were not significant (I2
= 40%, P value 0.20; Analysis 4.3), and only one study reported
a baseline mean FEV1 above 50% predicted (Shaker 2009).
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Comparison five: sensitivity analysis-risk of bias
5.1 Non-fatal serious adverse pneumonia events
5.1.1 Fluticasone versus controls
Four fluticasone studies representing six comparisons rated at high
risk for attrition were removed from the primary outcome in a
sensitivity analysis. The estimate gave a slightly larger effect of
fluticasone on pneumonia than the main analysis (15 RCTs; n =
16,338; OR 1.82, 95% CI 1.52 to 2.19).
5.1.2 Budesonide versus controls
Three studies judged to be at high risk of bias due to high or uneven
levels of attrition were removed from the primary outcome in a
sensitivity analysis. The effect from the remaining four studies was
larger but more imprecise because far fewer events were included
in the analysis (5 RCTs; n = 3515; OR 3.28, 95% CI 1.22 to
8.81).
Comparison six: indirect comparison of fluticasone
and budesonide monotherapy
We calculated the relative effects of fluticasone and budesonide
for four outcomes by comparing their effects against placebo (see
Figure 1). No studies directly comparing the two drugs met this
review’s inclusion criteria, but cohort data are summarised in
Agreements and disagreements with other studies or reviews.
All four outcomes were downgraded for indirectness because no
direct evidence was found and the estimate was obtained purely
from indirect comparisons. None of the outcomes were down-
graded for risk of bias or inconsistency. The indirect comparisons
are presented in Figure 5 and are summarised below, and the sen-
sitivity analysis removing Calverley 2007 TORCH is shown in
Figure 6.
Figure 5. Indirect comparisons of fluticasone and budesonide monotherapy.Non-fatal serious adverse
pneumonia events were defined as those requiring hospital admission.
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Figure 6. Indirect comparisons of fluticasone and budesonide monotherapy-Sensitivity analysis removing
(Calverley 2007 TORCH).
6.1 Non-fatal serious adverse pneumonia events
The point estimate favoured fluticasone, but the difference was
not significant and the confidence intervals were very wide (OR
0.53, 95% CI 0.16 to 1.71). In addition to being downgraded for
indirectness, the outcome was downgraded twice for imprecision
and was rated as very low quality.
6.2 Mortality, all-cause
The point estimate favoured budesonide, but the difference was
not significant and the confidence intervals were wide (OR 1.24,
95% CI 0.74 to 2.07). Evidence was also downgraded once for
imprecision and was rated of low quality.
6.3 All non-fatal serious adverse events
The difference between fluticasone and budesonide was not sig-
nificant, and the confidence intervals were much tighter than for
the other two indirect comparisons (OR 0.96, 95% CI 0.77 to
1.20). The evidence was not downgraded for any other reason and
was rated of moderate quality.
6.4 All pneumonia events
A significant difference was noted between fluticasone and budes-
onide, although the confidence interval was quite wide (OR 1.86,
95% CI 1.04 to 3.34). The evidence was not downgraded for any
other reason and was rated of moderate quality. When Calverley
2007 TORCH was removed from the sensitivity analysis, the dif-
ference was larger in magnitude but was much less precise and was
not statistically significant (OR 2.30, 95% CI 0.79 to 6.67).
Comparison seven: indirect comparison of
fluticasone/LABA and budesonide/LABA
combination therapy
For the reasons described in ’Transitivity and similarity’, we chose
not to calculate an indirect comparison for combination ther-
apy. Recent studies directly comparing fluticasone/salmeterol with
budesonide/formoterol were not comparable with the design or
time scales used in the rest of this review (Blais 2010; Janson 2013
[PATHOS]; Partridge 2009; Roberts 2011), but their findings are
discussed in Agreements and disagreements with other studies or
reviews.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Budesonide for chronic obstructive pulmonary disease
Patient or population: patients with chronic obstructive pulmonary disease
Intervention: budesonide (alone or with LABA co-intervention)
Comparison: placebo or LABA monotherapy (dependent upon whether fluticasone was given with LABA in the intervention group)
Setting: community
Outcomes
Follow-ups presented as
weighted means
Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Budesonide
Non-fatal, serious adverse
pneumonia events (requiring
hospital admission)
Follow-up: 9 months
9 per 1000 15 per 1000
(9 to 24)
OR 1.62
(1.00 to 2.62)
6472
(7 studies)
⊕⊕⊕©
moderate1,2
Mortality, all-cause
Follow-up: 14 months
17 per 1000 16 per 1000
(11 to 21)
OR 0.90
(0.65 to 1.24)
10,009
(12 studies)
⊕⊕⊕©
moderate3
Mortality, due to pneumonia
Follow-up: 12 months
0 per 1000 0 per 1000
(0 to 0)
OR 4.46
(0.07 to 286.99)
1511
(3 studies)
⊕©©©
very low2, 4
Non-fatal, serious adverse
events (all)
Follow-up: 14 months
145 per 1000 146 per 1000
(124 to 172)
OR 1.01
(0.83 to 1.22)
10,009
(12 studies)
⊕⊕⊕©
moderate5
All pneumonia events
Follow-up: 10 months
28 per 1000 31 per 1000
(23 to 41)
OR 1.12
(0.83 to 1.51)
7011
(6 studies)
⊕⊕⊕©
moderate1,2
Withdrawals
Follow-up: 14 months
280 per 1000 232 per 1000
(216 to 248)
OR 0.78
(0.71 to 0.85)
10150
(15 studies)
⊕⊕⊕⊕
high
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
Unless otherwise stated, subgroup differences between monotherapy studies (budesonide versus placebo) and combination therapy studies (budesonide/LABA versus LABA) were not
significant
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Confidence intervals are quite wide but are not considered serious enough to downgrade.
2More than half the studies did not report the outcome (-1 for publication bias).
3Confidence interval includes significant benefit and potential harm.
4Very wide confidence intervals. Only one death observed over the three studies (-2 for imprecision).
5I2 = 59%, P value 0.002 (-1 for inconsistency).
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D I S C U S S I O N
Summary of main results
We found a total of 43 studies that met the inclusion criteria for
this review, with more evidence for fluticasone (26 studies, n =
21,247) than budesonide (17 studies, n = 10,150). Evidence from
the budesonide studies was more inconsistent and less precise, and
the mean duration of trials was shorter.
Fluticasone increased non-fatal serious adverse pneumonia events
(i.e. those requiring a hospital admission) (OR 1.78, 95% CI 1.50
to 2.12; high-quality evidence), and no significant evidence sug-
gested that this was different when fluticasone was delivered in
combination with salmeterol or vilanterol (subgroup differences,
I2 = 0%, P value 0.51). We did not find that different doses, trial
duration or baseline severity significantly affected this estimate.
Budesonide also increased non-fatal serious adverse pneumonia
events, but the effect was less precise (OR 1.62, 95% CI 1.00
to 2.62; moderate-quality evidence). Some of the variation in the
budesonide data could be explained by a significant difference be-
tween the two commonly used doses: 640 mcg showed a larger
increase than 320 mcg (subgroup differences, I2 = 74%, P value
0.05). An indirect comparison of budesonide and fluticasone us-
ing placebo as a common comparator showed no significant dif-
ferences with respect to serious adverse events (pneumonia-related
or all-cause) or mortality.
No difference in overall mortality rates was noted between either of
the inhaled steroids and the control interventions (both high-qual-
ity evidence), but no conclusions could be drawn regarding deaths
that were pneumonia-related, as so few events were reported. Ev-
idence of total pneumonia events on fluticasone was dominated
by the three-year Calverley 2007 TORCH study, and far fewer
budesonide studies reported the outcome.
Indirect comparisons of budesonide and fluticasone monotherapy
showed no significant differences with respect to serious adverse
events (pneumonia-related or all-cause) or mortality. The risk of
any pneumonia event (i.e. less serious cases treated in the com-
munity) was higher with fluticasone than with budesonide (OR
1.86, 95%CI 1.04 to 3.34); this was the only significant difference
found between the two drugs. However, this finding should be
interpreted with caution because of possible differences in assign-
ment of a diagnosis of pneumonia, and because no trials directly
compared the two drugs.
Fewer people in the inhaled steroid groups withdrew from study
medication; this was true for both monotherapy versus placebo
and combination therapy versus LABA trials. It is possible that
this was a result of lack of efficacy in the control groups, but it was
not formally evaluated. High or uneven dropout was considered to
show a high risk of bias in almost 40%of the trials, but conclusions
for the primary outcome did not change when the trials at high
risk of bias were removed in a sensitivity analysis.
Overall completeness and applicability of
evidence
Efforts were made to contact all trial authors to obtain additional
data when outcomes did not appear in the available reports. Al-
though this resulted in some additional data being provided-both
numerical and related to study conduct-most studies do not ap-
pear in every analysis; only around a third of the studies contribute
data to the primary outcome.
We chose to look at fluticasone and budesonide as the two most
widely used inhaled steroids that are also commonly prescribed in
combination with the long-acting beta2-agonists salmeterol and
formoterol, respectively, and we did not include trials studying
other available inhaled steroids (e.g. mometasone, triamcinolone,
ciclesonide, beclomethasone, flunisolide). As such, the study re-
sults can be applied only to the inhaled steroids in question, not
to the class in general.
The plan to indirectly compare budesonide/formoterol and flu-
ticasone/salmeterol combination therapies was more complicated
than it was for monotherapy, and by choosing not to conduct the
indirect comparison, we were unable to draw conclusions about
the relative safety of budesonide andfluticasonewhenused in com-
bination with a LABA. Even without the addition of the fluticas-
one furoate/vilanterol studies, we considered the LABA compara-
tor to differ systematically between fluticasone and budesonide
combination therapy studies, hence violating the transitivity as-
sumption. Variation in the LABA usedwithin the fluticasone trials
further reduced our confidence in the indirect comparison.
Inhaled corticosteroids are not equal in strength, and their doses
are normally expressed as equivalents to budesonide dipropionate
(BDP) doses (Table 3). By pooling data for all doses of fluticasone
for comparison with all doses of budesonide, the indirect compar-
ison could not account for the dose-related effects that we found
with budesonide, or for differences in dose equivalence between
the two sets of data.
Quality of the evidence
We wrote to all study authors when numerical outcome data or
details related to risk of bias could not be obtained from available
reports. Of all the studies, nine reported all information and did
not need to be contacted; we failed to find contact details for a
further six. Of the remaining 28 studies, 13 study authors did not
reply, six provided additional data or confirmed that all measured
outcomes were reported in the original reports, four forwarded the
request to the drug company that held the data, four were requests
sent directly to GlaxoSmithKline and one could not provide data.
No drug company data were provided by the time the review was
published, and the application for data is ongoing and may be
incorporated in future updates. In addition, nearly half of the
studies were conducted 10 or more years ago; this made it difficult
for review authors to locate contact details and for study authors
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to locate the data requested.
The definition of pneumonia and the method of diagnosis were
routinely missing from trial reports, and this information could
not be obtained to conduct a subgroup analysis on this basis. We
were unsure whether pneumonia was radiographically confirmed
in most cases, and the trials were not designed for the purpose of
measuring the incidence of pneumonia. In addition, the extent to
which pneumonia events are misclassified as acute exacerbations
of COPD (and vice versa) is somewhat unclear (Marzoratti 2013).
We could not obtain information to judge whether ascertainment
of pneumonia was systematically different between funding drug
companies or between healthcare systems in which studies were
conducted; this is a potential source of bias.
Despite a relatively low rate of response from trial authors, all out-
comes based on direct evidence were rated as high or moderate
quality with GRADE. All trials were generally of good method-
ological quality, having been conducted by large pharmaceutical
companies. In addition, more than 40 studies were found that
contributed data to at least one analysis. Some imprecision was
noted for rare events such as mortality due to pneumonia; we were
unable to draw conclusions in these cases, especially for budes-
onide, for which less evidence was available. For this reason, we
were generally less confident in the budesonide outcomes.
We identified two potential confounds, which we did not con-
sider to be sufficient to downgrade the quality of the evidence.
First, most of the budesonide studies were funded by AstraZeneca,
and most of the fluticasone studies by GlaxoSmithKline. How-
ever, systematic differences in study conduct were not identified
in the assessments of bias. Second, budesonide monotherapy and
combination therapy are delivered via a Turbuhaler, and flutica-
sone is given via a Diskus or Accuhaler device. We assumed that
participants in the trials were given adequate training for the de-
vice used, and that this did not systematically affect the amount
of drug delivered or the likelihood of compliance between the two
drugs. For this reason, and because in each double-blind trial the
placebo device matched that of the active drug, we did not con-
sider different drug devices a reason not to conduct the indirect
comparison of budesonide versus fluticasone.
When the protocol for this review was written, we did not an-
ticipate the inclusion of a new preparation of fluticasone furoate
in combination with the long-acting beta2-agonist vilanterol. In-
cluding these studies may have introduced heterogeneity into the
direct fluticasone versus placebo comparison, and into the fluti-
casone/LABA versus LABA comparison, although a recent ran-
domised trial comparing fluticasone/vilanterol with fluticasone/
salmeterol found no significant differences in their efficacy or sa-
fety profiles (Agusti 2013). Inclusion of these studiesmay also have
reduced the reliability of the indirect comparisons by increasing
variation within the fluticasone monotherapy node and the fluti-
casone/salmeterol node (by including fluticasone/vilanterol stud-
ies in a combined fluticasone/LABA node), but the absence of sta-
tistical heterogeneity in the analyses did not suggest that this was
the case. The expected publication of further RCTs of fluticasone
furoate and other new preparations will increase the likelihood
of detecting any differences which may exist between their safety
profiles and more established corticosteroids. This may warrant
dealing with different preparations separately in future updates of
this review, which was not possible with the current evidence base.
Our decision to conduct the monotherapy indirect compari-
son was based on statistical consistency within the two sets of
monotherapy trials (budesonide vs placebo and fluticasone vs
placebo) and on a comprehensive assessment of transitivity across
these two sets of trials. As such, we considered the indirect com-
parison to be valid, but the quality of the evidence remains limited
by the observational nature of indirect comparisons, and by the
lack of head-to-head trials comparing fluticasone and budesonide.
Potential biases in the review process
We made every effort to adhere to Cochrane methods during the
review process. As stated in the protocol, all numerical data were
extracted by two review authors, and discrepancies were resolved
through discussion. The same was true for the risk of bias ratings.
Neither of the review authors have conflicting interests.
It is unlikely that the review is biased as a result of published stud-
ies missed during study selection. The electronic searches were
relatively broad, and review authors searched additional resources
to locate any studies that might have been missed (e.g. trial reg-
istration websites, drug company databases, reference lists of in-
cluded studies). In addition, review authors attempted to contact
all study authors when data or details of study methodology were
not reported in the published reports.
Agreements and disagreements with other
studies or reviews
Two Cochrane reviews that are related to this safety review have re-
cently been updated: Yang 2012, looking at the safety and efficacy
of any inhaled corticosteroid versus placebo, and Nannini 2012,
focusing on ICS/LABA combination therapy versus LABA alone.
Both reviews are consistent with the findings and conclusions of
this review; no effect was observed for mortality, and increased
rates of pneumonia seen with inhaled steroids were not signifi-
cantly different between types of inhaled steroids. Nannini 2012
called for more evidence regarding differential safety of different
doses of inhaled steroids, which this review has helped to clarify.
Both author teams correctly point out in their reviews that evi-
dence for harms associated with these medications needs to be as-
sessed in conjunction with good evidence of the clinical benefit of
inhaled steroids (notably, fewer exacerbations and improved qual-
ity of life). In contrast to other previous meta-analyses (Ruiz 2011;
Sin 2009), this review found evidence for an association between
budesonide and serious adverse pneumonia events, and indirect
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comparison with fluticasone yielded little evidence for differential
safety between the two drugs. It is problematic to incorporate ev-
idence for dose-related safety with efficacy data to assess whether
a particular dose of a drug is preferable to another; evidence from
Calverley 2007 TORCH suggests that the trade-off between re-
ducing exacerbations and increasing pneumonia changes over time
for fluticasone, but it is not yet clear whether this is true for dif-
ferent doses and products (Cates 2013).
Evidence from cohorts corroborates the data from randomised tri-
als, showing increased rates of pneumonia in those treated with in-
haled steroids andmore clearly demonstrating a dose-related effect
(Ernst 2007; Janson 2013 [PATHOS]; Suissa 2013; Yawn 2013).
Evidence from one of the cohorts, which observed more than
20,000 serious pneumonias, revealed increased risk with fluticas-
one (RR 2.01, 95% CI 1.93 to 2.10) compared with budesonide
(RR 1.17, 95% CI 1.09 to 1.26) (Suissa 2013); this conclusion
could not be drawn from the randomised trial evidence. Although
we believe that it was not viable to make an indirect comparison of
budesonide combination therapy versus fluticasone combination
therapy, cohort data suggest that the fluticasone combination is
associated with higher rates of pneumonia, deaths related to pneu-
monia and admissions to hospital than budesonide/formoterol,
but the duration of admissions for pneumonia and overall mor-
tality were similar (Janson 2013 [PATHOS]). We found no in-
direct comparisons of budesonide/formoterol and fluticasone/sal-
meterol using a LABA control group, but indirect evidence based
on randomised trials using placebo as the common comparator
supported the cohort findings (Halpin 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Safety concerns related to inhaled steroids highlighted in this re-
view should be balanced with recent cohort data and established
randomised evidence of efficacy regarding exacerbations and qual-
ity of life. Budesonide and fluticasone, delivered as monotherapy
or in combination with a LABA, are associated with increased risk
of serious adverse pneumonia events, but neither significantly af-
fected mortality compared with controls. Comparison of the two
drugs showed no statistical difference in serious pneumonias, mor-
tality or serious adverse events, but the risk of any pneumonia (i.e.
less serious cases dealt with in the community) was higher with
fluticasone than with budesonide. However, definitions used by
the respective manufacturers is a potential confound in their com-
parison.
Implications for research
Primary research into the use of inhaled steroids for COPD in
particular should accurately measure pneumonia outcomes and
clarify both the definition and the method of diagnosis used. This
is particularly important for studies conducted on emerging cor-
ticosteroid preparations and combinations , for which little evi-
dence is currently available on associated pneumonia risk. Simi-
larly, systematic reviews, meta-analyses and cohorts should address
the reliability of assigning ’pneumonia’ as an adverse event or a
cause of death and should explain how this affects the applicability
of findings.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anzueto 2009
Methods Design: randomised, double-blind, parallel-group study
12-Month treatment period
Conducted at 98 research sites in the United States and Canada
Participants Participants: 797 people were randomly assigned to fluticasone/salmeterol combination
(394) and salmeterol alone (403)
Baseline characteristics:
Male %: flut/sal 51, sal 57
Mean age (SD), years: flut/sal 65.4 (9.1), sal 65.3 (8.8)
Smoking history (mean (SD) pack-years): flut/sal 57.8 (32.7), sal 56.5 (27.8)
Mean % predicted pre-FEV1 (SD): 34.1 (11.1), 33.9 (10.6)
Inclusion criteria:≥ 40 years of age with a diagnosis of COPD (chronic bronchitis and/
or emphysema), a cigarette smoking history ≥ 10 pack-years, a prealbuterol FEV1/FVC
≤ 0.70, an FEV1 ≤ 50% of predicted normal and a documented history of at least one
COPD exacerbation the year before the study that required treatment with antibiotics
or oral corticosteroids and/or hospitalisation
Exclusion criteria: Individuals were excluded if they had a current diagnosis of asthma,
a respiratory disorder other than COPD, historical or current evidence of a clinically sig-
nificant uncontrolled disease or a COPD exacerbation that was not resolved at screening
Interventions Run-in: Four-week run-in period during which participants received open-label FSC
250/50 via DISKUS twice daily
Treatments:
1. Fluticasone/salmeterol 250/50 mcg twice daily
2. Salmeterol 50 mcg twice daily
Inhaler device: Diskus
Co-treatment: Concurrent use of inhaled long-acting bronchodilators was not allowed
during the study period. Oral corticosteroids and antibiotics were allowed for short-term
treatment of a COPD exacerbation
Outcomes Primary: annual rate of moderate/severe exacerbations
Secondary: time to first moderate/severe exacerbation, annual rate of exacerbations
requiring oral corticosteroids, predose FEV1, time to onset of each moderate/severe
exacerbation, diary records of dyspnoea scores, night-time awakenings due to COPD
and use of supplemental albuterol
Notes Funding: GSK
Clinicaltrials.gov: NCT00115492
Definition of pneumonia: confirmed by chest x-ray
Risk of bias
Bias Authors’ judgement Support for judgement
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Anzueto 2009 (Continued)
Random sequence generation (selection
bias)
Low risk Treatments were assigned in blocks using
a centre-based randomisation schedule. As
bronchodilator response to FSC 250/50 is
generally larger in individuals with COPD
who demonstrate FEV1 reversibility to al-
buterol, assignment to blinded study med-
ication was stratified on the basis of partici-
pants’ FEV1 response to albuterol at screen-
ing to provide a similar distribution of al-
buterol-responsive andnon-responsive par-
ticipants in each treatment group
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (assumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal rates were very high compared
with the numbers of events for different
outcomes
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported and could be included
Bourbeau 1998
Methods Design: double-blind, randomised, parallel-group trial of high-dose inhaled budesonide
versus placebo
Six-month treatment period (originally intended as 12 months)
Conducted at a single centre in Canada
Participants Participants: 79 people were randomly assigned to budesonide (39) and placebo (40)
Baseline characteristics:
Male %: bud 84.6, placebo 72.5
Mean age (SD), years: bud 66 (8), placebo 66 (8)
Smoking history (mean (SD) pack-years): bud 52 (27), placebo 50 (28)
Mean % predicted pre-FEV1 (SD): bud 36 (12), placebo 37 (10)
Inclusion criteria: 40 years of age or older; smokers or ex-smokers; absence of an exac-
erbation in
respiratory symptoms during the twomonths before the study; pre-bronchodilator FEV1
less than 65% of predicted and FEV1/forced vital capacity (FVC) less than 0.65; post-
bronchodilator FEV1 less than 80%; regular treatment with at least one bronchodilator
Exclusion criteria: history of allergic asthma during childhood or as an adult; inhaled
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Bourbeau 1998 (Continued)
corticosteroids in the previous month or oral corticosteroids in the previous two months;
any other active lung disease; diabetes, active peptic ulcer disease, uncontrolled high
blood pressure or congestive heart failure; disease other than COPD that might interfere
with quality of life
Interventions Run-in: All participants were assessed in a single-blind manner with a two-week course
of oral placebo followed by two weeks of prednisone 40 mg daily. The prednisone was
subsequently tapered and was discontinued completely during the third week. Those
who did not respond were randomly assigned
Treatments:
1. Budesonide 400 mcg twice daily
2. Placebo twice daily
Inhaler device: Turbohaler
Co-treatment: Allmedications needed for the well-being of participants were permitted,
except inhaled corticosteroids other than budesonide. In cases of treatment failure, rescue
medication with beta2-agonists or systemic steroids was available
Outcomes Primary: change in FEV1
Secondary: pre-bronchodilator and postbronchodilator FEV1 and FVC, pre-bron-
chodilator six-minute walking test, dyspnoea with exercise, quality of life questionnaires,
morning and evening PEFR, symptom scores and adverse events
Notes Funding: Astra Pharma Inc
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated list of random
numbers
Allocation concealment (selection bias) Low risk Identification of individual treatment as-
signments was possible only in cases of
emergency by breaking the sealed envelope
kept by the investigator. The envelopes had
to be kept with the case record forms and
had to be returned unbroken at the end of
the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To ensure that outcomes were measured
similarly in the treatment groups, both par-
ticipants and investigators were blinded to
the study treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk To ensure that outcomes were measured
similarly in the treatment groups, both par-
ticipants and investigators were blinded to
the study treatment
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Bourbeau 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Uneven dropout. Much higher in placebo
group (25% vs 7.7% in the ICS group)
Selective reporting (reporting bias) High risk Key outcomes missing (mortality, adverse
events). No reply from study author
Bourbeau 2007
Methods Design: randomised, double-blind, parallel-group, placebo-controlled trial
Three-month treatment period
Conducted at two respiratory centres in Canada
Participants Participants: 41 people were randomly assigned to fluticasone (20) and placebo (21)
Baseline characteristics:
Male %: flut 84.6, placebo 72.5
Mean age (SD), years: flut 66 (8), placebo 66 (8)
Smoking history (mean (SD) pack-years): flut 52 (27), placebo 50 (28)
Mean % predicted FEV1 (SD): flut 36 (12), placebo 37 (10)
Inclusion criteria: Age > 40 and < 75 years; smoking history (> 10 pack-years); post-
bronchodilator FEV1 > 25% of predicted
value and FEV1/forced vital capacity (FVC) < 0.70
Exclusion criteria: history of asthma, atopy (as assessed by an allergy skin prick test
during screening) or any other active lung disease. Individuals receiving home oxygen
or with raised carbon dioxide tension (.44 mm Hg), α1-antitrypsin deficiency, recent
exacerbation (in the last 4 weeks), uncontrolled medical condition or hypersensitivity to
inhaled corticosteroids and bronchodilators were not eligible for the study
Interventions Run-in: unclear duration
Treatments:
1. Fluticasone 500 mcg twice daily
2. Placebo twice daily
Participants were also randomly assigned to fluticasone/salmeterol combination, but this
was not included in the present review because no salmeterol arm was available for
comparison
Inhaler device: Diskus
Co-treatment: short-acting bronchodilators, short- and long-acting anticholinergics or
theophylline was allowed throughout the study. Oral corticosteroids and/or antibiotics
could be given only in short courses for exacerbation treatment
Outcomes Primary: treatment difference in the numbers of CD8+ T lymphocytes and CD68+
macrophages on bronchial biopsies
Secondary: numbers of neutrophils and eosinophils in bronchial biopsies
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
43Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bourbeau 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated list of random
numbers
Allocation concealment (selection bias) Low risk Set up by a data management/randomisa-
tion company (GEREQ, Montreal, Que-
bec). A procedure was established by
GEREQ, which was in possession of the
treatment code, to ensure that the treat-
ment code would be broken only in accor-
dance with the protocol and the criteria set
up for unbinding of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Observers and participants were blinded to
drug treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Observers were blinded to whether the
biopsies were performed post-treatment or
pretreatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout uneven but low in both groups
(5% ICS and 14% placebo)
Selective reporting (reporting bias) High risk Key outcomes not reported. No reply from
study author
Burge 2000
Methods Design: double-blind, placebo-controlled study
Three-year treatment period
Conducted at 18 hospitals in the UK
Participants Participants: 740 people were randomly assigned to fluticasone (372) and placebo (370)
Baseline characteristics:
Male %: flut 75.0, placebo 74.1
Mean age (SD), years: flut 63.7 (7.1), placebo 63.8 (7.1)
Smoking history (mean (SD) pack-years): flut 44 (30), placebo 44 (34)
Mean % predicted FEV1 (SD): flut 50.3 (14.9), placebo 50.0 (14.9)
Inclusion criteria: current or former smokers 40 to 75 years of age with nonasthmatic
chronic obstructive pulmonary disease. Baseline FEV1 after bronchodilator was at least 0.
8 L but less than 85% of predicted normal, and the ratio of FEV1 to forced vital capacity
was less than 70%. Previous use of inhaled and oral corticosteroids was permitted
Exclusion criteria: Individuals were excluded if their FEV1 response to 400 mcg salbu-
tamol exceeded 10% of predicted normal, if they had a life expectancy of less than five
years from concurrent disease or if they used beta blockers
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Interventions Run-in: eight-week runin period after withdrawal from any oral or inhaled corticos-
teroids
Treatments:
1. Fluticasone propionate 500 mcg daily
2. Placebo twice daily
Inhaler device: metered-dose inhaler with a spacer device
Co-treatment: Nasal and ophthalmic corticosteroids, theophyllines and all other bron-
chodilators were allowed during the study
Outcomes Primary: decline (mL/y) in FEV1 after bronchodilator
Secondary: frequency of exacerbations, changes in health status, withdrawals due to
respiratory disease, morning serum cortisol concentrations and adverse events
Notes Funding: GlaxoWellcome Research and Development
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation (block size
of six)
Allocation concealment (selection bias) Low risk Participants were randomly assigned se-
quentially from a list comprising treatment
numbers only
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Three-year double-blind phase using an
identical placebo inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Very high dropout in both groups (43%
and 53%)
Selective reporting (reporting bias) Unclear risk Nooutcomes appear to bemissing, but pro-
tocol could not be located to ensure that
all were reported. Author attempted con-
tact with GSK statistician, but no data were
provided in time for publication
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Calverley 2003 TRISTAN
Methods Design: multi-centre, randomised, double-blind, parallel-group, placebo-controlled
study
12-Month treatment period
Conducted at 196 hospitals in 25 countries
Participants Participants: 1465 people were randomly assigned to fluticasone/salmeterol combina-
tion (358), fluticasone (374), salmeterol (372) and placebo (361)
Baseline characteristics:
Male %: flut/salm 75, flut 70, salm 70, placebo 75
Mean age (SD), years: flut/salm 62.7 (8.7), flut 63.5 (8.5), salm 63.2 (8.6), placebo 63.
4 (8.6)
Smoking history (mean (SD) pack-years): flut/salm 42.0 (22.4), flut 41.5 (20.7), salm
43.7 (21.9), placebo 43.4 (22.4)
Mean % predicted FEV1 (SD): flut/salm 44.8 (14.7), flut 45.0 (13.6), salm 44.3 (13.8)
, placebo 44.2 (13.7)
Inclusion criteria: All participants had a baseline FEV1 before bronchodilation that
was 25% to 70% of that predicted, an increase of less than 10% of predicted FEV1
30 minutes after inhalation of 400 mcg salbutamol and a pre-bronchodilator FEV1/
forced vital capacity (FVC) ratio of 70% or less. Participants also had a history of at
least 10 pack-years of smoking, chronic bronchitis, at least one episode of acute COPD
symptom exacerbation per year in the previous 3 years and at least one exacerbation in
the year immediately before trial entry that required treatment with oral corticosteroids,
antibiotics or both
Exclusion criteria: We excluded individuals who had respiratory disorders other than
COPD, required regular oxygen treatment or had received systemic corticosteroids,
high doses of inhaled corticosteroids (> 1000 mcg daily beclomethasone dipropionate,
budesonide or flunisolide, or > 500 mcg daily fluticasone) or antibiotics in the 4 weeks
before the 2 week run-in period before the trial began
Interventions Run-in: During the 2-week run-in, participants stopped taking regular inhaled corti-
costeroids or long-acting beta2-agonists
Treatments:
1. Fluticasone/salmeterol 500/50 mcg twice daily
2. Fluticasone 500 mcg twice daily
3. Salmeterol 50 mcg twice daily
4. Placebo twice daily
Inhaler device: multi-dose dry powder inhaler (Diskus or Accuhaler)
Co-treatment: Inhaled salbutamol was used as relief medication throughout the study,
and regular treatment with anticholinergics, mucolytics and theophylline was allowed.
All non-COPD medications could be continued if the dose remained constant when
possible, and if their use would not be expected to affect lung function
Outcomes Primary: FEV1 at least 6 and 12 hours after study medication
Secondary: pretreatment FVC and post-treatment FEV1 and FVC, daily record card
symptoms, morning and evening PEF, use of relief medication, night-time awakenings,
acute exacerbations, health-related quality of life (SGRQ), adverse events and electro-
cardiology
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Calverley 2003 TRISTAN (Continued)
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation schedule generated by
the participant allocation for clinical trials
(PACT) programme to assign participants
to study treatment groups
Allocation concealment (selection bias) Unclear risk Every participating centre was supplied
with a list of participant numbers (assigned
toparticipants at their first visit) and a list of
treatment numbers. Participants who satis-
fied the eligibility criteria were assigned the
next sequential treatment number from the
list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Salmeterol and fluticasone combination,
salmeterol, fluticasone and placebo were
packaged in identical inhaler devices
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Adverse event information was obtained
at each clinic visit by recording sponta-
neously reported complaints from partici-
pants and asking general questions about
medical troubles and concomitant medica-
tions
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal rates varied from 25% in the
combination inhaler group to 39% in the
placebo group. These numbers are substan-
tially higher than the numbers of events re-
ported for any of the outcomes. The un-
known outcome of participant withdrawal
from the study could have a major impact
on the result
Selective reporting (reporting bias) Low risk All outcomes reported.Checkedwith study
authors
47Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Calverley 2003b
Methods Design: multi-centre, randomised, double-blind, parallel-group, placebo-controlled
study
12-Month treatment period
Conducted at 109 centres in 15 countries
Participants Participants: 1022 people were randomly assigned to budesonide/formoterol combina-
tion (254), budesonide (257), formoterol (255) and placebo (256)
Baseline characteristics:
Male %: bud/form 78, bud 74, form 75, placebo 75
Mean age (range), years: bud/form 64 (42 to 86), bud 64 (41 to 85), form 63 (41 to 84)
, placebo 65 (43 to 85)
Smoking history (mean pack-years): bud/form 33, bud 39, form 36, placebo 30
Mean % predicted FEV1 (SD): bud/form 36 (10), bud 36 (10), form 36 (10), placebo
36 (10)
Inclusion criteria:GOLD-definedCOPD (stages III and IV);≥ 40 years; COPD symp-
toms > 2 years; smoking history ≥ 10 pack-years; FEV1/FVC ≤ 70% pre-bronchodila-
tor; FEV1 ≤ 50% predicted; use of short-acting beta2-agonists as reliever medication; ≥
1 COPD exacerbation requiring oral corticosteroids/antibiotics 2 to 12 months before
first clinic visit
Exclusion criteria: history of asthma/rhinitis before 40 years of age; any relevant cardio-
vascular disorders; exacerbation of COPD requiring medical intervention within 4weeks
of run-in/during run-in phase; non-allowed medications: oxygen therapy; ICS (aside
from study medication), disodium cromoglycate, leukotriene-antagonists, 5-lipoxyge-
nase inhibitors, bronchodilators (other than study medication and terbutaline 0.5 mg as
needed), antihistamines, medication containing ephedrine, beta-blocking agents
Interventions Run-in: All participants received 30 mg oral prednisolone twice daily and 2 × 4.5 mg
formoterol twice daily (2 weeks)
Treatments:
1. Budesonide/formoterol 320/9 mcg twice daily
2. Budesonide 400 mcg twice daily
3. Formoterol 9 mcg twice daily
4. Placebo twice daily
Inhaler device: Turbuhaler
Co-treatment: terbutaline 0.5 mg as needed, courses of oral corticosteroids (maximum
3 weeks per course) and antibiotics in the event of exacerbations, parenteral steroids and/
or nebulised treatment (single injections/inhalations) at emergency visits
Outcomes Primary: time to first exacerbation and change in postmedication FEV1
Secondary: number of exacerbations, time to and number of oral corticosteroid-treated
episodes, change in postdose FEV1, slow VC, morning and evening PEF, quality of life
(SGRQ), symptoms, use of reliever medication and adverse events
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Calverley 2003b (Continued)
Random sequence generation (selection
bias)
Low risk Randomised trial (no other details-funded
by AstraZeneca and presumed to adhere to
usual methods)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (assume participants and
personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk An intention-to-treat analysis was used but
dropout was high in all groups (ranging
from 29% to 44%)
Selective reporting (reporting bias) Low risk All outcomes stated in the industry docu-
ment were reported in full. Checked with
study authors
Calverley 2007 TORCH
Methods Design: multi-centre, double-blind, placebo-controlled, randomised, parallel-group
study
Three-year treatment period
Conducted at 444 centres in 42 countries
Participants Participants: 6184 people were randomly assigned to fluticasone/salmeterol combina-
tion (1546), fluticasone (1551), salmeterol (1542) and placebo (1545)
Baseline characteristics:
Male %: flut/salm 75, flut 75, salm 76, placebo 76
Mean age (SD), years: flut/salm 65.0 (8.3), flut 65.0 (8.4), salm 65.1 (8.2), placebo 65.
0 (8.2)
Smoking history (mean (SD) pack-years): flut/salm 47.0 (26.5), flut 49.2 (28.6), salm
49.3 (27.7), placebo 48.6 (26.9)
Mean % predicted FEV1 (SD): flut/salm 44.3 (12.3), flut 44.1 (12.3), salm 43.6 (12.6)
, placebo 44.1 (12.3)
Inclusion criteria: current or former smokerswith at least a 10-pack-year history. Eligible
individuals were 40 to 80 years of age and had received a diagnosis of COPD, with a
pre-bronchodilator forced expiratory volume in one second (FEV1) of less than 60% of
predicted value, an increase in FEV1 with the use of 400 mcg of albuterol of less than
10% of the predicted value for that individual and a ratio of pre-bronchodilator FEV1
to forced vital capacity (FVC) equal to or less than 0.70
Exclusion criteria: diagnosis of asthma, current respiratory disorders other than COPD
(e.g. lung cancer, sarcoidosis, tuberculosis, lung fibrosis); chest x-ray indicating diagnosis
other than COPD that might interfere with the study (chest x-ray to be taken up to six
49Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Calverley 2007 TORCH (Continued)
months before entry to the treatment period); lung volume reduction surgery and/or
lung transplant, requirement for long-term oxygen therapy (LTOT is defined as oxygen
therapy prescribed for 12 or more hours per day) at start of study; receiving long-term
oral corticosteroid therapy defined as continuous use for longer than 6 weeks; serious,
uncontrolled disease (including serious psychological disorders) likely to interfere with
the study and/or likely to cause death within the 3-year study duration; received any other
investigational drugs in the last 4 weeks before entry to visit one; evidence of alcohol,
drug or solvent abuse; known or suspected hypersensitivity to inhaled corticosteroids,
bronchodilators or lactose; known deficiency of α1-antitrypsin
Interventions Run-in: Before the 2 week run-in period, all use of corticosteroids and inhaled long-
acting bronchodilators was stopped, but participants could continue other medications
for COPD
Treatments:
1. Fluticasone/salmeterol 500/50 mcg twice daily
2. Fluticasone 500 mcg twice daily
3. Salmeterol 50 mcg twice daily
4. Placebo twice daily
Inhaler device: multi-dose dry powder inhaler (Diskus or Accuhaler)
Co-treatment: all COPD medications except corticosteroids and inhaled long-acting
bronchodilators
Outcomes Primary: time to death from any cause by three years
Secondary: frequency of exacerbations, health status (SGRQ), postbronchodilator
spirometry and adverse events
Notes Funding: GSK
Clinicaltrials.gov ID: NCT00268216
Definition of pneumonia: Study authors state there was no prospective definition be-
cause the finding was unexpected
NOTE: Participants previously enrolled into TRISTAN (SFCB3024) may be recruited
to this trial 4 weeks after stopping their previous study medication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment with permuted blocks
with stratification
Allocation concealment (selection bias) Low risk Medication was allocated with the use of
three numbers as follows
1. Each participant who was screened
was allocated a participant number. This
number was unique to each participant
and was assigned from a list provided to
the site, in chronological order
2. Each participant who satisfied the
randomisation criteria was assigned a
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Calverley 2007 TORCH (Continued)
unique treatment number from the
interactive voice response (IVR) system,
which is part of the system for central
allocation of drug (SCAD). Once a
treatment number had been assigned to a
participant, it could not be assigned to
any other participant. Neither the
participant nor the investigator knew to
which treatment arm a participant had
been allocated
3. At each treatment visit, the
participant was provided with a treatment
pack. Each pack number was unique and
corresponded to the study medication
pack dispensed to the participant at the
visit
A specialist IVR system company, Clin-
Phone, managed this system. At the ran-
domisation visit (visit two), the principal
investigator or designee contacted the IVR
system through an automated 24-hour tele-
phone number; upon provision of a unique
personal identification number (PIN) and
answers to a series of questions, the site was
provided with the participant’s treatment
number as well as a pack number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither the subject nor the investigator
knew to which treatment arm a partici-
pant had been allocated. At each treatment
visit, each participant was issued with a
treatment pack containing DISKUS/AC-
CUHALER inhalers. The inhalers con-
tained one of the four treatments (salme-
terol/fluticasone propionate combination
product, fluticasone propionate, salmeterol
or placebo) in accordance with the ran-
domisation schedule. The inhalers were la-
belled in accordance with all applicable reg-
ulatory requirements. Each treatment pack
and study treatment inhaler was labelled
with the protocol number; storage and dos-
ing instructions were provided by GW Re-
search and Development
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The investigator is responsible for the de-
tection and documentation of events meet-
ing the definition of an AE or SAE as
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Calverley 2007 TORCH (Continued)
provided in this protocol. However, no
prospective definition of pneumonia is pro-
vided in the study protocol
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcome all-cause mortality: Partici-
pants who prematurely discontinue study
drug will be followed up for 156 weeks
from randomisation for assessment of sur-
vival. The risk of bias due to incomplete
outcome data for mortality is low
General
Withdrawal rates were high but fairly even
(with the exception of the placebo group,
which had an even higher withdrawal rate;
placebo 44%, LABA 36%, ICS 38% and
ICS/LABA 34%). However, for partici-
pants whowithdrew from the study prema-
turely, all data on exacerbations, health sta-
tus and lung function available at the time
of a participant’s withdrawal from the study
were included in the analysis. All efficacy
analyses were performed according to the
intention-to-treat principle
Selective reporting (reporting bias) Low risk All collected data reported. Checked with
study authors
Calverley 2010
Methods Design: double-blind, double-dummy, randomised, active-controlled, parallel-group
study
11-Month treatment period (48 weeks)
Conducted at 76 centres in 8 countries across Europe
Participants Participants: 481 people were randomly assigned to budesonide/formoterol combina-
tion (242) and formoterol (239)
Baseline characteristics:
Male %: bud/form 81.5, form 81.1
Mean age (SD), years: bud/form 64.1 (9.1), form 63.7 (8.8)
Smoking history (mean (SD) pack-years): bud/form 37.8 (14.6), form 39.7 (19.1)
Mean % predicted FEV1 (SD): bud/form 42.3 (6.0), form 42.5 (5.9)
Inclusion criteria: hospital outpatients with severe stable COPD according to the
GOLD guidelines; 40 years of age with a diagnosis of symptomatic COPD for > 2 years,
at least a 20-pack-year smoking history, a postbronchodilator FEV1 between 30% and
50% of predicted normal and at least 0.7 L absolute value and a predose FEV1/forced
vital capacity (FVC) of 0.7; at least one exacerbation requiring medical intervention
(oral corticosteroid and/or antibiotic treatment and/or need for a visit to an emergency
department and/or hospitalisation) within 2 to 12 months before the screening visit and
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the need to be clinically stable for the 2 months before study entry; change in FEV1 <
12% of predicted normal value 30minutes following inhalation of 200 mg of salbutamol
pMDI
Exclusion criteria: history of asthma, allergic rhinitis or other atopic disease, variabil-
ity of symptoms from day to day and frequent symptoms at night and early morning
(suggestive of asthma); receiving long-term oxygen therapy or having a lower respiratory
tract infection or having been hospitalised for an acute COPD exacerbation within two
months before screening or during the run-in period. Treatments with oral, injectable
or depot corticosteroids and antibiotics, long-acting antihistamines and changes in the
dose of an oral modified-release theophylline in the two months before screening and
during the run-in period were excluded
Interventions Run-in: During the 4-week run-in period, all non-permitted COPD treatments were
discontinued and eligible participants were treatedwith combination ipratropium/salbu-
tamol (20/100 mg, two inhalations three times daily)
Treatments:
1. Budesonide/formoterol 400/12 mcg twice daily
2. Formoterol 12 mcg twice daily
Inhaler device: dry powder inhaler
Co-treatment: not described
Outcomes Primary: change in predose morning FEV1 and mean rate of COPD exacerbations per
participant per year
Secondary: FVC, PEF, SGRQ total score, six-minute walking test, BMI, BODE index,
safety evaluations including ECG
Notes Funding: Chiesi Farmaceutici
Clinicaltrials.gov ID: NCT00476099
Definition of pneumonia: not defined
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation scheme followed a bal-
anced-block centre-stratified design and
was prepared via a computerised system
Allocation concealment (selection bias) Low risk Participants were centrally assigned, in each
centre, to one of the three treatment arms
at the end of the run-in period through
an Interactive voice/web response System
(IXRS)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk On each study day, participants took both
active medications and matched placebo
twice daily, to maintain blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk On each study day, participants took both
active medications and matched placebo
twice daily, to maintain blinding. In cases
of emergency, unbinding of the treatment
code was done through IXRS
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12.3% withdrew from the combination
group and 14.2% from the formoterol
group. Judged to be relatively low and even
between groups, and for the intention-to-
treat population, last observation carried
forward was used
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Choudhury 2005
Methods Design: randomised, double-blind, placebo-controlled trial
12-Month treatment period in total, but participants/clinicians could stop study inhalers
and return to usual (prerandomisation) steroid inhalers at any point during the study.
These participants remained in the study, continued completing their diary cards and
were followed up
Conducted at 31 general practices in East London and Essex, UK
Participants Participants: 260 people were randomly assigned to fluticasone (128) and placebo (132)
Baseline characteristics:
Male %: flut 48, placebo 56
Mean age (SD), years: flut 67.6 (8.9), placebo 67.3 (9.0)
Smoking history (mean (SD) pack-years): flut 40.0 (24.2), placebo 38.8 (22.3)
Mean % predicted FEV1 (SD): flut 53.2 (18.2), placebo 55.0 (17.1)
Inclusion criteria: Investigators searched the medical record database at each practise
to identify people 40 years of age and older, with a history of smoking, who had been
prescribed ICS for a minimum of six months. We invited people who fulfilled these
criteria to attend a recruitment interview. Individuals with lung function consistent
with international guidelines for the diagnosis of COPD were invited to join the study:
postbronchodilator FEV1 less than 80% predicted, FEV1/FVC ratio less than 70% and a
pre-bronchodilator to postbronchodilator change in FEV1 of less than 15%. Participants
with an FEV1 greater than 15% but with a volume change of less than 200 mL were also
included
Exclusion criteria: At interview, we excluded people if they were on long-term oral
corticosteroids, were not taking their prescribed ICS for at least four days a week or had
other chronic active lung disease or lung cancer
Interventions Run-in: two-week run-in period before randomisation, when participants stopped their
regular ICS
Treatments:
1. Fluticasone propionate 500 mcg twice daily
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2. Placebo twice daily
Inhaler device: Accuhaler
Co-treatment: General practitioners were advised to manage exacerbations according
to usual guidance with antibiotics and/or oral steroids. Decisions about stopping study
inhalers and returning to usual (prerandomisation) steroid inhalers were made by the
general practitioner and the participant. Participants who did return to their usual steroid
inhaler after randomisation remained in the study, continued completing their diary
cards and were followed up for one year
Outcomes Primary: COPD exacerbation frequency
Secondary: time to first exacerbation (from diary cards and medical records), reported
symptoms, peak expiratory flow rate and reliever inhaler use (from diary cards) and lung
function and health=related quality of life (at follow-up visits)
Notes Funding: The British Lung Foundation and Newham National Health Service Trust
Research and Development funded the study. GlaxoSmithKline provided the study in-
halers free of charge but was not involved in study design, data collection or analysis or
interpretation of results
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated with minimisa-
tion to intervention or control using the
programme MINIM v1.3. Minimisation
factors were age, smoking status, pretrial
weekly dose of ICS, self reported COPD
exacerbation frequency andpercentage pre-
dicted FEV1
Allocation concealment (selection bias) Low risk Inhalerswere given an alphanumerical code
to conceal allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study nurses and regular clinicians were
blind to allocation throughout the study.
Inhalerswere given an alphanumerical code
to conceal allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study nurses performed the measurements
and were blind to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Decisions about stopping study inhalers
and returning to usual (prerandomisation)
steroid inhalers were made by the general
practitioner and the participant. Partici-
pants who did return to their usual steroid
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inhaler after randomisation remained in
the study, continued completing their di-
ary cards and were followed up for one year
Selective reporting (reporting bias) High risk Key outcomes were not reported (e.g. total
mortality, breakdown of all and serious ad-
verse events). No reply from study authors
Dal Negro 2003
Methods Design: randomised, double-blind, parallel-group, pilot study
12-Month treatment period
Conducted at a single centre in Italy
Participants Participants: 12 people were randomly assigned to fluticasone/salmeterol combination
(6) and salmeterol alone (6)
Baseline characteristics:
Male %: flut/salm 83.3, salm 100
Age range (mean not reported), years: flut/salm 53 to 77, salm 55 to 78
Smoking history (mean (SD) pack-years): flut/salm 40.1 (6.3), salm 43.1 (5.3)
Mean % predicted FEV1 (SD): flut/salm 50 (2.0), salm 48 (5.6)
Inclusion criteria: basal FEV1 < 80% predicted normal value, but > 800 mL; FEV1/
FVC ratio < 70% predicted; FEV1 change of < 12% as a percentage of predicted normal
value following salbutamol 400 mg; regular treatment with oral theophylline 200 mg
bid and short-acting beta2-adrenergics prn for a period of at least six months; current
smokers or ex-smokers with a smoking history of at least 10 pack-years
Exclusion criteria: current evidence of asthma or other pulmonary diseases; regular
treatment with ICS; unstable respiratory disease requiring oral/parenteral corticosteroids
within four weeks before the beginning of the study; changes in COPD medication
in the last four weeks before entering the run-in period; upper or lower respiratory
tract infection within four weeks before the screening visit; unstable angina or unstable
arrhythmias; recent myocardial infarction or hearth failure; insulin-dependent diabetes
mellitus; neuropsychiatric disorders; concurrent use of medications that affected COPD
(e.g. beta-blockers) or interacted with methylxanthine products such as macrolides or
fluoroquinolones; known or suspected hypersensitivity to ICS, beta2-agonist or lactose;
evidence of alcohol abuse
Interventions Run-in: Patients entered a two-week run-in period during which they assumed their
regular treatment with theophylline and salbutamol as required
Treatments:
1. Fluticasone/salmeterol 250/50 mcg twice daily
2. Salmeterol 50 mcg twice daily
Participants were also randomly assigned to placebo (6), but this group was not included
in the current review because no group received fluticasone monotherapy
Inhaler device: Diskus
Co-treatment: theophylline and salbutamol as required
56Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dal Negro 2003 (Continued)
Outcomes Unclear which outcome was primary
Exacerbations per year, FEV1, morning PEF, daily symptom scores, use of rescue medi-
cation and adverse events
Notes Funding: unclear
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk At the end of the run-in, eligible partici-
pants will be randomly assigned to receive
one of the three double-blind treatments
(no other details and does not appear to be
industry funded)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Assigned to receive one of the three double-
blind treatments, all via Diskus
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) High risk Several key outcomes not reported (mor-
tality, adverse events). Difficulty contacting
study authors
Dransfield 2013
Methods Design: two replicate double-blind parallel-group trials
12-Month treatment period
Study one was conducted at 167 centres in 15 countries (Argentina, Australia, Canada,
Chile, Estonia, Germany, Italy, Mexico, Netherlands, Peru, Phillipines, South Africa,
Sweden, the United Kingdom and the United States). Study two was conducted at 183
centres in 15 countries
Participants Participants: 1622 people were randomly assigned in study one and 1633 in study two
to vilanterol 25 (818), fluticasone/vilanterol combination 50/25 (820), 100/25 (806)
and 200/25 (811)
Baseline characteristics:
Male %: Vil 58.0, F/Vil 50/25 58.0, F/Vil 100/25 56.2, F/Vil 200/25 57.6
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Mean age, years: Vil 63.6, F/Vil 50/25 63.7, F/Vil 100/25 63.8, F/Vil 200/25 63.7
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1: Vil 45.2, F/Vil 50/25 45.4, F/Vil 100/25 46.1, F/Vil 200/25
45.2
Inclusion criteria: Eligible patients were 40 years of age or older and had a history of
COPD, a smoking history of 10 or more pack-years, a ratio of forced expiratory volume
in one second (FEV1) to forced vital capacity of 0.70 or less after bronchodilators (and
an FEV1 of 70% or less of predicted) and a documented history of one or more moderate
or severe disease exacerbations in the year before screening
Exclusion criteria: Appendix listing the exclusion criteria and the drugs that were and
were not permissible for the study duration could not be located
Interventions Run-in: four weeks during which participants received open-label combination fluticas-
one propionate (250) and salmeterol (50) twice daily to establish adherence to treatment
and a stable baseline
Treatments:
1. Fluticasone furoate/vilanterol 50/25 mcg daily
2. Fluticasone furoate/vilanterol 100/25 mcg daily
3. Fluticasone furoate/vilanterol 200/25 mcg daily
4. Vilanterol 25 daily
Inhaler device: dry powder inhaler
Co-treatment: Appendix listing the exclusion criteria and the drugs that were and were
not permissible for the study duration could not be located
Outcomes Primary: annual rate of moderate and severe exacerbations
Secondary: time to first moderate or severe exacerbation; annual rate of exacerbations
requiring oral corticosteroids; predose AM FEV1
Notes Funding: GSK
Clinicaltrials.gov ID: NCT01009463 and NCT01017952
Definition of pneumonia: confirmed by chest x-ray
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The central randomisation schedule was
generated by the GSK statistics group,
which used a validated computerised sys-
tem (RandAll; GSK, London, UK)
Allocation concealment (selection bias) Unclear risk The statistician entered the parameters for
the randomisation but was masked to treat-
ment assignment and did not have access
to the master randomisation schedule until
the study was unmasked at database lock.
The Registration and Medication Order-
ing System (RAMOS; GSK, London, UK)
was used to register and randomly assign
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participants and assign drugs
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators were masked
to allocation, and the Ellipta dry powder
inhalerswere identical in appearance. Every
effort was made to ensure that the statistics
and programming department of GSK was
not unmasked to any treatment allocations
ahead of the database freeze
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and investigators were masked
to allocation, and the Ellipta dry powder
inhalerswere identical in appearance. Every
effort was made to ensure that the statistics
and programming department of GSK was
not unmasked to any treatment allocations
ahead of the database freeze
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout quite high but even between
groups (ranging from 23% to 31%). A gen-
eralised linear model was used for the in-
tention-to-treat analyses of each study, in-
cluding all randomly assigned participants
receiving at least one dose of study drug
(representing 100% of those randomly as-
signed)
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in the
published paper
Ferguson 2008
Methods Design: randomised, double-blind, parallel-group study
12-Month study period
Conducted at 94 research sites in the United States and Canada
Participants Participants: 782 people were randomly assigned to fluticasone/salmeterol combination
(394) and salmeterol alone (388)
Baseline characteristics:
Male %: flut/salm 58, salm 52
Mean age (SD), years: flut/salm 64.9 (9.0), salm 65.0 (9.1)
Smoking history (mean (SD) pack-years): flut/salm 58.5 (30.6), salm 54.4 (25.7)
Mean % predicted FEV1 (SD): flut/salm 32.8 (11.0), salm 32.8 (10.1)
Inclusion criteria:40years of age or olderwith a diagnosis ofCOPD, a cigarette smoking
history of greater than or equal to 10 pack-years, a prealbuterol FEV1/FVC of 0.70 or
less, an FEV1 of 50% of predicted normal or less and a history of 1 or more exacerbations
of COPD in the year before the study, which required treatment with oral corticosteroids
or antibiotics, or hospitalisation
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Exclusion criteria: diagnosis of asthma, a significant lung disease other than COPD,
a clinically significant and uncontrolled medical disorder including but not limited to
cardiovascular, endocrine or metabolic, neurological, psychiatric, hepatic, renal, gastric
and neuromuscular diseases, or had a COPD exacerbation that was not resolved at
screening
Interventions Run-in: four-week run-in period during which participants received open-label flutica-
sone/salmeterol 250/50 via Diskus twice daily
Treatments:
1. Fluticasone/salmeterol 250/50 mcg twice daily
2. Salmterol 50 mcg twice daily
Inhaler device: Diskus
Co-treatment: As-needed albuterol was provided for use throughout the study. Con-
current inhaled long-acting bronchodilators (beta2-agonist and anticholinergic), iprat-
ropium/albuterol combination products, oral beta-agonists, inhaled corticosteroids and
theophylline preparations were not allowed during the treatment period. Oral corticos-
teroids and antibiotics were allowed for the short-term treatment of COPD exacerba-
tions
Outcomes Primary: annual rate of moderate to severe exacerbations
Secondary: time to first moderate to severe exacerbation, annual rate of exacerbations re-
quiring oral corticosteroids, predose FEV1, diary records of dyspnoea, night-time awak-
enings due to COPD and use of supplemental albuterol
Notes Funding: GSK (ID SCO40043)
Clinicaltrials.gov ID: NCT00144911
Definition of pneumonia: no objective definition given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centre-based randomisation schedule
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout high and fairly even (30% vs
38%). Method of imputation described
only for the primary outcome (‘Endpoint
was defined as the last scheduled measure-
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ment of predose AM FEV1 during the 52-
week treatment period’)
Selective reporting (reporting bias) Low risk Checked GSK documents-all stated and
expected outcomes are reported
Fukuchi 2013
Methods Design: randomised, double-blind, parallel-group study
Three-month study period
Conducted at 163 centres in 9 countries (India, Japan, Republic of Korea, Phillipines,
Poland, Russian Federation, Taiwan, Ukraine and Vietnam)
Participants Participants: 1293 people were randomly assigned to budesonide/formoterol combina-
tion (636) and formoterol alone (657)
Baseline characteristics:
Male %: bud/form 87.6, form 90.3
Mean age (range), years: bud/form 64.5 (40 to 89), form 65.6 (40 to 87)
Smoking history (mean (range) pack-years): bud/form 43.4 (10 to 160), form 44.7 (0
to 300)
Mean % predicted FEV1 (range): bud/form 40.9 (12 to 79), form 40.8 (8-84)
Inclusion criteria:male and female individuals, 40 years of age or older with a diagnosis
of moderate to severe COPD for at least 2 years (pre-bronchodilator forced expiratory
volume in one second (FEV1) 50% of predicted normal or less, postbronchodilator
FEV1/forced vital capacity (FVC) < 70%), current or previous smoking history of 10 or
more pack-years and having at least one COPD exacerbation in 12 months
Exclusion criteria: history or current clinical diagnosis of asthma or atopic disease such
as allergic rhinitis; significant or unstable ischaemic heart disease, arrhythmia, cardiomy-
opathy, heart failure, uncontrolled hypertension or any other relevant cardiovascular dis-
order; experiencing a COPD exacerbation during the run-in period or within 4 weeks
before randomisation that required hospitalisation and/or a course of oral or parenteral
steroids; and requiring regular oxygen therapy
Interventions Run-in: 1- to 2-week run-in period during which participants received open-label for-
moterol 4.5 mg two inhalations twice daily and all other COPD medications were dis-
continued, with the exception of salbutamol 100 mg/actuation via pMDI
Treatments:
1. Budesonide/formoterol combination 320/9 mcg twice daily
2. Formoterol 9 mcg twice daily
Inhaler device: Turbuhaler
Co-treatment: Salbutamol 100 mg/actuation was available as reliever medication
throughout the treatment period. During the randomised treatment period, partici-
pants were not permitted to take any other medication for their COPD, including
beta2-agonists, anticholinergics, leukotriene receptor antagonists, medications contain-
ing ephedrine or xanthine-containing derivatives or inhaled corticosteroids
Outcomes Primary: change in predose FEV1 from baseline to treatment period
Secondary: 1 hour postdose FEV1, predose and one hour postdose FVC, COPD symp-
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toms, time to first COPD exacerbation, number of COPD exacerbations, health-related
quality of life on the SGRQ, morning and evening PEF, adverse events and vital signs
Notes Funding: AstraZeneca (ID: D589DC00007)
Clinicaltrials.gov ID: NCT01069289
Definition of pneumonia: pneumonia, brochopneumonia and bacterial pneumonia
counted as serious adverse events. Diagnosis not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned 1:1
to study treatment. No details of sequence
generation methods, but presumed to ad-
here to usual AstraZeneca methods
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk From clinicaltrials.gov: masking: double-
blind (participant, caregiver, investigator,
outcomes assessor)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk From clinicaltrials.gov: masking: double-
blind (participant, caregiver, investigator,
outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low and even between groups
Selective reporting (reporting bias) Low risk All outcomes were fully reported on clini-
cal.trials.gov and in the published report
GSK FCO30002 2005
Methods Design: multi-centre, randomised, placebo-controlled, double-blind trial
Three-month treatment period
Conducted at 32 centres in Germany
Participants Participants: 140 people were randomly assigned to salmeterol plus fluticasone (68) and
salmeterol plus placebo (69)
Baseline characteristics:
Male %: flut+salm 60.6, salm+placebo 71.2
Mean age (SD), years: flut+salm 61 (8), salm+placebo 63 (10)
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1 (SD): not reported
Inclusion criteria: documented history of COPD; male and female subjects 40 to 79
years of age; smokers and ex-smokers with a smoking history of ≥ 10 pack-years; FEV1
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40% to 80% of predicted, FEV1/FVC < 70% at visit 1 or 2; low reversibility of airway
obstruction at visit 1 or 2: increase in FEV1 (normal value) < 10% at 30 minutes after
inhalation of 200 mcg salbutamol; symptomatic COPDduring run-in as documented in
the participant diary: on≥ 5 days, symptom score was > 5 and/or salbutamol inhalation;
ability to correctly use the Mini-Wright Peak-Flow-Meter and the Diskus™ inhaler
Exclusion criteria: long-term oxygen therapy; use of inhaled or systemic corticosteroids
during the 8weeks before study entry; acute exacerbation, antibiotic treatment or hospital
stay within 4 weeks before study entry; use of beta blockers within two weeks before
study entry
Interventions Run-in: 2 weeks during which all participants received salmeterol 50 mcg twice daily as
bronchodilator treatment and salbutamol as rescue medication
Treatments:
1. Salmeterol 50 mcg plus fluticasone 500 mcg twice daily (and placebo tablets for 2
weeks)
2. Salmeterol 50 mcg plus placebo inhaler twice daily (and placebo tablets for 2 weeks)
A third group receiving oral prednisolone in combination with salmeterol was not in-
cluded in this review
Inhaler device: Diskus
Co-treatment: salbutamol as rescue medication
Outcomes Primary: change in FEV1
Secondary: Participants’ self assessment of exercise capacity and morning serum cortisol
concentrations
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomised (presumed to ad-
here to usual GSK methodology)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low and even between
groups (17.6% vs 14.5%). Full analysis set
(FAS) and per-protocol analyses were re-
ported, but only the FAS was extracted
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Selective reporting (reporting bias) Unclear risk All outcomes stated were reported. Pneu-
monia-related outcomeswere not reported.
GSK data request was not successful at the
time of publication
GSK FLTA3025 2005
Methods Design: randomised, double-blind, parallel-group, comparative trial
Six-month treatment period
Conducted at 55 centres in the United States
Participants Participants: 640 people were randomly assigned to fluticasone 250 (216), fluticasone
500 (218) and placebo (206)
Baseline characteristics:
Male %: flut250 72.2, flut500 66.1, placebo 68.0
Mean age (SD), years: flut250 65.2 (8.7), flut500 63.3 (10.0), placebo 64.8 (9.5)
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1 (SD): not reported
Inclusion criteria: Male or female individuals were eligible if they were diagnosed with
COPD; were at least 40 years of age; had a current or prior history of at least 20 pack-
years of cigarette smoking; had a history of cough productive of sputum on most days
for at least 3 months of the year, for at least 2 years that was not attributable to another
disease process; had a baseline FEV1 < 65% of predicted normal but > 0.70 L or FEV1
≤ 0.70 L and > 40% of predicted normal and FEV1/forced vital capacity (FVC) ratio
of < 0.70; had a score of ≥ 2 on the Modified Medical Research Council (MMRC)
Dyspnea Scale at screening and a score of ≥ 4 on the CBSQ at randomisation and had
not received systemic corticosteroids or high-dose inhaled corticosteroid therapy for at
least 6 months before screening
Exclusion criteria: current diagnosis of asthma, concurrent participation in a pulmonary
rehabilitation programme, respiratory disease other than COPD or other significant
concurrent disease, an abnormal and clinically significant ECG at screening and the
occurrence of a moderate or severe COPD exacerbation during the run-in period
Interventions Run-in: 2-week placebo run-in period
Treatments:
1. Fluticasone propionate 250 mcg twice daily
2. Fluticasone propionate 500 mcg twice daily
3. Placebo twice daily
Inhaler device: Diskus
Co-treatment: Concurrent use of the following respiratory medications was not al-
lowed: beta-agonists (other than salbutamol), cromolyns, corticosteroids (oral, inhaled
and intranasal), anti-leukotrienes and ipratropium. Concurrent use of theophylline was
allowed. Use of antibiotics for the treatment of up to three COPD exacerbations was
allowed
Outcomes Primary: morning predose FEV1
Secondary: Chronic Bronchitis Symptoms Questionnaire (CBSQ), Transition Dysp-
noea Index (TDI, exacerbations of COPD, participant-recorded daily morning PEF rate,
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supplemental salbutamol use, night-time awakenings and quality of life (CDRQ)
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised trial (GSK funded, likely to
be computerised randomisation schedule)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded trial (presumed partici-
pant and personnel/investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout high but even across groups. The
intent-to-treat (ITT) population consisted
of all randomly assigned participants who
received at least 1 dose of studymedication.
The ITT population was the primary pop-
ulation for all efficacy and safety analyses
Selective reporting (reporting bias) Low risk All outcomes were reported in the results
summary
GSK SCO100470 2006
Methods Design:multi-centre, randomised, double-blind, double-dummy, parallel-group design
6 month treatment period
Conducted at 135 centres in 20 countries (Australia (10), Bulgaria (5), Croatia (1), Czech
Republic (8), France (14), Germany (18), Greece (4), Italy (16), Latvia (5), Lithuania
(2), Netherlands (12), Philippines (3), Poland (5), Romania (3), Russian Federation (8)
, Slovakia (4), Slovenia (4), Sweden (4), Thailand (4) and United Kingdom (5))
Participants Participants: 1050 people were randomly assigned to fluticasone/salmeterol combina-
tion (518) and salmeterol alone (532)
Baseline characteristics:
Male %: flut/salm 78.4, salm 77.3
Mean age (SD), years: flut/salm 63.5 (9.4), salm 63.7 (9.0)
Smoking history (mean pack-years): not reported
Mean % predicted FEV1 (SD): not reported
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Inclusion criteria: male or female, 40 to 80 years of age with an established history
of GOLD stage II COPD; poor reversibility of airflow obstruction (defined as ≤ 10%
increase in FEV1 as a percentage of normal predicted value); minimum score of ≥ 2 on
the Modified Medical Research Council Dyspnoea Scale and a smoking history of at
least 10 pack-years. In addition, participants had to achieve a composite symptom score
of≥ 120 (out of 400 maximum score, measured using visual analogue scales) on at least
4 of the last 7 days of the run-in period, and to have a Baseline Dyspnoea Index (BDI)
score of ≤ 7 units at visit 2
Exclusion criteria: Participants would be excluded if they had asthma or atopic disease,
had a lung disease likely to confound the drug response other than COPD, had a recent
exacerbation (within 4 weeks of screening or during run-in); were receiving long-term
oxygen therapy or pulmonary rehabilitation or had taken tiotropium bromide, inhaled
corticosteroids or anti-leukotriene medication within 14 days of visit one
Interventions Run-in: run-in mentioned, unclear duration
Treatments:
1. Salmeterol/fluticasone propionate 50/250 mcg twice daily
2. Salmeterol 50 mcg twice daily
Inhaler device: Diskus accuhaler
Co-treatment: not reported
Outcomes Primary: FEV1, Transitional Dyspnoea Index (TDI)
Secondary: change from baseline in trough FEV1, change from baseline in trough FVC
and FVC/FEV1 ratio, TDI focal score, change from baseline in postdose FEV1, FVC
and FVC/FEV1 ratio, change from baseline in mean morning PEF, change from baseline
in St George’s Respiratory Questionnaire
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomised (assumed to ad-
here to usual GSK methodology)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described-only results summary avail-
able
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low and even between groups (11.
4% vs 13.9%). The ITT (intent-to-treat)
population (all participants randomly as-
signed and confirmed as having received at
least one dose of double-blind study med-
ication) was the primary population for
analysis of all efficacy and health outcome
variables; the safety population (identical
to the ITT population) was used for anal-
ysis of all safety variables
Selective reporting (reporting bias) Low risk All stated outcomes were reported and no
expected outcomes were missing
GSK SCO104925 2008
Methods Design: multi-centre, randomised, double-blind, placebo-controlled, parallel-group
study
Three-month treatment period
Conducted at 11 centres (4 centres in the Russian Federation, 4 centres in the United
States, 2 centres in Chile and 1 centre in Estonia)
Participants Participants: 161 people were randomly assigned to fluticasone (42), placebo (42),
fluticasone/salmeterol combination (39) and salmeterol (38)
Baseline characteristics:
Male %: flut 69.0, placebo 76.2, flut/salm 82.1, salm 78.9
Mean age (SD), years: flut 64.2 (11.2), placebo 65.2 (8.6), flut/salm 63.6 (7.8), salm
64.0 (9.3)
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1 (SD): not reported
Inclusion criteria: Males or females of non-childbearing potential 40 years of age or
older were eligible to participate if they had an established clinical history of COPD,
evidence of bronchitis as a component of theCOPDdisease and a current or prior history
of at least 10 pack-years of cigarette smoking. Participants had a measured postalbuterol
FEV1/FVC ≤ 70% at visit 1 (screening) and a measured postalbuterol FEV1 ≥ 30%
and ≤ 70% of predicted normal
Exclusion criteria: no other criteria reported
Interventions Run-in: not reported
Treatments:
1. Fluticasone propionate 500 mcg twice daily
2. Placebo twice daily
3. Fluticasone/salmeterol combination 500/50 mcg twice daily
4. Salmeterol 50 mcg twice daily
Inhaler device: not reported
Co-treatment: not reported
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Outcomes Primary: predose resistance difference between 5Hz and 15Hz (R5 to R15) asmeasured
by IOS
Secondary: predose- and 2 hours postdose low-frequency reactance area (AX); 2 hours
postdose R5 to R15; postalbuterol computed tomography (CT) parameters of area of
airway wall and area of airway lumen
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to treatment (assumed
to adhere to GSK protocol)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal uneven between groups but all
less than 20%. ITT analysis used
Selective reporting (reporting bias) Low risk All outcomes reported in detail
GSK SCO30002 2005
Methods Design: multi-centre, randomised, double-blind, parallel-group, placebo-controlled
study
12-Month treatment period
Conducted at 49 centres in Italy and 7 in Poland
Participants Participants: 256 people were randomly assigned to fluticasone (131) and placebo (125)
Baseline characteristics:
Male %: flut 83, placebo 80
Mean age (SD), years: flut 64.6 (8.7), placebo 65.7 (9.0)
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1 (SD): not reported
Inclusion criteria:male or female individuals aged > 40 years with an established clinical
history of COPD; participants who demonstrated at visit 1 a pre-bronchodilator baseline
FEV1/VC < 88% for men and < 89% for women of predicted normal values and FEV1
≤ 70% of predicted normal value, but > 800 mL; participants who demonstrated at visit
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1, poor reversibility of airflow obstruction, defined as an increase in FEV1 < 10% of the
normal predicted FEV1 value (or < 200 mL from baseline), 30 minutes after inhalation
of 400 mcg salbutamol via MDI; current smokers or ex-smokers with a smoking history
of at least 10 pack-years
Exclusion criteria: as above
Interventions Run-in: two-week run-in during which all inhaled corticosteroids and long-acting beta2-
agonists were discontinued
Treatments:
1. Fluticasone propionate 500 mcg twice daily
2. Placebo twice daily
Inhaler device: metered-dose inhaler
Co-treatment: not reported
Outcomes Primary: time to first moderate or severe exacerbation
Secondary: number and severity of exacerbations, withdrawals due to exacerbations,
clinic FEV1, VC, FEV1/VC, daily record card symptoms, PEFR, distance walked in the
six-minute walk test (SWT), perceived breathlessness before and after SWT, quality of
life (SGRQ), use of relief medication, adverse events, SAEs on therapy
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to treatment. No de-
tails given but assumed to adhere to GSK
methodology
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout high at 26%and 32% for ICS and
placebo, respectively. The safety popula-
tion/Intent-to-treat (ITT) population con-
sisted of all randomly assigned participants
who took study medication (all of those
randomly assigned)
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Selective reporting (reporting bias) Low risk All outcomes stated in the GSK summary
were reported in detail
GSK SCO40041 2008
Methods Design: randomised, double-blind, parallel-group trial
Three-year treatment period
Conducted at 31 centres in the United States
Participants Participants: 186 people were randomly assigned to fluticasone/salmeterol combination
(92) and salmeterol alone (94)
Baseline characteristics:
Male %: flut/salm 59.8, salm 62.8
Mean age (SD), years: flut/salm 65.4 (8.4), salm 65.9 (9.5)
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1 (SD): not reported
Inclusion criteria: male/female participants with an established clinical history of
COPD (including a history of exacerbations), a baseline (pre-bronchodilator) FEV1 <
70% of the predicted normal value, a baseline (pre-bronchodilator) FEV1/FVC ratio of
70%, at least one evaluable native hip and a smoking history of ≥ 10 pack-years
Exclusion criteria: no information
Interventions Run-in: not reported
Treatments:
1. Fluticasone propionate/salmeterol 250/50 mcg twice daily
2. Salmeterol 50 mcg twice daily
Inhaler device: Diskus
Co-treatment: ’permitted COPD therapy’ unclear
Outcomes Primary: change in bone mineral density at the lumbar spine
Secondary: change in bone mineral density at the hip, adverse events, serious adverse
events, fatal SAEs
Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to treatment (no spe-
cific information but assumed to adhere to
GSK methods)
Allocation concealment (selection bias) Unclear risk Not described
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind (presumed participant and
personnel/investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal very high in both groups (39%
and 41%)
Selective reporting (reporting bias) Low risk All outcomes described in the GSK sum-
mary were reported
Hanania 2003
Methods Design: randomised, double-blind, multi-centre, placebo-controlled study
Six-month treatment period
Conducted at 76 investigative sites in the United States
Participants Participants: 723 people were randomly assigned to fluticasone/salmeterol combination
(178), fluticasone (183), salmeterol (177) and placebo (185)
Baseline characteristics:
Male %: flut/salm 61, flut 66, salm 58, placebo 68
Mean age (range), years: flut/salm 63 (40 to 87), flut 63 (40 to 84), salm 64 (42 to 87),
placebo 65 (40 to 81)
Smoking history (median (range) pack-years): flut/salm 53 (20 to 220), flut 60 (20 to
162), salm 57 (20 to 224), placebo 56 (20 to 165)
Mean % predicted FEV1 (SD): flut/salm 41 (11), flut 42 (11), salm 42 (12), placebo 42
(12)
Inclusion criteria: Participants were > 40 years of age, were current or former smokers
with a > 20 pack-year history and had received a diagnosis of COPD, as defined by the
American Thoracic Society. Inclusion criteria required a baseline FEV1/FVC ratio of <
70% and a baseline FEV1 of < 65% of predicted normal, but > 0.70 L (or if < 0.70
L, then > 40% of predicted normal). Participants were required to have symptoms of
chronic bronchitis and moderate dyspnoea
Exclusion criteria: current diagnosis of asthma; use of oral corticosteroids within the
past six weeks; abnormal clinically significant ECG; long-term oxygen therapy; moderate
or severe exacerbation during the run-in period; and any significant medical disorder
that would place the individual at risk, interfere with evaluations or influence study
participation
Interventions Run-in: two-week, single-blind run-in periodduringwhich participants received placebo
and albuterol and discontinued use of corticosteroids and bronchodilators with the
exception of stable regimens of theophylline
Treatments:
1. Fluticasone propionate 250 mcg twice daily
2. Salmeterol 50 mcg twice daily
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3. Fluticasone/salmeterol 250/50 mcg twice daily
4. Placebo twice daily
Inhaler device: Diskus
Co-treatment: Participants were given as-needed albuterol and were not allowed corti-
costeroids or bronchodilators, with the exception of stable regimens of theophylline
Outcomes Primary: predose and 2 hours postdose FEV1
Secondary: morning PEF, dyspnoea (TDI), supplemental albuterol use, health status
(CRDQ), Chronic Bronchitis Symptom Questionnaire, exacerbations, adverse events,
ECG, vital signs and clinical laboratory evaluations
Notes Funding: GSK (ID: SFCA3007)
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by reversibil-
ity (noother info butGSK sponsored-likely
to adhere to GSK methods)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind trial (presumed participant
and personnel/investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively high but even across
groups. To account for participant with-
drawals, endpoint was used as the primary
time point and was defined as the last on-
treatment post-baseline assessment exclud-
ing any data from the discontinuation visit
Selective reporting (reporting bias) Low risk Compared with GSK result summary and
protocol-no evidence of publication bias
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Methods Design: double-blind, placebo-controlled study
Three-month study period
Conducted at the London Chest Hospital
Participants Participants: 36 people were randomly assigned to fluticasone (17) and placebo (19)
Baseline characteristics:
Male %: flut 81.3, placebo 92.9
Mean age (SD), years: flut 64.7 (6.2), placebo 64.7 (6.5)
Smoking history (mean (SD) pack-years): flut 64.9 (50.3), placebo 60.3 (46.6)
Mean % predicted FEV1 (SD): flut 46.2 (13.6), placebo 45.5 (16.1)
Inclusion criteria: male or female, 40 to 75 years of age, current smokers or ex-smokers
with more than 20 pack-years of smoking, non-atopic and with an FEV1 25% to 80%
of predicted, which improved by less than 15% over baseline and 200 mL after 200 mcg
inhaled salbutamol
Exclusion criteria: Individuals with severe concurrent medical problems, psychological
impairment on immunosuppressive treatment or with a chest infection within 8 weeks
were excluded. Participants who were already taking inhaled steroids had the drug with-
drawn and had to be stable for at least 8 weeks before the first biopsy
Interventions Run-in: After recruitment, participants had a run-in period of 8 weeks to ensure that
they were stable before the first bronchoscopy
Treatments:
1. Fluticasone 500 mcg twice daily
2. Placebo twice daily
Inhaler device: multi-dose dry powder Accuhaler
Co-treatment:All relievermedications (inhaled beta2-agonist, anticholinergics and theo-
phylline) were continued as before
Outcomes Primary: bronchoscopy
Secondary: spirometry (FEV1 and VC), biopsy processing and counts, symptom scores
Notes Funding: Glaxo-Wellcome and Departmental Funds
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to FP
or P in a double-blind manner using a ran-
dom numbers table
Allocation concealment (selection bias) Low risk Randomly assigned in a double-blindman-
ner
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Seven of the randomly assigned partici-
pants did not appear in the analyses (18.
9%) but were counted in the adverse event
data relevant for this review
Selective reporting (reporting bias) High risk Serious adverse events not reported. No re-
ply from study authors at time of publica-
tion
Kardos 2007
Methods Design: randomised, double-blind, parallel-group study
10-Month study period
Conducted at 95 respiratory centres in Germany
Participants Participants: 994 people were randomly assigned to fluticasone/salmeterol combination
(507) and salmeterol alone (487)
Baseline characteristics:
Male %: flut/salm 74.0, salm 77.6
Mean age (SD), years: flut/salm 63.8 (8.3), salm 64.0 (8.2)
Smoking history (mean pack-years): flut/salm 36.8, salm 37.0
Mean % predicted FEV1 (SD): flut/salm 40.4 (8.9), salm 40.3 (8.5)
Inclusion criteria: outpatients with postbronchodilator FEV1 < 50% predicted, FEV1/
FVC of 70% predicted or less, age 40 years or older, smoking history of 10 or more
pack-years and a documented history of two or more moderate to severe exacerbations
during the year before the study
Exclusion criteria: IndividualswithCOPDexacerbations, hospital admissions or change
in COPD therapy during the 4 weeks before visit one or during the 4-week run-in period
were excluded. Those with asthma, significant lung diseases other than COPD and need
for long-term oxygen therapy or long-term systemic steroid use were also excluded
Interventions Run-in: four weeks
Treatments:
1. Salmeterol/fluticasone 50/500 mcg twice daily
2. Salmeterol 50 mcg twice daily
Inhaler device: Diskus
Co-treatment: Inhaled salbutamol was used as relievermedication, and regular treatment
with short-acting bronchodilators, antioxidants/mucolytics, short-acting oral beta2-ag-
onists and theophylline was permitted
Outcomes Primary: number of exacerbations
Secondary: Time to first exacerbation, pre-bronchodilator PEF, postbronchodilator
FEV1, SGRQ, symptoms and breathlessness, reliever medication use and use of other
COPD medications were recorded on diary cards
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Notes Funding: GSK
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Consecutive numbers assigned to partic-
ipants determined the blinded treatment
based on a centrally generated list with
blocks of six
Allocation concealment (selection bias) Low risk Randomisation list was centrally generated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind treatment (pre-
sumed participants and personnel/investi-
gators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar withdrawal rates in each group.
ITT included 99.6% of the randomly as-
signed population (4 participants were ex-
cluded as the result of a randomisation er-
ror)
Selective reporting (reporting bias) Unclear risk Unable to locate prospective trial registra-
tion to check that all outcomes were re-
ported. Study author contacted and for-
warded request to GSK-no data were pro-
vided in time for publication
Kerwin 2013
Methods Design: randomised, multi-centre, placebo-controlled, parallel-group trial
Six-month treatment period
Conducted at 221 centres in nine countries (Chile, Estonia, Germany, Japan, Korea,
Phillipines, Poland, Russian Federation and the United States)
Participants Participants: 1030 people were randomly assigned to placebo (207), fluticasone furoate
100 mcg (206), vilanterol 25 mcg (205), fluticasone furoate 50 mcg and vilanterol
combination (206) and fluticasone furoate 100 mcg and vilanterol combination (206)
Baseline characteristics:
Male %: placebo 68, flut100 64, vil 68, flut50/vil 66, flut100/vil 67
Mean age (SD), years: placebo 62.1, flut100 62.7, vil 63.4, flut50/vil 62.8, flut100/vil
62.3
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Smoking history (mean (SD) pack-years): placebo 45.6, flut100 46.2, vil 47.6, flut50/
vil 44.2, flut100/vil 46.6
Mean % predicted FEV1 (SD): placebo 42.4, flut10041.5, vil 44.5, flut50/vil 42.5,
flut100/vil 42.3
Inclusion criteria: over 40 years of age and have a clinical diagnosis of COPD, a smoking
history of 10 pack-years, a postbronchodilator FEV1/forced vital capacity (FVC) ratio
of less than or equal to 0.70, a postbronchodilator FEV1 less than or equal to 70%
predicted (NHANES III) and a score of greater than or equal to 2 on the Modified
Medical Research Council Dyspnoea Scale (mMRC). A history of COPD exacerbations
was not required for individuals to be eligible to enter the study. Albuterol reversibility
was assessed at the screening visit, and both reversible and non-reversible individuals
were eligible to enter the study
Exclusion criteria: current diagnosis of asthma or other non-COPD respiratory disor-
ders; lung volume reduction surgery within 12 months of visit one; poorly controlled
COPD, defined as acute worsening of COPD requiring patient-managed therapy with
corticosteroids or antibiotics or treatment prescribed by a physician within 6 weeks be-
fore visit 1; hospitalisation due to poorly controlled COPD within 12 weeks before visit
1; lower respiratory tract infection that required the use of antibiotics within 6 weeks be-
fore visit 1; the need for long-term oxygen therapy or nocturnal oxygen therapy (greater
than or equal to 12 hours/d)
Interventions Run-in: 2-week, single-blind run-in period during which participants received placebo
once daily in the morning via a dry powder inhaler that contains two strips
Treatments:
1. Fluticasone furoate 100 mcg daily
2. Vilanterol 25 mcg daily
3. Fluticasone 50 mcg/ vilanterol 25 mcg daily
4. Fluticasone 100 mcg/ vilanterol 25 mcg daily
5. Placebo
Inhaler device: dry powder inhaler
Co-treatment: Albuterol, ipratropium (provided that the person was on a stable dose
from the screening visit throughout the study), mucolytics, antibiotics for short-term
treatment, cough suppressants for short-term treatment, intranasal decongestants and
corticosteroids, flu and pneumonia vaccines, MAOIs, medications for other disorders as
long as the dose remained constant whenever possible and their use were not expected
to affect lung function
Outcomes Primary: weighted mean FEV1 (0 to 4 hours postdose) on day 168 to assess bronchodi-
lation by FF/VI and VI (vs placebo) and FF/VI vs FF; and the change from baseline in
trough (23 to 24 hours postdose) FEV1 on day 169 to assess the 24-hour effect of VI
and to determine the contribution of FF to lung function (i.e. FF/VI vs VI)
Secondary: CRQ self administered standardised dyspnoea domain on day 168, various
FEV1 parameters, PEF, symptommeasures, adverse events, exacerbations andpneumonia
events
Notes Funding: GSK (ID: HZC112206)
Clinicaltrials.gov ID: NCT01053988
Definition of pneumonia: presumptive diagnosis or radiographically confirmed
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated using a validated computerised sys-
tem (RandAll; GlaxoSmithKline, London,
UK)
Allocation concealment (selection bias) Low risk Participants were randomly assigned using
the Registration and Medication Ordering
System (RAMOS; GlaxoSmithKline, Lon-
don UK) to register and randomly assign
the participant and to receive medication
assignment information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Protocol stated that the study medication
was double-blind for participant and inves-
tigator
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in protocol. Some details in sup-
plementary material about outcome asses-
sors but unclear who was blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was quite high but even across
groups (26.7% to 33.3%). ITT population
used
Selective reporting (reporting bias) Low risk All stated outcomes were available in full in
the published report and on clinicaltrials.
gov
Lapperre 2009
Methods Design: double-blind, parallel, 4-group, placebo-controlled, randomised design
2.5-Year treatment period
Conducted at 2 centres in the Netherlands
Participants Participants: 55 people were randomly assigned to fluticasone (26) and placebo (29)
Baseline characteristics:
Male %: flut 88.5, placebo 83.3
Mean age (SD), years: flut 62 (8), placebo 59 (8)
Smoking history (mean (range) pack-years): flut 44 (31 to 55), placebo 42 (34 to 54)
Mean % predicted FEV1 (SD): flut 57 (9.9), placebo 54 (8.3)
Inclusion criteria: 45 to 75 years of age, were current or former smokers, had smoked
for 10 or more pack-years and had lung function levels compatible with Global Initiative
for Chronic Obstructive Lung Disease (GOLD) stages II and III
Exclusion criteria: asthma and receipt of ICS within 6 months before random assign-
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ment. Important co-morbid conditions
Interventions Run-in: not reported
Treatments:
1. Fluticasone 500 mcg twice daily
2. Placebo twice daily
Inhaler device: Diskus dry powder inhaler
Co-treatment: short-acting bronchodilators
Outcomes Primary: inflammatory cell counts in bronchial biopsies and induced sputum
Secondary: postbronchodilator spirometry, hyperresponsiveness tomethacholine PC20,
dyspnoea score by the MRC scale, health status by the SGRQ and the Clinical COPD
Questionnaire
Notes Funding: Netherlands Asthma Foundation, both centres and GSK
Clinicaltrials.gov ID: NCT00158847
Definition of pneumonia: confirmed by chest x-ray
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk At entry, an independent randomisation
centre provided participant and medica-
tion numbers by using a minimisation
procedure that balanced treatment groups
for centre, sex, smoking status, FEV1/
IVC 60% and methacholine PC20 (the
provocative concentration of methacholine
that causes a 20% decrease in FEV1) 2 mg/
mL)
Allocation concealment (selection bias) Low risk An independent randomisation centre pro-
vided participant and medication numbers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study medications were individually num-
bered, and we used Diskus dry pow-
der inhalers (GlaxoSmithKline, Zeist, The
Netherlands) with 60 doses per inhaler; all
active treatment medications and placebo
were identical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal rates were very high compared
with the numbers of events for the different
outcomes. Per-protocol analysis was used
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Selective reporting (reporting bias) Low risk Data for several outcomes not available
from the published report, but study au-
thors provided data upon request
Laptseva 2002
Methods Design: randomised, double-blind, parallel-group study
Six-month treatment period
Participants Participants: 49 people were randomly assigned to budesonide (25) and placebo (24)
Baseline characteristics: none reported-abstract only
Inclusion criteria: individuals between 40 and 65 years of age, FEV1 40% to 60% of
predicted normal, FEV1/VC < 55%, bronchodilator reversibility < 15%
Exclusion criteria: not reported
Interventions Run-in: not reported
Treatments:
1. Budesonide 400 mcg twice daily
2. Placebo
Inhaler device: not reported
Co-treatment: All participants received anticholinergic drug and methylxanthine or
short-acting beta2 agent
Outcomes Number and severity of exacerbations, FEV1, FVC, diary card symptoms, PEFR
Notes Abstract only
Funding: not reported
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided
Selective reporting (reporting bias) High risk Only abstract available. Outcomes could
not be used. Could not find contact infor-
mation for study authors
Mahler 2002
Methods Design: randomised, double-blind, placebo-controlled, parallel-group,multi-centre trial
6 -month treatment period
Conducted at 65 centres
Participants Participants: 674 people were randomly assigned to fluticasone (168), placebo (181),
fluticasone/salmeterol combination (165) and salmeterol alone (160)
Baseline characteristics:
Male %: flut 61, placebo 75, flut/salm 62, salm 64
Mean age (range), years: flut 64.4 (42 to 82), placebo 64 (44 to 90), flut/salm 61.9 (40
to 86), salm 63.5 (40 to 84)
Smoking history (median (range) pack-years): flut 54 (20 to 200), placebo 60 (20 to
165), flut/salm 55 (15 to 150), salm 52.5 (20 to 193)
Mean % predicted FEV1 (no SD reported): flut 41, placebo 41, flut/salm 41, salm 40
Inclusion criteria: baseline FEV1/FVC of 70% or less and baseline FEV1 of less than
65% of predicted but more than 0.70 L. Participants were required to have daily cough
productive of sputum for 3 months of the year for 2 consecutive years and dyspnoea
Exclusion criteria: Specific exclusion criteria were current diagnosis of asthma, oral cor-
ticosteroid use within the past 6 weeks, abnormal clinically significant electrocardiogram,
long-term oxygen therapy, moderate or severe exacerbation during the run-in and any
clinically significant medical disorder
Interventions Run-in: 2-week, single-blind, run-in period during which participants received placebo
via Diskus on an as-needed basis and discontinued use of corticosteroids and bron-
chodilators, with the exception of stable regimens of theophylline
Treatments:
1. Fluticasone 500 mcg twice daily
2. Placebo twice daily
3. Fluticasone/Salmeterol combination 500/50 mcg twice daily
4. Salmeterol 50 mcg twice daily
Inhaler device: Diskus
Co-treatment: as needed albuterol and stable regimens of theophylline
Outcomes Primary: change in predose FEV1 values and change in 2-hour postdose FEV1 values
Secondary:morning and evening PEF, supplemental albuterol use, dyspnoea as assessed
by the TDI, Chronic Bronchitis Symptom Questionnaire, exacerbations defined by
treatment, health status on the Chronic Respiratory Disease Questionnaire, adverse
events, 24-hour Holter monitoring and vital signs
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Notes Funding: GSK (protocol number SFCA3006)
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by reversibil-
ity and investigative site to ensure balance
between treatment groups at each site and
in terms of the number of reversible par-
ticipants (no other details, industry-spon-
sored)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipant and personnel/investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk 17participants at one investigative sitewere
not evaluable because of poor study prac-
tices, and of the remaining 674 partici-
pants, 645 had an evaluable baseline assess-
ment. A total of 234 participants were dis-
continued from the study (between 28%
and 40% across groups)
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were re-
ported in detail. Only one secondary out-
come was not available
Martinez 2013
Methods Design: multi-centre, randomised, stratified (by smoking status), placebo-controlled,
double-blind, parallel-group study
6 month treatment period
Conducted at 145 study centres in 8 countries (CzechRepublic, Germany, Japan, Poland,
Romania, Russian Federation, Ukraine and the United States)
Participants Participants: 1224 people were randomly assigned to fluticasone furoate 100 mcg (204)
, fluticasone furoate 200 mcg (203), placebo (205), fluticasone furoate 100 mcg and
vilanterol combination (204), fluticasone furoate 100 mcg and vilanterol combination
(205) and vilanterol (203)
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Baseline characteristics:
Male %: flut100 74, flut200 74, placebo 74, flut100/vil 71, flut200/vil 67, vil 74
Mean age (SD), years: flut100 61.8 (8.3), flut200 61.8 (9.0), placebo 61.9 (8.1), flut100/
vil 61.9 (8.8), flut200/vil 61.1 (8.6), vil 61.2 (8.6)
Smoking history (mean (SD) pack-years): flut100 39.8 (21.3), flut200 43.5 (22.5),
placebo 45.7 (25.8), flut100/vil 42.8 (23.9), flut200/vil 41.5 (23.4), vil 42.0 (23.3)
Mean % predicted FEV1 (SD): flut100 48.4 (12.2), flut200 47.1 (12.0), placebo 48.3
(12.7), flut100/vil 48.1 (12.9), flut200/vil 47.1 (12.8), vil 48.5 (12.9)
Inclusion criteria: clinical diagnosis of COPD, 40 years of age or older, smoking history
of 10 or more pack-years, postbronchodilator FEV1/ forced vital capacity (FVC) ratio of
0.70 or less, postbronchodilator FEV1 70% predicted or less (NHANES III) and score
of 2 or higher on theModified Medical Research Council Dyspnoea Scale (mMRC). No
prior history of COPD exacerbations was required for individuals to be eligible to enter
the study. Reversibility to albuterol was assessed at the screening visit; both reversible
and non-reversible individuals were eligible to enter the study
Exclusion criteria: any respiratory disorder other than COPD; lung volume reduction
surgery within 12 months of screening; acute worsening (participant-managed corticos-
teroid or antibiotic treatment or physician prescription) of COPD within six weeks of
screening, hospitalisation for COPD over 12 weeks or lower respiratory tract infection
that required the use of antibiotics in the 6 weeks before screening; the need for long-
term oxygen therapy or nocturnal oxygen therapy (12 or more hours/d)
Interventions Run-in: 2-week, single-blind run-in period during which participants received placebo
once daily in the morning via a dry powder inhaler (DPI) that contained two strips
Treatments:
1. Fluticasone furoate 100 mcg daily
2. Fluticasone furoate 200 mcg daily
3. Placebo
4. Fluticasone furoate 100 mcg/vilanterol 25 mcg daily
5. Fluticasone furoate 200 mcg/vilanterol 25 mcg daily
6. Vilanterol 25 mcg
Inhaler device: dry powder inhaler
Co-treatment: albuterol, ipratropium (provided that the person was on a stable dose
from the screening visit throughout the study), mucolytics, antibiotics for short-term
treatment, cough suppressants for short-term treatment, intranasal decongestants and
corticosteroids, flu and pneumonia vaccines, MAOIs, medications for other disorders
as long as the dose remained constant whenever possible and when their use was not
expected to affect lung function
Outcomes Primary: weighted mean FEV1 (zero to four hours postdose) on day 168 to assess
bronchodilation by FF/VI andVI (vs placebo) and FF/VI versus FF; change frombaseline
in trough (23 to 24 hours postdose) FEV1 on day 169 to assess the 24-hour effect of VI
and to determine the contribution of FF to lung function (i.e. FF/VI vs VI)
Secondary: CRQ self administered standardised dyspnoea domain on day 168, various
FEV parameters, PEF, symptommeasures, adverse events, exacerbations and pneumonia
events
Notes Funding: GSK (ID: HZC112207)
Clinicaltrials.gov ID: NCT01054885
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Definition of pneumonia: presumptive diagnosis or radiographically confirmed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated using a validated computerised sys-
tem (RandAll; GlaxoSmithKline, London,
UK)
Allocation concealment (selection bias) Low risk Participants were randomly assigned using
the Registration and Medication Ordering
System (RAMOS; GlaxoSmithKline, Lon-
don, UK) to register and randomly assign
the participant and to receive medication
assignment information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Protocol stated that the study medication
was double-blind for participant and inves-
tigator
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in protocol. Some details in sup-
plementary material about outcome asses-
sors but unclear who was blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout in all groups was less than 30%
(range 20.1% to 29.4%) and an ITT anal-
ysis was used
Selective reporting (reporting bias) Low risk All stated outcomes were available in full in
the published report and in supplementary
tables
Mirici 2001
Methods Design: randomised, placebo-controlled, double-blind, parallel-group study
Three-month treatment period
Conducted at a single centre in Turkey
Participants Participants: 50 people were randomly assigned to budesonide (25) and placebo (25)
Baseline characteristics:
Male %: bud 70, placebo 80
Mean age (SD), years: bud 51.8 (9.5), placebo 54.5 (10.3)
Smoking history (mean (SD) pack-years): bud 21.7 (12.5), placebo 31.3 (19.1)
Mean % predicted FEV1 (SD): bud 64.1 (6.5), placebo 59.9 (8.2)
Inclusion criteria: FEV1 < 70%, FEV1 reversibility after inhalation of terbutaline from a
Turbuhaler of less than 15% of pre-bronchodilator FEV1. All participants were smokers
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who refused or failed a programme to quit smoking
Exclusion criteria: long-term treatment with oral or inhaled corticosteroids within 6
months of study entry, respiratory tract infection in the previous 3 months, pregnancy
or lactation and the presence of other serious systemic disease
Interventions Run-in: not reported
Treatments:
1. Budesonide 400 mcg twice daily
2. Placebo twice daily
Inhaler device: Turbuhaler
Co-treatment: Beta2-agonists of all kinds, theophylline and mucolytics were allowed.
Inhaled corticosteroids other than studymedication and oral or parenteral corticosteroids
were not allowed
Outcomes Spirometry and sputum cell analysis
Notes Funding: unclear
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence was computer-
generated at theResearchCentre of the Fac-
ulty of Medicine
Allocation concealment (selection bias) Low risk Randomisation was masked and case num-
bers were allocated in consecutive order
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind. All inhalers had
the same appearance and did not have drug
labels
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All spirometric indices and sputum cell
analyses were performed at baseline and af-
ter treatment, blind to the clinical details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Equal and fairly low dropout per group,
values not imputed
Selective reporting (reporting bias) High risk Key expected outcomes were not reported
(mortality and adverse events).Namedout-
comes were well reported. No reply from
authors at the time of publication
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Ozol 2005
Methods Design: randomised, double-blind, placebo-controlled design
Six-month treatment period
Conducted at a single centre in Turkey
Participants Participants: 26 people were randomly assigned to budesonide (13) and placebo (13)
Baseline characteristics:
Male %: bud 84.6, placebo 53.8
Mean age (SD), years: bud 64.9 (6.1), placebo 65.9 (8.1)
Smoking history (mean (SD) pack-years): bud 45.6 (22.2), placebo 44.4 (23.0)
Mean % predicted FEV1 (SD): bud 61.1 (9.7), placebo 57.3 (11.2)
Inclusion criteria: (1) FEV1/FVC <70% and FEV1 50% of predicted value, (2) re-
versibility with inhaled beta2-agonists (400 mg salbutamol) of less than 200 mL or less
than 12% of predicted FEV1, (3) stable COPD defined as no acute exacerbation within
preceding 3 months, (4) no history of systemic disease or other pulmonary disease, (5)
no therapy with inhaled or systemic corticosteroids within 3 months before entry into
the study and (6) no history of asthma or atopy
Exclusion criteria: no additional information
Interventions Run-in: not reported
Treatments:
1. Budesonide 400 mcg twice daily
2. Placebo twice daily
Inhaler device: dry powder inhaler
Co-treatment: All participants were receiving therapy with inhaled salbutamol and ipra-
tropium bromide. For 9 participants, sustained-released theophyline was also given
Outcomes Primary: unclear
Secondary: FVC, FEV1, diary card data, inflammatory measures
Notes Funding: unclear
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned by a
computer-generated, blinded randomisa-
tion list
Allocation concealment (selection bias) Low risk ‘Blinded’ randomisation list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Cells were counted by our pathologist, who
was also blinded. Not clear for other out-
comes
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ‘The results presented are an analysis of
22 subjects (12budesonide-treated subjects
and 10 placebo-treated subjects) who com-
pleted the study’. Both dropout rates were
low but uneven between groups (two were
excluded from the placebo group and one
from the budesonide group.One extra, pre-
sumed to have been randomly assigned to
placebo (assuming equal group size at ran-
domisation) was excluded for failure to take
the medication consistently)
Selective reporting (reporting bias) High risk Key expected outcomes missing (mortal-
ity, serious adverse events). No reply from
study authors by time of publication
Paggiaro 1998
Methods Design: multi-centre, randomised, placebo-controlled trial
Six-month treatment period
Conducted in 13 European countries, New Zealand and South Africa
Participants Participants: 281 people were randomly assigned to fluticasone (142) and placebo (139)
Baseline characteristics:
Male %: flut 70, placebo 78
Mean age (no SD reported), years: flut 62, placebo 64
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1 (SD): flut 59 (18), placebo 55 (17)
Inclusion criteria: current or ex-smokers, 50 to 75 years of age with a history of smoking
equivalent to at least 10 pack-years and chronic bronchitis (a cough with excess sputum
production for at least 3 months in at least 2 consecutive years with no other pathology).
Participants also had to have a history of at least one exacerbation per year for the previous
3 years that required a visit to their doctor or hospital; high expectation, according to
the investigator, of experiencing an exacerbation during the 6-month treatment period;
regular productive cough; predicted FEV1 of 35% to 90%, ratio of FEV1 to forced vital
capacity of 70% or less and reversibility in FEV1 of less than 15% after inhalation of
400 mcg or 800 mcg salbutamol via a metered-dose inhaler or Diskhaler
Exclusion criteria: Individuals with abnormal chest radiographs or who had received
oral or depot steroids, inhaled steroids of more than 500 mcg daily or antibiotic therapy;
had been admitted to hospital in the 4 weeks before the study; or were currently taking
fluticasone propionate were excluded
Interventions Run-in: 2 week run-in period during which usual inhaled steroids were stopped and
participants received salbutamol as required
Treatments:
1. Fluticasone propionate 500 mcg twice daily
2. Placebo twice daily
Inhaler device: metered-dose inhalers, with a spacer if desired
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Paggiaro 1998 (Continued)
Co-treatment: Participants could take short-acting beta2-agonists for relief of symptoms
as required throughout the study. Other COPD medications, such as anticholinergics
and xanthine derivatives, could be continued throughout the study without dose changes
Outcomes Primary: COPD exacerbations
Secondary: FEV1, morning PEF, FVC, 6-minute walk test, Borg score, diary card symp-
tom scores, daily sputum volume, total adverse events, serum cortisol concentration
Notes Funding: unclear (‘code was held by the sponsor company’s statisticians’)
Definition of pneumonia:Not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers were computer-gener-
ated on PACT (version 2.7)
Allocation concealment (selection bias) Low risk All investigators were given a set of four
or more sealed envelopes containing as-
signment codes, from which they assigned
treatment, starting with the lowest number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipant and personnel/investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk ’We did analysis by intention to treat of all
patients who took at least one dose of study
medication’
‘Only available data was analysed’.
Dropout uneven
Selective reporting (reporting bias) High risk Key expected outcomes not reported (mor-
tality and serious adverse events). No reply
from study authors by time of publication
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Pauwels 1999
Methods Design: parallel-group, double-blind, placebo-controlled, randomised, multi-centre
study
3 year treatment period
Conducted at 39 study centres in nine European countries (Belgium,Denmark, Finland,
Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom)
Participants Participants: 1277 people were randomly assigned to budesonide (634) and placebo
(643)
Baseline characteristics:
Male %: bud 73.5, placebo 72.2
Mean age (SD), years: bud 52.5 (7.5), placebo 52.4 (7.7)
Smoking history (mean (SD) pack-years): bud 39.4 (20.1), placebo 39.2 (20.2)
Mean % predicted FEV1 (SD): bud 76.8 (12.4), placebo 76.9 (13.2)
Inclusion criteria: Persons 30 to 65 years of age were eligible if they were currently
smoking at least five cigarettes per day and had smoked cigarettes for at least 10 years or
had a smoking history of at least 5 pack-years. FEV1 after use of a bronchodilator had to
be between 50% and 100% of predicted normal value, and ratio of pre-bronchodilator
FEV1 to slow vital capacity had to be less than 70%. Increase in FEV1 after inhalation
of 1 mg of terbutaline from a dry powder inhaler had to be less than 10% of predicted
normal value. Change in FEV1 between the end of the first three-month period of the
run-in phase and the end of the second had to be less than 15%
Exclusion criteria:Participants with history of asthma, allergic rhinitis or allergic eczema
and those who had used oral glucocorticoids for longer than four weeks during the
preceding six months were excluded. Use of inhaled glucocorticoids other than the study
medication, beta-blockers, cromones or long-acting inhaled beta2-adrenergic agonists
was not allowed
Interventions Run-in: three-month smoking cessation programme. For participants who did not stop
smoking, this phase was followed by a three-month period during which compliance
with inhaled medication was assessed with the use of a placebo containing dry powder
inhaler with a hidden mechanical counter. Participants who continued smoking and
were at least 75% compliant with the recommended treatment regimen were randomly
assigned
Treatments:
1. Budesonide 400 mcg twice daily
2. Placebo twice daily
Inhaler device: 1, Pulmicort; 2, dry powder turbuhaler
Co-treatment: Use of inhaled glucocorticoids other than the study medication, beta-
blockers, cromones or long-acting inhaled beta2-adrenergic agonists was not allowed
Outcomes Primary: change over time in postdose FEV1
Secondary: serious adverse events, mortality, glucocorticoid-related adverse effects, bone
density, non-serious adverse events
Notes Funding: funded by a grant from Astra Draco, Lund, Sweden
Definition of pneumonia: not reported
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ‘Randomly assigned’. No specific details
given but industry-sponsored
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipant and personnel/investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Central evaluator who was unaware of the
treatment received and was analysed ac-
cording to a standardised computerised
protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data on randomly assigned participants
were analysed on an intention-to-treat ba-
sis. Withdrawal rates under 30% and even
in both groups
Selective reporting (reporting bias) High risk Severalmissing outcomes.Couldnot locate
protocol to check that all prospectively reg-
istered outcomes were reported. Contacted
second study author; no reply by time of
publication
Renkema 1996
Methods Design: parallel-group, double-blind, randomised, placebo-controlled study
2-year study period
Conducted at a single centre in the Netherlands
Participants Participants: 39 people were randomly assigned to budesonide (21) and placebo (18)
Baseline characteristics:
Male %: bud 100, placebo 100
Mean age (SD), years: bud 56 (8), placebo 54 (10)
Smoking history, cigarettes/year (SD): bud 635 (530), placebo 729 (495)
Mean % predicted FEV1 (SD): bud 67 (15), placebo 60 (18)
Inclusion criteria: clinical diagnosis of COPD based on history (persistent dyspnoea,
mainly on exertion, without sudden attacks of dyspnoea); FEV1 less than 80% of pre-
dicted value; residual volume (RV) greater than 100% of predicted value; specific com-
pliance expressed as percentage of predicted value greater than 100% after bronchodila-
tion; when, however, air trapping (calculated as thoracic gas volume measured by body
plethysmography minus functional residual capacity measured with an indicator gas)
was greater than 1.5 L Csp was allowed to be less than 100% of predicted; no signs of
allergy (negative skin test results, total serum IgE < 200 IU/mL, eosinophils in peripheral
blood < 250 × l03/mL); and stable phase of the disease
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Renkema 1996 (Continued)
Exclusion criteria: Excluded were participants older than 70 years at entry, participants
receiving continuous corticosteroid therapy and participants with severe concomitant
disease, likely to interfere with the purpose of the study. All participants had alpha-1
antitrypsin serum levels within the normal range. All participants were smokers or ex-
smokers. Smoking history was expressed as cigarette-years
Interventions Run-in: three months with no corticosteroid medication
Treatments:
1. Budesonide 800 mcg twice daily (plus placebo tablet once daily)
2. Placebo twice daily (plus placebo tablet once daily)
Inhaler device: metered-dose inhaler (MDI) through a 750-mL spacer (Nebuhaler;
ASTRA, Ryswylc, The Netherlands)
Co-treatment:Throughout the study, participants were maintained on regimens of their
usual bronchodilator medication, consisting of anticholinergics. beta-agonists, theo-
phylline or a combination of these drugs
Outcomes Primary: FEV1
Secondary: compliance, symptom scores, fasting morning plasma cortisol levels
Notes Funding: grants from the Netherlands Asthma Foundation, ASTRA BV Holland and
AB DRACO Sweden
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk By computerised randomisation, stratified
for smoking
Allocation concealment (selection bias) Low risk Allocated blindly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (presumed participants and
personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Uneven withdrawal rates, no description of
imputation to account for dropout
Selective reporting (reporting bias) High risk Key expected outcomes not reported (mor-
tality and adverse events). No reply from
study authors by time of publication
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Rennard 2009
Methods Design:Randomised, double-blind, double-dummy, parallel-group, active- andplacebo-
controlled, multi-centre study
12-Month treatment period
237 sites in the US, Europe and Mexico
Participants Participants: 1483 people were randomly assigned to budesonide/formoterol at high
(494) and low dose (494), and to formoterol alone (495)
Baseline characteristics:
Male %: bud/form high 62.3, bud/form low 62.8, form 65.3
Mean age (SD), years: bud/form high 63.2 (8.9), bud/form low 63.6 (9.2), form 62.9
(9.1)
Smoking history (median pack-years): bud/form high 40, bud/form low 40, form 40
Mean % predicted FEV1 (SD): bud/form high 38.6 (11.4), bud/form low 39.6 (10.9),
form 39.3 (11.9)
Inclusion criteria: current smokers or ex-smokers aged > 40 years with clinical diag-
nosis of COPD and symptoms for > 2 years were eligible for this study. Participants
were required to have a history of at least one COPD exacerbation treated with a course
of oral corticosteroids and/or antibacterials, with 1 to 12 months before screening and
documented use of an inhaled short-acting bronchodilator as rescue medication. Pre-
bronchodilator FEV1 of < 50% of predicted normal and pre-bronchodilator FEV1/FVC
of < 70% were required at screening. Smoking history of at least 10 pack-years, score
≥ 2 on the Modified Medical Research Council dyspnoea scale at the time of screening
and breathlessness, cough and sputum scale score ≥ 2 per day for at least half of the 2-
week run-in period
Exclusion criteria: Individuals were excluded if they had any of the following condi-
tions: history of asthma, history of allergic rhinitis before 40 years of age, significant/
unstable CV disorder, clinically significant respiratory tract disorder other than COPD
and homozygous alpha1-antitrypsin deficiency or any other clinically significant co-mor-
bidities. Individuals were also excluded if they needed additions or alterations to their
usual COPDmaintenance therapy or an increment in rescue therapy because of worsen-
ing symptoms within 30 days before screening. Oral or ophthalmic non-cardioselective
beta-adrenoceptor antagonists, oral corticosteroids, pregnancy and breast-feeding also
were exclusionary
Interventions Run-in: 2 weeks during which previous inhaled corticosteroids were discontinued
Treatments:
1. Budesonide/formoterol 320/9 mcg twice daily
2. Budesonide/formoterol 160/9 mcg twice daily
3. Formoterol 9 mcg twice daily
Inhaler device: 1 and 2, pressurised metered-dose inhaler. 3, dry powder inhaler
Co-treatment: salbutamol allowed as reliever medication
Outcomes Primary: predose FEV1 and one hour postdose FEV1
Secondary: morning and evening PEF, COPD exacerbations, quality of life (SGRQ),
symptom scores, percentage of awakening-free nights, any adverse event (AE), pneumo-
nia-related AEs, serious AEs, mortality, vital signs and cortisol levels
Notes Funding: AstraZeneca
Clinicaltrials.gov ID: NCT00206167
Definition of pneumonia: reported by physicians based on the Medical Dictionary for
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Regulatory Activities (version 10.0)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described. Industry sponsored, pre-
sumed to follow usual AZ methods
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind [presumed par-
ticipants and personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Safety was assessed by adverse event (AE)
reporting. Pneumonia events were reported
by physicians based on the Medical Dic-
tionary for Regulatory Activities (version
10.0) pneumonia-related preferred terms
(pneumonia, bronchopneumonia, lobar
pneumonia or pneumonia staphylococcal)
Incomplete outcome data (attrition bias)
All outcomes
High risk The withdrawal rates were very high com-
pared to the number of events for the dif-
ferent outcomes
Selective reporting (reporting bias) Low risk All outcomes reported [checked against
protocol]. Only one secondary outcome
not reported
Schermer 2009
Methods Design: randomised, double-blind, double-dummy, placebo-controlled phase IV trial
Three-year treatment period
Conducted at 44 general practices in the Netherlands
Participants Participants: 190 people were randomly assigned to fluticasone (94) and placebo (96)
Baseline characteristics:
Male %: flut 73, placebo 68
Mean age (SD), years: flut 58.4 (9.9), placebo 59.6 (10.1)
Smoking history (mean (SD) pack-years): flut 30.2 (18.2), placebo 26.5 (16.7)
Mean % predicted FEV1 (SD): flut 63.2 (17.1), placebo 65.7 (17.7)
Inclusion criteria: age 35 to 75 years; current or former smoker; chronic dyspnoea,
sputum production and cough for at least three consecutive months per year during the
previous two years; postbronchodilator forced expiratory volume in one second (FEV1)
< 90% of predicted value and/or postbronchodilator FEV1/FVC (forced vital capacity)
of predicted value < 88% for men and < 89% for women
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Schermer 2009 (Continued)
Exclusion criteria: postbronchodilator FEV1 < 40% of predicted and/or a history of
asthma, allergic rhinitis or allergic eczema
Interventions Run-in: Trial was preceded by the following (in chronological order): an optional smok-
ing cessation attempt supported by the GP in trial candidates who were current smok-
ers; a three-month washout phase to eliminate possible carry-over effects of a successful
smoking cessation attempt or withdrawal of prior treatment with N-acetylcysteine and/
or inhaled corticosteroids; and a 14-day pretreatment phase (30 mg oral prednisolone)
to attain the highest possible baseline condition
Treatments:
1. Fluticasone propionate 500 mcg twice daily
2. Placebo twice daily
Inhaler device: Diskus dry powder inhaler. Unclear from trial report whether placebo
was administered to match the fluticasone inhaler or the other active treatment, which
was delivered as effervescent tablets dissolved in a glass of tap
Co-treatment: not reported
Outcomes Primary: rate of exacerbation and quality of life as measured by the interviewer-admin-
istered version of the Chronic Respiratory Questionnaire (CRQ)
Notes Funding: Dutch Council for Health Insurances, with complementary funding by the
Netherlands Asthma Foundation (authors had received various GSK and other pharma
research grants)
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An independent statistician generated a
randomisation list based on a block size of
three for treatment allocation to balance the
three treatment arms by study centre
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither investigators nor patients were
aware of the group assignment. Placebo de-
scribed as ‘matching’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Neither investigators nor patients were
aware of the group assignment [presuming
the investigators were those doing the out-
come assessments]
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was high in both groups. The pri-
mary analyses were done on an intention-
to-treat basis. Additional per protocol anal-
yseswere done onpatientswith a trialmedi-
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cation compliance rate >80%.Unclear how
data were imputed or who was included in
the ITT population
Selective reporting (reporting bias) High risk All outcomes stated in the protocol were
reported but some key expected outcomes
were missing (serious adverse events and
pneumonia). No reply from author by time
of publication
Senderovitz 1999
Methods Design: placebo-controlled, randomised, double-blind, multi-centre trial
Six-month treatment period
Five centres in Denmark
Participants Participants: unclear how many people were randomly assigned. 26 were evaluable in
the budesonide (14) and placebo (12) groups
Baseline characteristics:
Male %: bud 57, placebo 50
Median age (range), years: bud 58.5 (51 to 74), placebo 62.5 (57 to 74)
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1 (SD): not reported
Inclusion criteria: outpatients 18 to 75 years of age with stable COPD were included.
FEV1, forced vital capacity (FVC) < 0.7, postbronchodilator FEV1 < 70% of predicted,
FEV1 > 40% of predicted and increase in FEV1 < 15% after inhalation of 0 to 5 mg
terbutaline
Exclusion criteria: clinical evidence of asthma (e.g. pollen season-related symptoms,
exercise-induced symptoms only and significantly elevated levels of eosinophils and IgE)
, history of atopy (hay fever and/or atopic dermatitis), treatment with inhaled corticos-
teroids within the past 6 months, treatment with oral corticosteroids, cromoglycate or
nedocromil within the past 4 weeks, other systemic disease making compliance and par-
ticipation in the study difficult, pregnancy and breast-feeding and an increase in FEV1
> 30% of baseline after 2 weeks of prednisolone treatment
Interventions Run-in: All participants received 2 weeks of treatment with oral prednisolone 37.5 mg
daily. Reversible participants with 15% < AFEV1 < 30% of baseline and irreversible par-
ticipants with AFEV1 < 15% were separately randomly assigned to inhaled budesonide
400 pg bid or placebo
Treatments:
1. Budesonide 400 mcg twice daily
2. Placebo twice daily
Inhaler device: Spirocort Turbuhaler
Co-treatment: not reported
Outcomes Primary: FEV1
Secondary: exacerbations, adverse events and symptom scores
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Notes Funding: not reported
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reversible participants with 15% <AFEV1
< 30% of baseline and irreversible partici-
pants with AFEV1 < 15% were separately
randomly assigned
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 26 of 37 were evaluable (12 in placebo
group, 14 in active group-30% dropout
overall). Number randomly assigned and
number of dropouts not provided for each
group. ITT not adopted
Selective reporting (reporting bias) High risk Several key expected outcomes not re-
ported (mortality, adverse events, with-
drawal per group). Study author contacted
but not able to provide data
Shaker 2009
Methods Design: randomised, double-blinded, placebo-controlled, parallel-group, single-centre
study
Two- to four-year treatment period
Conducted at a single centre in Denmark
Participants Participants: 254 people were randomly assigned to budesonide (127) and placebo (127)
Baseline characteristics:
Male %: bud 62.2, placebo 54.3
Mean age (SD), years: bud 63.6 (7.5), placebo (63.6 (7.2)
Smoking history (mean (SD) pack-years): bud 56 (23), placebo 56 (24)
Mean % predicted FEV1 (SD): bud 51 (11), placebo 53 (11)
Inclusion criteria: Individuals 50 to 80 years of age were eligible if they were current
smokers with a clinical diagnosis of COPD for not less than 2 years. All participants
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should have a significant smoking history of at least 10 cigarettes per day during the past
6 months and a previous history of at least 20 pack-years. Ex-smokers were excluded.
Baseline lung function criteria were as follows: FEV1 between 35% and 70% of predicted
(pre-bronchodilator), and FEV1/forced vital capacity (FEV1/FVC) ≤ 60%
Exclusion criteria: Reversibility of ≥ 12% and 200 mL in FEV1 from baseline values,
15 minutes after inhalation of 1 mg terbutaline or ≥ 15% and 300 mL after 2 weeks on
oral prednisolone (25 mg), was an exclusion criterion. Individuals were also excluded if
they had any severe concomitant disease; had an exacerbation within 30 days before the
first visit; received oral steroids for longer than four weeks within six months of the first
visit; or were on long-term oxygen therapy
Interventions Run-in: two-week run-in period on oral prednisolone
Treatments:
1. Budesonide 400 mcg twice daily
2. Placebo twice daily
Inhaler device: Pulmicort Turbuhaler
Co-treatment: Bronchodilators, mucolytics and short courses of oral corticosteroids
(maximum 3 courses of 4 weeks’ duration per year) and antibiotics were allowed during
the study
Outcomes Primary: 15th percentile density (PD15)
Secondary: change over time in the relative area of emphysema at a threshold of -910
Hounsfield units (RA-910), FEV1 and diffusion capacity (DLCO) and in number of
exacerbations, which was defined as a combination of 2 of the 3 following criteria:
increased dyspnoea, increased sputum production and change in sputum colour
Notes Funding: AstraZeneca
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated to either group
in a proportion of 1:1 by block randomi-
sation using a random sequence generated
by a computer programme at AstraZeneca
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. To maintain blinding, all
Turbuhalers were of identical appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Incomplete outcome data (attrition bias)
All outcomes
High risk High proportion of dropouts in both
groups (43% intervention and 49%
placebo)
Selective reporting (reporting bias) Low risk Could not locate protocol to check that all
prospectively registered outcomes were re-
ported, but study authors provided all rel-
evant outcomes upon request
Sharafkhaneh 2012
Methods Design: randomised, double-blind, double-dummy, parallel-group, multi-centre study
12-Month treatment period
Conducted at 180 study sites in the United States (106 sites), Central and South America
(53 sites) and South Africa (21 sites)
Participants Participants: 1219 people were randomly assigned to high-dose budesonide/formoterol
(407), low-dose budesonide/formoterol (408) and formoterol alone (404)
Baseline characteristics:
Male %: bud/form high 64.4, bud/form low 64.7, form 56.8
Mean age (SD), years: bud/form high 63.8 (9.4), bud/form low 62.8 (9.2), form 62.5
(9.4)
Smoking history (mean pack-years): bud/form high 46, bud/form low 44, form 43
Mean % predicted FEV1 (SD): bud/form high 37.9 (11.8), bud/form low 37.6 (11.6),
form 37.5 (12.4)
Inclusion criteria: Individuals were current smokers or ex-smokers with a smoking his-
tory of 10 pack-years, 40 years of age, with a clinical diagnosis of COPD with symp-
toms for >2 years. Participants were required to have a history of 1 COPD exacerbation
requiring treatment with a course of systemic corticosteroids, antibiotics or both, within
one to 12 months before screening (visit 1) and documented use of an inhaled short-
acting bronchodilator as rescue medication. At screening, a pre-bronchodilator forced
expiratory volume in one second (FEV1) of 50% of predicted normal and a pre-bron-
chodilator FEV1/forced vital capacity (FVC) of < 70% also were required
Exclusion criteria: Exclusion criteria included current, previous (within past 60 days)
or planned enrolment in a COPD pulmonary rehabilitation programme, treatment with
oral corticosteroids and incidence of a COPD exacerbation or any other significant
medical diagnosis between screening and randomisation visits
Interventions Run-in: 2-week run-in period
Treatments:
1. Budesonide/formoterol 320/9 mcg twice daily
2. Budesonide/formoterol 160/9 mcg twice daily
3. Formoterol DPI 9 mcg twice daily
Inhaler device: 1 and 2, pressurised metered-dose inhaler. 3, dry powder inhaler
Co-treatment: Rescue medication (albuterol pMDI 90 mg 2 inhalations) was provided
for as needed use during screening and run-in, and throughout the study
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Sharafkhaneh 2012 (Continued)
Outcomes Primary: COPD exacerbations
Secondary: FEV1, FVC, morning and evening PEF, diary card symptoms, rescue medi-
cation use, BODE index, exercise capacity, health-related quality of life (SGRQ), adverse
events. Unclear which was primary
Notes Funding: AstraZeneca ID: D589CC00003
Clinicaltrials.gov ID: NCT00419744
Definition of pneumonia: based on clinical judgement, not on radiological or microbial
assessments
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Assignments were made sequentially by in-
teractive voice response system in a a com-
puter generated allocation schedule pro-
duced in advance
Allocation concealment (selection bias) Low risk Assignments were made sequentially by in-
teractive voice response system following
a computer generated allocation schedule
produced in advance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tomaintain patient and investigator blind-
ing, all active treatments were provided
in blinded treatment kits. Patients in the
budesonide/formoterol pMDI groups re-
ceived a placebo DPI and those in the
formoterol DPI group received a placebo
pMDI
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk The withdrawal rates were relatively even
but high, especially compared to the low
event rates for the outcomes of interest
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported in detail
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Szafranski 2003
Methods Design: Randomised, double-blind, placebo-controlled, parallel-group, multi-centre
study
12 month treatment period
Conducted in 89 centres from 11 countries
Participants Participants: 812 people were randomly assigned to budesonide (198), placebo (205),
budesonide/formoterol (208) and formoterol (201)
Baseline characteristics:
Male %: bud 80, placebo 83, bud/form 76, form 76
Mean age (range), years: bud 64 (40 to 90), placebo 65 (47 to 92), bud/form 64 (41 to
82), form 63 (40 to 90)
Smoking history (mean pack-years (SD not reported)): bud 44, placebo 45, bud/form
44, form 45
Mean % predicted FEV1 (SD not reported): bud 37, placebo 36, bud/form 36, form 36
Inclusion criteria: Adults with moderate to severe asthma were included and were se-
lected according to the following criteria: outpatients aged 0 to 40 years; COPD symp-
toms for 2 years; > 10 pack-year smoking history; FEV1/FVC 70%; FEV1 50% predicted
normal (stages IIB and III according to the GOLD classification); total symptom score
of two per day during at least 7 days of the run-in period; documented use of short-
acting inhaled bronchodilators for reliever medication; > 1 severe COPD exacerbation
within 2 to 12 months before the first clinic visit
Exclusion criteria: History of asthma and/or seasonal allergic rhinitis before the age of
40; any relevant cardiovascular disorders as judged by the investigator; using beta-block-
ing agents; current respiratory tract disorders other than COPD or any other significant
diseases or disorders that may have put them at risk or that may have influenced the
results of the study; requirement for regular use of oxygen therapy or an exacerbation
during run-in. Individuals for whom it would have been considered unethical to with-
draw inhaled steroids were also excluded
Interventions Run-in: 2-week run-in period
Treatments:
1. Budesonide 400 mcg twice daily (Pulmicort)
2. Placebo twice daily
3. Budesonide/formoterol 320/9 mcg twice daily (Symbicort)
4. Formoterol 9 mcg twice daily (Oxis)
Inhaler device: as above
Co-treatment: Only study medication was allowed during the treatment period, plus
terbutaline 0.5 mg when needed as reliever medication
Outcomes Primary: severe exacerbations and FEV1
Secondary:VCandPEF, health-related quality of life, diary card data, relievermedication
use, mild exacerbations, adverse events and clinical chemistry
Notes Funding: AstraZeneca
Definition of pneumonia: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Szafranski 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Total of 812 participants were randomly
assigned (no other details, industry-spon-
sored)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal high and uneven between
groups (formoterol 31.8%, placebo43.9%,
31% ICS and 28% LABA/ICS). An inten-
tion-to-treat analysis was used, but impu-
tation methods were unclear for some out-
comes
Selective reporting (reporting bias) Unclear risk Could not locate trial registration to check
protocol adherence-pneumonia outcomes
not reported. Difficulty contacting study
author to clarify
Tashkin 2008 SHINE
Methods Design: randomised, double-blind, double-dummy, placebo-controlled, parallel-group,
multi-centre study
Six-month treatment period
Conducted at 194 centres in the US, Czech Republic, the Netherlands, Poland and
South Africa
Participants Participants: 1704 people were randomly assigned to six groups, but the three ICS/
LABA groupsweremerged for analysis. Participant numbers in the four categories were as
follows: budesonide (275), placebo (300), budesonide/formoterol (845) and formoterol
(284)
Baseline characteristics:
Male %: bud 67.6, placebo 69.0, bud/form 68.9, form 65.5
Mean age (SD), years: bud 63.4 (8.8), placebo 63.2 (9.6), bud/form 63.5, form 63.5 (9.
5)
Smoking history (mean pack-years (SD not reported)): bud 41, placebo 40, bud/form
41, form 40
Mean % predicted FEV1 (SD): bud 39.7 (12.0), placebo 41.3 (12.1), bud/form 39.4,
form 39.6 (12.8)
Inclusion criteria: Current smokers or ex-smokers older than 40 years of age with a
clinical diagnosis of COPD and symptoms for longer than two years were eligible for this
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Tashkin 2008 SHINE (Continued)
study. Participants were required to have a history of at least one COPD exacerbation
treated with a course of oral corticosteroids and/or antibacterials with documented use
of an inhaled short-acting bronchodilator as rescue medication one to 12 months before
screening. Prebronchodilator FEV1 < 50% of predicted normal and pre-bronchodilator
FEV1/FVC < 70% were required at screening. Smoking history of at least 10 pack-years,
score two or higher on the Modified Medical Research Council dyspnoea scale at the
time of screening and a breathlessness, cough and sputum scale score of 2 or higher per
day for at least half of the 2-week run-in period
Exclusion criteria: Individuals were excluded if they had any of the following condi-
tions: history of asthma, history of allergic rhinitis before 40 years of age, significant/
unstable CV disorder, clinically significant respiratory tract disorder other than COPD
and homozygous alpha1-antitrypsin deficiency or any other clinically significant co-mor-
bidities. Individuals were excluded if they needed additions or alterations to their usual
COPD maintenance therapy or an increment in rescue therapy because of worsening
symptoms within 30 days before screening. Oral or ophthalmic non-cardioselective beta-
adrenoceptor antagonists, oral corticosteroids, pregnancy and breast-feeding also were
exclusionary
Interventions Run-in: 2-week run-in period
Treatments:
1. Budesonide 160 mcg × 2 inhalations (320 mcg) twice daily
2. Placebo twice daily
3. Budesonide/formoterol 160/4.5 mcg × 2 inhalations (320/9 mcg) twice daily OR
Budesonide/formoterol 80/4.5 mcg × 2 inhalations (160/9 mcg) twice daily OR
Budesonide 160 mcg × 2 inhalations (320 mcg) twice daily plus formoterol DPI 4.5
mcg × 2 inhalations (9 mcg) twice daily
4. Formoterol DPI 4.5 mcg × 2 inhalations (9 mcg) twice daily
Inhaler device: 1 and 3, pressurised metered-dose inhaler. 4, dry powder inhaler. 2,
unclear
Co-treatment: Participants were allowed the following concomitant medications during
the study period: ephedrine-free antitussives and mucolytics, nasal corticosteroids, sta-
ble-dose non-nebulised ipratropium bromide, oral or ophthalmic cardioselective beta-
adrenoceptor antagonists or study-provided salbutamol as rescuemedication.The follow-
ing medications were allowed for exacerbations after randomisation: oral and parenteral
corticosteroids, short-term use of xanthines, increased use of inhaled beta2-adrenocep-
tor agonists and ipratropium bromide, nebulised beta2-adrenoceptor agonists and ipra-
tropium bromide
Outcomes Primary: predose FEV1 and 1 hour postdose FEV1
Secondary: 12-hour spirometry, predose and 1 hour postdose morning and evening
PEF, dyspnoea, health-related quality of life, COPD exacerbations, breathlessness diary
and symptom scores, use of rescue medication, adverse events, serious adverse events and
mortality
Notes Funding: AstraZeneca
Clinicantrials.gov identifier: NCT00206154
Definition of pneumonia: not reported
Risk of bias
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Tashkin 2008 SHINE (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible participants were randomly as-
signed in balanced blocks according
to a computer-generated randomisation
scheme at each site
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. To maintain blinding, par-
ticipants received both a pressurised me-
tered-dose inhaler (pMDI) and a dry pow-
der inhaler (DPI) containing active treat-
ment or placebo (PL), or combinations of
active treatment and placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ECG results were evaluated by a cardiolo-
gist in a blinded fashion through an inde-
pendent ECG service provider. Unclear for
other outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates lower in combination
groups (14.8% combined) than in other
groups (22.9%, 25.7% and 21.5% for ICS,
placebo andLABA, respectively). ITTanal-
ysis used with last observation carried for-
ward for missing values
Selective reporting (reporting bias) Low risk Checked against protocol and contacted
study authors. All stated outcomes reported
in full
van Grunsven 2003
Methods Design: randomised, placebo-controlled, double-blind trial
24-Month treatment period
Conducted at 10 general practices in Holland
Participants Participants: 48 people were randomly assigned to fluticasone (24) and placebo (24)
Baseline characteristics:
Male %: flut 50, placebo 54
Mean age (SD), years: flut 46 (10), placebo 47 (11)
Smoking history (mean (SD) pack-years): flut 11.9 (9.5), placebo 5.8 (8.4)
Mean % predicted FEV1 (SD): flut 95 (18), placebo 98 (17)
Inclusion criteria: chronic cough and/or sputum production for at least three consecu-
tive months and showed an annual decline in pre-bronchodilator FEV1 of 40 to 80 mL
Exclusion criteria: previous diagnosis of a pulmonary condition; presence of a co-
morbid condition with reduced life expectancy; intolerance for inhaled beta2-agonists;
102Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
van Grunsven 2003 (Continued)
use of beta-blocking agents; inability to use inhalation devices or peak flow meters
Interventions Run-in: general population screened, followed by 2-yearmonitoring of participants with
respiratory symptoms, then randomisation
Treatments:
1. Fluticasone propionate 250 mcg twice daily
2. Placebo twice daily
Inhaler device: Rotadisk dry powder inhaler
Co-treatment: Apart from short-acting (“rescue”) bronchodilators in case of acute dys-
pnoea, participants were not allowed to use other pulmonary medication
Outcomes Primary outcome: FEV1
Secondary outcomes: PC20, exacerbations, COOP/WONCA
Notes Funding: GSK
Definition of pneumonia: not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised.Nodetails but assumed to ad-
here to usual GSK methods
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout high but even between groups
(25%). All participantswith at least one fol-
low-up measurement for the primary out-
come (postbronchodilator FEV1) were in-
cluded in an intention to-treat analysis
Selective reporting (reporting bias) High risk Key outcomes not reported (e.g. mortality)
. SAEs not given per arm. No reply from
study authors by time of publication
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Verhoeven 2002
Methods Design: randomised, double-blind, placebo-controlled study
Six-month treatment period
Single study centre in the Netherlands
Participants Participants: 23 people were randomly assigned to fluticasone (10) and placebo (13)
Baseline characteristics:
Male %: flut 80, placebo 84.6
Mean age (range), years: flut 54 (42 to 65), placebo 56 (42 to 67)
Smoking history (mean (range) pack-years): flut 25 (five to 50), placebo 26 (11 to 50)
Mean % predicted FEV1 (range): flut 66 (55 to 93), placebo 61 (34 to 72)
Inclusion criteria: chronic productive cough, FEV1 < 70% of predicted normal value,
FEV1 reversibility of < 10% predicted after 750 mg terbutaline administered bymetered-
dose inhalation, negative serological examination (Phadiatop test) and negative skin prick
tests for standard inhaled allergens. Individuals with an FEV1/inspiratory vital capacity
(IVC) ratio of < 0.70 were also included, provided their total lung capacity (TLC) was
greater than the predicted value + 1.64 SD. Participants had to be current and persistent
smokers 40 to 70 years of age
Exclusion criteria:history of asthma characterised by attacks of dyspnoea, chest tightness
or wheezing; respiratory tract infection in the 4weeks preceding the first visit; or suffering
from serious or unstable concomitant disease
Interventions Run-in: two weeks
Treatments:
1. Fluticasone propionate 500 mcg twice daily
2. Placebo
Inhaler device: Diskhaler
Co-treatment: Eligible participants using anti-inflammatory treatment including non-
steroidal anti-inflammatory drugs were asked to refrain from oral prescriptions for at
least threemonths and from inhaled corticosteroids, sodium cromoglycate or nedocromil
sodium for at least 6 weeks before the start of the study. Long-acting beta2-agonists,
xanthine derivatives and antihistamine drugs also had to be stopped at least 6 weeks
before the start of the study
Outcomes Primary outcome unclear. Outcomes reported were use of secondary medication, com-
pliance, FEV1, PC20, FEV1/FVC, cortisol levels and inflammatory markers
Notes Funding: GlaxoWellcome (FLIL44/FMS40060)
Definition of pneumonia: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated (no details, but indus-
try-funded)
Allocation concealment (selection bias) Unclear risk Not described
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Verhoeven 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts in either group
Selective reporting (reporting bias) Low risk Adverse event data not adequately reported
but information supplied by the study au-
thor
Vestbo 1999
Methods Design: double-blind, parallel-group, randomised clinical trial nested in a continuing
epidemiological study, the Copenhagen City Heart Study (CCHS)
36-Month treatment period
Conducted at a single centre in Denmark
Participants Participants: 290 people were randomly assigned to budesonide (145) and placebo (145)
Baseline characteristics:
Male %: bud 85, placebo 90
Mean age (SD), years: bud 59 (8.3), placebo 59.1 (9.7)
Smoking history (mean (SD) pack-years): not reported
Mean % predicted FEV1 (SD): bud 86.2 (20.6), placebo 86.9 (21.1)
Inclusion criteria: CCHS participant; 30 to 70 years of age; FEV1/vital capacity ratio
0.7 or less; FEV1 reversibility after inhalation of 1·0 mg terbutaline from Turbuhaler
(Bricanyl, Lund, Sweden) of less than 15% of pre-bronchodilator FEV1; FEV1 reversibil-
ity after 10 days of treatment with oral prednisolone 37.5 mg daily of less than 15%
of pre-bronchodilator FEV1; and informed consent. Pack-years and other measures of
cigarette smoking were not part of inclusion criteria
Exclusion criteria: Long-term treatment (more than two episodes of longer than 4
weeks) with oral or inhaled steroids within 6 months of study entry. Other exclusion
criteria were pregnancy or lactation, intention to become pregnant, other serious systemic
disease that could influence the results of this study (investigators’ judgement), chronic
alcohol or drug use and participation in other clinical studies of COPD within 1 month
of inclusion
Interventions Run-in: not described
Treatments:
1. First six months: budesonide 800 mcg am and 400 mcg pm; following 30 months:
400 mcg twice daily
2. Placebo twice daily
Inhaler device: Turbuhaler
Co-treatment: Continuous use of inhaled corticosteroids other than study medication
was not allowed. Oral, inhaled or parenteral steroids could be used during exacerbations
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Vestbo 1999 (Continued)
for up to three periods of four weeks each year. Treatment with beta2-agonists of all kinds,
theophylline, disodium cromoglycate and mucolytics was allowed but kept constant.
Concomitant use of beta-blockers during the study was not allowed
Outcomes Primary: spirometric indices (FEV1, VC, FVC)
Secondary: respiratory symptoms (e.g. wheeze, wheeze without a cold, breathlessness
at rest and at different grades of exertion, cough night and day, phlegm night and day,
chest tightness), exacerbations, chronic mucus hypersecretion, adverse events
Notes Funding: AstraZeneca
Definition of pneumonia: not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was masked and the ran-
domisation sequence generated by com-
puter at Astra. Study numbers were allo-
cated in a consecutive order
Allocation concealment (selection bias) Low risk The randomisation code was held by Astra
and was not available to the researchers un-
til the study had been completed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. All study inhalers (budes-
onide and placebo) had the same appear-
ance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout higher in placebo group (35% vs
25% in budesonide group). ITT used
Selective reporting (reporting bias) Unclear risk All stated outcomes reported but unable to
check against trial registration. Difficulty
contacting authors
Yildiz 2004
Methods Design: randomised, double-blind, placebo-controlled design
Three-month treatment period
Conducted at a single centre in Turkey
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Participants Participants: 38 people randomly assigned to budesonide plus existing bronchodilator
therapy (20) and placebo (18)
Baseline characteristics:
Male %: bud 100, placebo 100
Mean age (SD), years: bud 70 (7), placebo 64 (9)
Smoking history (mean (SD) pack-years): bud 55 (31), placebo 47.5 (18)
Mean % predicted FEV1 (SD): bud 51 (22), placebo 40 (14)
Inclusion criteria: pre-bronchodilator FEV1 between 30% and 80% of predicted and
FEV1/FVC < 70% (stage II according to the GOLD classification), irreversible airway
obstruction suggested by < 10% improvement in FEV1 after inhalation of 200 mg salbu-
tamol, smoking history of more than 20 pack-years and no exacerbation or respiratory
tract infection in the previous four weeks
Exclusion criteria: history suggestive of asthma, clinical signs of right heart failure,
recent hospitalisation or admission to the emergency department because of exacerbation,
requirement for regular use of oxygen therapy or used inhaled or oral ICS in the past six
weeks
Interventions Run-in: no information
Treatments:
1. 800 mcg budesonide twice daily plus existing bronchodilator therapy
2. Placebo twice daily plus existing bronchodilator therapy
Inhaler device: Miflonide inhaler, Novartis
Co-treatment: All participants were receiving combined bronchodilator therapy consist-
ing of inhaled long-acting beta2-agonist (Formoterol, Foradil Aerolizer, Novartis) plus
inhaled anticholinergic (ipratropium bromide, Atrovent inhaler, Boehringer Ingelheim)
Outcomes Primary: unclear which outcome was primary
Secondary: St. George’s Respiratory Questionnaire, FEV1, arterial blood gas analysis,
serious adverse events, exacerbations
Notes Funding: unclear
Definition of pneumonia: not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’. No other details, funding
unclear
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (presumed participants and
personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Yildiz 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were low (2/18 placebo,
0/20 ICS)
Selective reporting (reporting bias) Low risk All outcomes were reported except one sec-
ondary outcome-not deemed to reflect bias.
Difficulty finding correct contact details for
study author
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
GSK FLIP63 2005 Treatment period less than 12 weeks
GSK SAM30022 2005 Comparison not of interest (beclomethasone vs salmeterol/fluticasone combination)
GSK SAM40004 2006 Asthma, not COPD
GSK SAS40015 2007 Comparison not of interest (fluticasone plus oral montelukast vs salmeterol/fluticasone combination)
GSK SCO100540 2006 Comparison not of interest (salmeterol/fluticasone combination vs placebo)
GSK SCO100646 2008 Comparison not of interest (participants received salmeterol and salmeterol/fluticasone combination for
varying amounts of time during the study)
GSK SCO30005 2006 Comparison not of interest (salmeterol/fluticasone combination vs placebo)
GSK SCO40030 2005 Treatment period less than 12 weeks
GSK SCO40034 2009 Comparison not of interest (salmeterol/fluticasone combination vs tiotropium)
GSK SCO40036 2009 Comparison not of interest (salmeterol/fluticasone combination vs tiotropium)
GSK SFCB3019 2004 Asthma, not COPD
Lung Health Study 2000 Comparison not of interest (triamcinolone acetonide used as inhaled steroid)
van der Valk 2002 ICS discontinuation study; all participants received treatment for three months before randomisation
Weir 1999 Comparison not of interest (beclomethasone used as inhaled steroid)
Wouters 2005 ICS discontinuation study; all participants received treatment for three months before randomisation
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Characteristics of studies awaiting assessment [ordered by study ID]
Ohar 2013
Methods Six-month randomised controlled trial
Participants Participants were > 40 years of age with a historical FEV1/FVC < 0.7. Six-month history of hospitalisation attributed
to AECOPD was also required
Interventions Fluticasone/salmeterol combination or salmeterol alone within 14 days of an exacerbation event: < 10-day hospitali-
sation for AECOPD, or AECOPD requiring treatment with OCS or OCS + antibiotics in an emergency department,
or during a physician’s office visit (if the index event was office-based)
Outcomes Exacerbation rates
Notes Abstract only
Characteristics of ongoing studies [ordered by study ID]
Vestbo 2013
Trial name or title The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol (NCT01313676)
Methods Design: multi-centre, placebo-controlled, double-blind, randomised, parallel-group trial
15- to 44-month treatment period (duration of treatment phase depended on mortality rate in the study; the
study will last until 1000 deaths have been recorded)
Participants Inclusion criteria: male or female, 40 to 80 years of age
Current smokers or ex-smokers with a smoking history of at least 10 pack-years
Established history of COPD with FEV1/FVC ratio 0.70 and FEV1 greater than 50 and less than 70% of
predicted normal
History of CVD or at increased risk for CVD
For participants older than40 years of age, this is defined as any one of the following: established coronary artery
disease, established peripheral vascular disease, previous stroke, previous myocardial infarction or diabetes
mellitus with target organ disease
For participants older than 60 years of age, any one of the above or two of the following: treated for hy-
percholesterolaemia, treated for hypertension, treated for diabetes mellitus or treated for peripheral vascular
disease
Exclusion criteria: current diagnosis of asthma or respiratory disorders other than COPD
Chest radiograph indicating diagnosis other than COPD
Undergone lung volume reduction surgery and/or lung transplant
Requirement for long-term oxygen therapy at start of study (12 hours per day)
Receiving long-term oral corticosteroid therapy
Current severe heart failure (NYHA class IV); individuals will also be excluded if they have a known ejection
fraction of 30% or if they have an implantable cardioverter-defibrillator
Any life-threatening condition with life expectancy of three years, other than vascular disease or COPD, that
might prevent the individual from completing the study
End-stage chronic renal disease
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Vestbo 2013 (Continued)
Interventions Run-in: 4 to 10 days
Treatments:
1. Placebo;
2. Fluticasone furoate (100 mcg once daily)
3. Vilanterol (25 mcg)
4. Fluticasone furoate/vilanterol combination (100/25 mcg once daily)
Inhaler device: novel dry powder inhaler
Co-treatment: All prior use of ICS and inhaled long-acting bronchodilators will be discontinued at entry to
the run-in period
Outcomes Primary: mortality
Secondary: decline in FEV1 and effect on a composite cardiovascular endpoint
Starting date Recruitment commenced in March 2011 and was ongoing in March 2013
Contact information J. Vestbo, Department of Respiratory Medicine J, Odense University Hospital, Sdr Ringvej 29, 5000 Odense
C, Denmark
E-mail: jvestbo@dadlnet.dk
Notes None
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D A T A A N D A N A L Y S E S
Comparison 1. Fluticasone versus controls (all outcomes by treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Non-fatal, serious adverse
pneumonia events
17 19504 Odds Ratio (M-H, Fixed, 95% CI) 1.78 [1.50, 2.12]
1.1 Fluticasone versus placebo 11 6635 Odds Ratio (M-H, Fixed, 95% CI) 1.84 [1.39, 2.44]
1.2 Fluticasone/LABA versus
LABA
13 12869 Odds Ratio (M-H, Fixed, 95% CI) 1.75 [1.41, 2.17]
2 Mortality, all-cause 22 20861 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.87, 1.13]
2.1 Fluticasone versus placebo 15 7857 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.88, 1.25]
2.2 Fluticasone/LABA versus
LABA
14 13004 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.78, 1.12]
3 Mortality, due to pneumonia 18 19532 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.23 [0.70, 2.15]
3.1 Fluticasone versus placebo 12 6665 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.20 [0.52, 2.77]
3.2 Fluticasone/LABA versus
LABA
13 12867 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.25 [0.59, 2.65]
4 Non-fatal, serious adverse events
(all)
19 20381 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.99, 1.14]
4.1 Fluticasone versus placebo 12 7377 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.95, 1.20]
4.2 Fluticasone/LABA versus
LABA
14 13004 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.96, 1.16]
5 All pneumonia events 11 15377 Odds Ratio (M-H, Fixed, 95% CI) 1.68 [1.49, 1.90]
5.1 Fluticasone versus placebo 6 4971 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [1.33, 1.97]
5.2 Fluticasone/LABA versus
LABA
9 10406 Odds Ratio (M-H, Fixed, 95% CI) 1.72 [1.47, 2.01]
6 Withdrawals 26 21243 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.77, 0.86]
6.1 Fluticasone versus placebo 18 8227 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.70, 0.84]
6.2 Fluticasone/LABA versus
LABA
15 13016 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.79, 0.92]
Comparison 2. Subgroup analyses-fluticasone versus controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dose-Non-fatal, serious adverse
pneumonia events
17 19504 Odds Ratio (M-H, Fixed, 95% CI) 1.76 [1.48, 2.08]
1.1 Fluticasone propionate
500 mcg (250 mcg bid)
6 3857 Odds Ratio (M-H, Fixed, 95% CI) 1.46 [0.91, 2.36]
1.2 Fluticasone propionate
1000 mcg (500 mcg bid)
9 10138 Odds Ratio (M-H, Fixed, 95% CI) 1.78 [1.47, 2.16]
1.3 Fluticasone furoate 50
mcg
2 1366 Odds Ratio (M-H, Fixed, 95% CI) 2.10 [0.73, 6.06]
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1.4 Fluticasone furoate 100
mcg
3 2447 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [0.70, 3.70]
1.5 Fluticasone furoate 200
mcg
2 1696 Odds Ratio (M-H, Fixed, 95% CI) 2.38 [0.87, 6.51]
2 Duration-Non-fatal, serious
adverse pneumonia events
17 19504 Odds Ratio (M-H, Fixed, 95% CI) 1.79 [1.51, 2.12]
2.1 Duration ≤ one year 14 13078 Odds Ratio (M-H, Fixed, 95% CI) 1.91 [1.39, 2.63]
2.2 Duration > one year 3 6426 Odds Ratio (M-H, Fixed, 95% CI) 1.74 [1.42, 2.13]
3 % FEV1 predicted
normal-Non-fatal, serious
adverse pneumonia events
12 17211 Odds Ratio (M-H, Fixed, 95% CI) 1.82 [1.53, 2.17]
3.1 FEV1 < 50% predicted 10 17133 Odds Ratio (M-H, Fixed, 95% CI) 1.84 [1.55, 2.20]
3.2 FEV1 ≥ 50% predicted 2 78 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.53]
Comparison 3. Budesonide versus controls (all outcomes by treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Non-fatal, serious adverse
pneumonia events
7 6472 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [1.00, 2.62]
1.1 Budesonide versus placebo 3 867 Odds Ratio (M-H, Fixed, 95% CI) 3.47 [1.11, 10.83]
1.2 Budesonide/formoterol
versus formoterol
5 5605 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.78, 2.28]
2 Mortality, all-cause 12 10009 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.65, 1.24]
2.1 Budesonide versus placebo 8 3487 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.52, 1.37]
2.2 Budesonide/formoterol
versus formoterol
7 6522 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.61, 1.46]
3 Mortality, due to pneumonia 3 1511 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.46 [0.07, 286.99]
3.1 Budesonide versus placebo 2 292 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Budesonide/formoterol
versus formoterol
1 1219 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.46 [0.07, 286.99]
4 Non-fatal, serious adverse events
(all)
12 10009 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.83, 1.22]
4.1 Budesonide versus placebo 8 3487 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.69, 1.50]
4.2 Budesonide/formoterol
versus formoterol
7 6522 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.78, 1.11]
5 All pneumonia events 6 7011 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.83, 1.51]
5.1 Budesonide versus placebo 3 1378 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.50, 1.50]
5.2 Budesonide/formoterol
versus formoterol
5 5633 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [0.87, 1.77]
6 Withdrawals 15 10150 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.71, 0.85]
6.1 Budesonide versus placebo 11 3627 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.69, 0.93]
6.2 Budesonide/formoterol
versus formoterol
7 6523 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.67, 0.86]
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Comparison 4. Subgroup analyses-budesonide versus controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dose - Non-fatal, serious adverse
pneumonia events
7 6472 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.96, 2.48]
1.1 Budesonide 320 mcg (160
mcg bid)
3 1775 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.27, 1.71]
1.2 Budesonide 640 mcg (320
mcg bid)
6 4659 Odds Ratio (M-H, Fixed, 95% CI) 2.02 [1.15, 3.57]
1.3 Budesonide 1280 mcg
(640 mcg bid)
1 38 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Duration - Non-fatal, serious
adverse pneumonia events
7 6471 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [1.00, 2.62]
2.1 Duration ≤ one year 6 6217 Odds Ratio (M-H, Fixed, 95% CI) 1.41 [0.83, 2.37]
2.2 Duration > one year 1 254 Odds Ratio (M-H, Fixed, 95% CI) 3.53 [0.95, 13.15]
3 % FEV1 predicted normal -
Non-fatal, serious adverse
pneumonia events
7 6471 Odds Ratio (M-H, Fixed, 95% CI) 1.60 [0.99, 2.59]
3.1 FEV1 < 50% predicted 6 6217 Odds Ratio (M-H, Fixed, 95% CI) 1.39 [0.82, 2.34]
3.2 FEV1 ≥ 50% predicted 1 254 Odds Ratio (M-H, Fixed, 95% CI) 3.53 [0.95, 13.15]
Comparison 5. Sensitivity analysis-risk of bias
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Non-fatal serious adverse
pneumonia events
16 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Fluticasone versus control 12 16338 Odds Ratio (M-H, Fixed, 95% CI) 1.82 [1.52, 2.19]
1.2 Budesonide versus control 4 3515 Odds Ratio (M-H, Fixed, 95% CI) 3.28 [1.22, 8.81]
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Analysis 1.1. Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 1 Non-fatal,
serious adverse pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone versus controls (all outcomes by treatment)
Outcome: 1 Non-fatal, serious adverse pneumonia events
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluticasone versus placebo
Verhoeven 2002 0/10 0/13 Not estimable
Mahler 2002 2/168 0/181 0.2 % 5.45 [ 0.26, 114.36 ]
Hanania 2003 1/183 0/185 0.2 % 3.05 [ 0.12, 75.34 ]
Calverley 2003 TRISTAN 9/375 3/363 1.4 % 2.95 [ 0.79, 10.99 ]
GSK FLTA3025 2005 4/434 1/206 0.7 % 1.91 [ 0.21, 17.17 ]
GSK SCO30002 2005 1/131 1/125 0.5 % 0.95 [ 0.06, 15.42 ]
Calverley 2007 TORCH 121/1552 69/1545 30.9 % 1.81 [ 1.33, 2.45 ]
GSK SCO104925 2008 1/42 0/42 0.2 % 3.07 [ 0.12, 77.59 ]
Lapperre 2009 0/26 2/29 1.1 % 0.21 [ 0.01, 4.53 ]
Kerwin 2013 2/206 1/207 0.5 % 2.02 [ 0.18, 22.45 ]
Martinez 2013 2/407 0/205 0.3 % 2.53 [ 0.12, 53.02 ]
Subtotal (95% CI) 3534 3101 36.2 % 1.84 [ 1.39, 2.44 ]
Total events: 143 (Fluticasone), 77 (Control)
Heterogeneity: Chi2 = 3.38, df = 9 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 4.26 (P = 0.000020)
2 Fluticasone/LABA versus LABA
Mahler 2002 2/165 0/160 0.2 % 4.91 [ 0.23, 103.04 ]
Calverley 2003 TRISTAN 7/358 9/373 4.2 % 0.81 [ 0.30, 2.19 ]
Hanania 2003 0/178 1/177 0.7 % 0.33 [ 0.01, 8.15 ]
GSK SCO100470 2006 2/518 4/532 1.9 % 0.51 [ 0.09, 2.81 ]
Kardos 2007 13/507 3/487 1.4 % 4.25 [ 1.20, 14.99 ]
Calverley 2007 TORCH 138/1546 82/1542 36.3 % 1.75 [ 1.32, 2.32 ]
GSK SCO40041 2008 5/92 4/94 1.8 % 1.29 [ 0.34, 4.98 ]
GSK SCO104925 2008 0/39 0/38 Not estimable
Ferguson 2008 19/394 10/388 4.7 % 1.92 [ 0.88, 4.17 ]
Anzueto 2009 13/394 8/403 3.7 % 1.68 [ 0.69, 4.11 ]
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(. . . Continued)
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kerwin 2013 (1) 2/412 3/205 1.9 % 0.33 [ 0.05, 1.98 ]
Dransfield 2013 72/2437 8/818 5.6 % 3.08 [ 1.48, 6.43 ]
Martinez 2013 (2) 3/409 2/203 1.3 % 0.74 [ 0.12, 4.48 ]
Subtotal (95% CI) 7449 5420 63.8 % 1.75 [ 1.41, 2.17 ]
Total events: 276 (Fluticasone), 134 (Control)
Heterogeneity: Chi2 = 14.43, df = 11 (P = 0.21); I2 =24%
Test for overall effect: Z = 5.09 (P < 0.00001)
Total (95% CI) 10983 8521 100.0 % 1.78 [ 1.50, 2.12 ]
Total events: 419 (Fluticasone), 211 (Control)
Heterogeneity: Chi2 = 17.97, df = 21 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 6.63 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 =0.0%
0.01 0.1 1 10 100
Favours fluticasone Favours control
(1) Two fluticasone/vilanterol dose groups merged
(2) Two fluticasone/vilanterol dose groups merged
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Analysis 1.2. Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 2 Mortality,
all-cause.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone versus controls (all outcomes by treatment)
Outcome: 2 Mortality, all-cause
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluticasone versus placebo
Burge 2000 32/372 36/370 6.9 % 0.87 [ 0.53, 1.44 ]
Calverley 2003 TRISTAN 3/375 7/363 1.5 % 0.41 [ 0.11, 1.60 ]
Calverley 2007 TORCH 246/1552 231/1545 40.5 % 1.07 [ 0.88, 1.30 ]
Choudhury 2005 3/128 0/132 0.1 % 7.39 [ 0.38, 144.52 ]
GSK FLTA3025 2005 0/434 0/206 Not estimable
GSK SCO104925 2008 1/42 0/42 0.1 % 3.07 [ 0.12, 77.59 ]
GSK SCO30002 2005 0/131 0/125 Not estimable
Hanania 2003 0/183 0/185 Not estimable
Hattotuwa 2002 0/16 1/14 0.3 % 0.27 [ 0.01, 7.25 ]
Kerwin 2013 0/206 0/207 Not estimable
Lapperre 2009 2/26 0/29 0.1 % 6.02 [ 0.28, 131.42 ]
Mahler 2002 0/168 3/181 0.7 % 0.15 [ 0.01, 2.95 ]
Martinez 2013 0/407 1/205 0.4 % 0.17 [ 0.01, 4.12 ]
Schermer 2009 8/94 3/96 0.6 % 2.88 [ 0.74, 11.22 ]
Verhoeven 2002 0/10 0/13 Not estimable
Subtotal (95% CI) 4144 3713 51.1 % 1.05 [ 0.88, 1.25 ]
Total events: 295 (Fluticasone), 282 (Control)
Heterogeneity: Chi2 = 11.37, df = 9 (P = 0.25); I2 =21%
Test for overall effect: Z = 0.50 (P = 0.62)
2 Fluticasone/LABA versus LABA
Anzueto 2009 4/394 6/403 1.2 % 0.68 [ 0.19, 2.42 ]
Calverley 2003 TRISTAN 2/358 3/373 0.6 % 0.69 [ 0.12, 4.17 ]
Calverley 2007 TORCH 193/1546 205/1542 37.3 % 0.93 [ 0.75, 1.15 ]
Dransfield 2013 40/2437 13/818 4.0 % 1.03 [ 0.55, 1.94 ]
Ferguson 2008 6/394 3/388 0.6 % 1.98 [ 0.49, 7.99 ]
GSK FCO30002 2005 1/68 2/69 0.4 % 0.50 [ 0.04, 5.65 ]
0.005 0.1 1 10 200
Favours fluticasone Favours control
(Continued . . . )
116Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GSK SCO100470 2006 3/518 3/532 0.6 % 1.03 [ 0.21, 5.11 ]
GSK SCO104925 2008 3/39 0/38 0.1 % 7.38 [ 0.37, 147.94 ]
GSK SCO40041 2008 5/92 7/94 1.4 % 0.71 [ 0.22, 2.34 ]
Hanania 2003 0/178 0/177 Not estimable
Kardos 2007 7/507 9/487 1.9 % 0.74 [ 0.27, 2.01 ]
Kerwin 2013 (1) 2/412 1/205 0.3 % 1.00 [ 0.09, 11.04 ]
Mahler 2002 0/165 0/160 Not estimable
Martinez 2013 (2) 2/407 2/203 0.6 % 0.50 [ 0.07, 3.55 ]
Subtotal (95% CI) 7515 5489 48.9 % 0.94 [ 0.78, 1.12 ]
Total events: 268 (Fluticasone), 254 (Control)
Heterogeneity: Chi2 = 4.47, df = 11 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 11659 9202 100.0 % 0.99 [ 0.87, 1.13 ]
Total events: 563 (Fluticasone), 536 (Control)
Heterogeneity: Chi2 = 16.64, df = 21 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Chi2 = 0.75, df = 1 (P = 0.39), I2 =0.0%
0.005 0.1 1 10 200
Favours fluticasone Favours control
(1) Two fluticasone/vilanterol dose groups merged
(2) Two fluticasone/vilanterol dose groups merged
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Analysis 1.3. Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 3 Mortality,
due to pneumonia.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone versus controls (all outcomes by treatment)
Outcome: 3 Mortality, due to pneumonia
Study or subgroup Fluticasone Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Fluticasone versus placebo
Calverley 2003 TRISTAN 0/375 0/363 Not estimable
Calverley 2007 TORCH 12/1552 9/1545 42.8 % 1.33 [ 0.56, 3.13 ]
GSK FLTA3025 2005 0/434 0/206 Not estimable
GSK SCO104925 2008 0/42 0/42 Not estimable
GSK SCO30002 2005 0/131 0/125 Not estimable
Hanania 2003 0/183 0/185 Not estimable
Hattotuwa 2002 0/16 0/14 Not estimable
Kerwin 2013 0/206 0/207 Not estimable
Lapperre 2009 0/26 0/29 Not estimable
Mahler 2002 0/168 1/181 2.0 % 0.15 [ 0.00, 7.35 ]
Martinez 2013 0/407 0/205 Not estimable
Verhoeven 2002 0/10 0/13 Not estimable
Subtotal (95% CI) 3550 3115 44.8 % 1.20 [ 0.52, 2.77 ]
Total events: 12 (Fluticasone), 10 (Control)
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Fluticasone/LABA versus LABA
Anzueto 2009 0/394 0/403 Not estimable
Calverley 2003 TRISTAN 0/358 0/373 Not estimable
Calverley 2007 TORCH 8/1546 10/1542 36.7 % 0.80 [ 0.32, 2.01 ]
Dransfield 2013 8/2437 0/818 12.3 % 3.81 [ 0.77, 18.87 ]
Ferguson 2008 0/394 0/388 Not estimable
GSK SCO100470 2006 0/518 0/532 Not estimable
GSK SCO104925 2008 0/39 0/38 Not estimable
GSK SCO40041 2008 1/92 0/94 2.1 % 7.55 [ 0.15, 380.66 ]
0.002 0.1 1 10 500
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(. . . Continued)
Study or subgroup Fluticasone Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Hanania 2003 0/178 0/177 Not estimable
Kardos 2007 1/507 1/487 4.1 % 0.96 [ 0.06, 15.39 ]
Kerwin 2013 (1) 0/412 0/205 Not estimable
Mahler 2002 0/165 0/160 Not estimable
Martinez 2013 (2) 0/407 0/203 Not estimable
Subtotal (95% CI) 7447 5420 55.2 % 1.25 [ 0.59, 2.65 ]
Total events: 18 (Fluticasone), 11 (Control)
Heterogeneity: Chi2 = 3.61, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 10997 8535 100.0 % 1.23 [ 0.70, 2.15 ]
Total events: 30 (Fluticasone), 21 (Control)
Heterogeneity: Chi2 = 4.78, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.002 0.1 1 10 500
Favours fluticasone Favours control
(1) Two fluticasone/vilanterol dose groups merged
(2) Two fluticasone/vilanterol dose groups merged
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Analysis 1.4. Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 4 Non-fatal,
serious adverse events (all).
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone versus controls (all outcomes by treatment)
Outcome: 4 Non-fatal, serious adverse events (all)
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluticasone versus placebo
Burge 2000 141/372 148/370 6.5 % 0.92 [ 0.68, 1.23 ]
Calverley 2003 TRISTAN 55/375 54/363 3.3 % 0.98 [ 0.65, 1.48 ]
Calverley 2007 TORCH 652/1552 618/1545 25.3 % 1.09 [ 0.94, 1.25 ]
GSK FLTA3025 2005 30/434 12/206 1.1 % 1.20 [ 0.60, 2.40 ]
GSK SCO104925 2008 1/42 1/42 0.1 % 1.00 [ 0.06, 16.53 ]
GSK SCO30002 2005 12/131 8/125 0.5 % 1.47 [ 0.58, 3.74 ]
Hanania 2003 10/183 11/185 0.7 % 0.91 [ 0.38, 2.21 ]
Kerwin 2013 16/206 11/207 0.7 % 1.50 [ 0.68, 3.32 ]
Lapperre 2009 4/26 8/29 0.5 % 0.48 [ 0.12, 1.82 ]
Mahler 2002 12/168 1/181 0.1 % 13.85 [ 1.78, 107.69 ]
Martinez 2013 16/407 10/205 0.9 % 0.80 [ 0.36, 1.79 ]
Verhoeven 2002 0/10 0/13 Not estimable
Subtotal (95% CI) 3906 3471 39.6 % 1.07 [ 0.95, 1.20 ]
Total events: 949 (Fluticasone), 882 (Control)
Heterogeneity: Chi2 = 10.54, df = 10 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Fluticasone/LABA versus LABA
Anzueto 2009 83/394 73/403 4.0 % 1.21 [ 0.85, 1.71 ]
Calverley 2003 TRISTAN 62/358 69/373 3.9 % 0.92 [ 0.63, 1.35 ]
Calverley 2007 TORCH 665/1546 617/1542 24.8 % 1.13 [ 0.98, 1.31 ]
Dransfield 2013 383/2437 126/818 11.2 % 1.02 [ 0.82, 1.27 ]
Ferguson 2008 87/394 78/388 4.3 % 1.13 [ 0.80, 1.59 ]
GSK FCO30002 2005 4/68 5/69 0.3 % 0.80 [ 0.21, 3.12 ]
GSK SCO100470 2006 32/518 24/532 1.6 % 1.39 [ 0.81, 2.40 ]
GSK SCO104925 2008 0/39 0/38 Not estimable
GSK SCO40041 2008 28/92 29/94 1.4 % 0.98 [ 0.53, 1.83 ]
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(. . . Continued)
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hanania 2003 8/178 5/177 0.3 % 1.62 [ 0.52, 5.05 ]
Kardos 2007 76/507 88/487 5.4 % 0.80 [ 0.57, 1.12 ]
Kerwin 2013 (1) 17/412 15/205 1.4 % 0.55 [ 0.27, 1.11 ]
Mahler 2002 9/165 7/160 0.5 % 1.26 [ 0.46, 3.47 ]
Martinez 2013 (2) 27/407 16/203 1.4 % 0.83 [ 0.44, 1.58 ]
Subtotal (95% CI) 7515 5489 60.4 % 1.06 [ 0.96, 1.16 ]
Total events: 1481 (Fluticasone), 1152 (Control)
Heterogeneity: Chi2 = 10.48, df = 12 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Total (95% CI) 11421 8960 100.0 % 1.06 [ 0.99, 1.14 ]
Total events: 2430 (Fluticasone), 2034 (Control)
Heterogeneity: Chi2 = 21.00, df = 23 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
0.01 0.1 1 10 100
Favours fluticasone Favours control
(1) Two fluticasone/vilanterol dose groups merged
(2) Two fluticasone/vilanterol dose groups merged
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Analysis 1.5. Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 5 All
pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone versus controls (all outcomes by treatment)
Outcome: 5 All pneumonia events
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluticasone versus placebo
Burge 2000 5/372 3/370 0.7 % 1.67 [ 0.40, 7.02 ]
Calverley 2007 TORCH 285/1552 190/1545 37.7 % 1.60 [ 1.31, 1.96 ]
GSK SCO104925 2008 1/42 0/42 0.1 % 3.07 [ 0.12, 77.59 ]
Kerwin 2013 4/206 3/207 0.7 % 1.35 [ 0.30, 6.09 ]
Martinez 2013 5/407 0/205 0.2 % 5.62 [ 0.31, 102.06 ]
Verhoeven 2002 0/10 0/13 Not estimable
Subtotal (95% CI) 2589 2382 39.4 % 1.62 [ 1.33, 1.97 ]
Total events: 300 (Fluticasone), 196 (Control)
Heterogeneity: Chi2 = 0.93, df = 4 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 4.88 (P < 0.00001)
2 Fluticasone/LABA versus LABA
Anzueto 2009 26/394 10/403 2.2 % 2.78 [ 1.32, 5.84 ]
Calverley 2007 TORCH 303/1546 205/1542 40.0 % 1.59 [ 1.31, 1.93 ]
Dransfield 2013 154/2437 27/818 9.2 % 1.98 [ 1.30, 3.00 ]
Ferguson 2008 29/394 15/388 3.4 % 1.98 [ 1.04, 3.75 ]
GSK SCO104925 2008 1/39 1/38 0.2 % 0.97 [ 0.06, 16.15 ]
GSK SCO40041 2008 8/92 6/94 1.3 % 1.40 [ 0.47, 4.20 ]
Kardos 2007 23/507 7/487 1.7 % 3.26 [ 1.39, 7.67 ]
Kerwin 2013 (1) 8/412 5/205 1.6 % 0.79 [ 0.26, 2.45 ]
Martinez 2013 (2) 5/407 3/203 1.0 % 0.83 [ 0.20, 3.50 ]
Subtotal (95% CI) 6228 4178 60.6 % 1.72 [ 1.47, 2.01 ]
Total events: 557 (Fluticasone), 279 (Control)
Heterogeneity: Chi2 = 8.07, df = 8 (P = 0.43); I2 =1%
Test for overall effect: Z = 6.79 (P < 0.00001)
Total (95% CI) 8817 6560 100.0 % 1.68 [ 1.49, 1.90 ]
Total events: 857 (Fluticasone), 475 (Control)
Heterogeneity: Chi2 = 9.17, df = 13 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 8.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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(1) Two fluticasone/vilanterol dose groups merged
(2) Two fluticasone/vilanterol dose groups merged
Analysis 1.6. Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 6
Withdrawals.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone versus controls (all outcomes by treatment)
Outcome: 6 Withdrawals
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluticasone versus placebo
Bourbeau 2007 1/20 3/21 0.1 % 0.32 [ 0.03, 3.32 ]
Burge 2000 160/372 195/370 4.8 % 0.68 [ 0.51, 0.90 ]
Calverley 2003 TRISTAN 109/375 142/363 4.4 % 0.64 [ 0.47, 0.87 ]
Calverley 2007 TORCH 587/1552 673/1545 18.0 % 0.79 [ 0.68, 0.91 ]
Choudhury 2005 56/128 78/132 1.8 % 0.54 [ 0.33, 0.88 ]
GSK FLTA3025 2005 147/434 79/206 3.0 % 0.82 [ 0.58, 1.16 ]
GSK SCO104925 2008 7/42 4/42 0.1 % 1.90 [ 0.51, 7.05 ]
GSK SCO30002 2005 34/131 40/125 1.3 % 0.74 [ 0.43, 1.28 ]
Hanania 2003 49/183 59/185 1.8 % 0.78 [ 0.50, 1.22 ]
Hattotuwa 2002 1/16 5/14 0.2 % 0.12 [ 0.01, 1.20 ]
Kerwin 2013 61/206 69/207 2.1 % 0.84 [ 0.56, 1.28 ]
Lapperre 2009 8/26 9/29 0.3 % 0.99 [ 0.31, 3.11 ]
Mahler 2002 68/168 69/181 1.7 % 1.10 [ 0.72, 1.70 ]
Martinez 2013 92/407 59/205 2.6 % 0.72 [ 0.49, 1.06 ]
Paggiaro 1998 19/142 27/139 1.0 % 0.64 [ 0.34, 1.22 ]
Schermer 2009 39/94 40/96 1.0 % 0.99 [ 0.56, 1.77 ]
van Grunsven 2003 6/24 6/24 0.2 % 1.00 [ 0.27, 3.69 ]
Verhoeven 2002 0/10 0/13 Not estimable
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(. . . Continued)
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 4330 3897 44.4 % 0.76 [ 0.70, 0.84 ]
Total events: 1444 (Fluticasone), 1557 (Control)
Heterogeneity: Chi2 = 13.74, df = 16 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 5.71 (P < 0.00001)
2 Fluticasone/LABA versus LABA
Anzueto 2009 125/394 156/403 4.5 % 0.74 [ 0.55, 0.99 ]
Calverley 2003 TRISTAN 89/358 120/373 3.8 % 0.70 [ 0.50, 0.96 ]
Calverley 2007 TORCH 522/1546 561/1542 15.9 % 0.89 [ 0.77, 1.03 ]
Dal Negro 2003 0/6 0/6 Not estimable
Dransfield 2013 609/2437 240/818 11.5 % 0.80 [ 0.67, 0.96 ]
Ferguson 2008 117/394 149/388 4.5 % 0.68 [ 0.50, 0.91 ]
GSK FCO30002 2005 12/68 10/69 0.4 % 1.26 [ 0.51, 3.16 ]
GSK SCO100470 2006 59/518 74/532 2.8 % 0.80 [ 0.55, 1.15 ]
GSK SCO104925 2008 4/39 3/38 0.1 % 1.33 [ 0.28, 6.40 ]
GSK SCO40041 2008 36/92 39/94 1.0 % 0.91 [ 0.50, 1.63 ]
Hanania 2003 53/178 57/177 1.7 % 0.89 [ 0.57, 1.40 ]
Kardos 2007 99/507 103/487 3.6 % 0.90 [ 0.66, 1.23 ]
Kerwin 2013 (1) 114/412 63/205 2.6 % 0.86 [ 0.60, 1.24 ]
Mahler 2002 53/165 45/160 1.3 % 1.21 [ 0.75, 1.94 ]
Martinez 2013 (2) 107/407 42/203 1.8 % 1.37 [ 0.91, 2.05 ]
Subtotal (95% CI) 7521 5495 55.6 % 0.85 [ 0.79, 0.92 ]
Total events: 1999 (Fluticasone), 1662 (Control)
Heterogeneity: Chi2 = 14.24, df = 13 (P = 0.36); I2 =9%
Test for overall effect: Z = 3.96 (P = 0.000074)
Total (95% CI) 11851 9392 100.0 % 0.81 [ 0.77, 0.86 ]
Total events: 3443 (Fluticasone), 3219 (Control)
Heterogeneity: Chi2 = 30.78, df = 30 (P = 0.43); I2 =3%
Test for overall effect: Z = 6.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.93, df = 1 (P = 0.09), I2 =66%
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Analysis 2.1. Comparison 2 Subgroup analyses-fluticasone versus controls, Outcome 1 Dose-Non-fatal,
serious adverse pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 2 Subgroup analyses fluticasone versus controls
Outcome: 1 Dose Non-fatal, serious adverse pneumonia events
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluticasone propionate 500 mcg (250 mcg bid)
Anzueto 2009 13/394 8/403 3.7 % 1.68 [ 0.69, 4.11 ]
Ferguson 2008 19/394 10/388 4.6 % 1.92 [ 0.88, 4.17 ]
GSK FLTA3025 2005 (1) 2/216 1/103 0.6 % 0.95 [ 0.09, 10.64 ]
GSK SCO100470 2006 2/518 4/532 1.9 % 0.51 [ 0.09, 2.81 ]
GSK SCO40041 2008 5/92 4/94 1.8 % 1.29 [ 0.34, 4.98 ]
Hanania 2003 1/183 0/185 0.2 % 3.05 [ 0.12, 75.34 ]
Hanania 2003 0/178 1/177 0.7 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 1975 1882 13.5 % 1.46 [ 0.91, 2.36 ]
Total events: 42 (Fluticasone), 28 (Control)
Heterogeneity: Chi2 = 3.20, df = 6 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
2 Fluticasone propionate 1000 mcg (500 mcg bid)
Calverley 2003 TRISTAN 7/358 9/373 4.1 % 0.81 [ 0.30, 2.19 ]
Calverley 2003 TRISTAN 9/375 3/363 1.4 % 2.95 [ 0.79, 10.99 ]
Calverley 2007 TORCH 138/1546 82/1542 35.7 % 1.75 [ 1.32, 2.32 ]
Calverley 2007 TORCH 121/1552 69/1545 30.4 % 1.81 [ 1.33, 2.45 ]
GSK FLTA3025 2005 2/218 1/103 0.6 % 0.94 [ 0.08, 10.54 ]
GSK SCO104925 2008 1/42 0/42 0.2 % 3.07 [ 0.12, 77.59 ]
GSK SCO104925 2008 0/39 0/38 Not estimable
GSK SCO30002 2005 1/131 1/125 0.5 % 0.95 [ 0.06, 15.42 ]
Kardos 2007 13/507 3/487 1.4 % 4.25 [ 1.20, 14.99 ]
Lapperre 2009 0/26 2/29 1.1 % 0.21 [ 0.01, 4.53 ]
Mahler 2002 2/168 0/181 0.2 % 5.45 [ 0.26, 114.36 ]
Mahler 2002 2/165 0/160 0.2 % 4.91 [ 0.23, 103.04 ]
Verhoeven 2002 0/10 0/13 Not estimable
Subtotal (95% CI) 5137 5001 76.0 % 1.78 [ 1.47, 2.16 ]
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(. . . Continued)
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 296 (Fluticasone), 170 (Control)
Heterogeneity: Chi2 = 8.22, df = 10 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 5.84 (P < 0.00001)
3 Fluticasone furoate 50 mcg
Dransfield 2013 (2) 24/820 3/272 2.1 % 2.70 [ 0.81, 9.05 ]
Kerwin 2013 (3) 1/206 1/68 0.7 % 0.33 [ 0.02, 5.30 ]
Subtotal (95% CI) 1026 340 2.8 % 2.10 [ 0.73, 6.06 ]
Total events: 25 (Fluticasone), 4 (Control)
Heterogeneity: Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.37 (P = 0.17)
4 Fluticasone furoate 100 mcg
Dransfield 2013 25/806 3/273 2.1 % 2.88 [ 0.86, 9.62 ]
Kerwin 2013 (4) 1/206 2/137 1.1 % 0.33 [ 0.03, 3.67 ]
Kerwin 2013 (5) 2/206 1/207 0.5 % 2.02 [ 0.18, 22.45 ]
Martinez 2013 (6) 0/204 1/101 1.0 % 0.16 [ 0.01, 4.06 ]
Martinez 2013 (7) 0/204 0/103 Not estimable
Subtotal (95% CI) 1626 821 4.6 % 1.61 [ 0.70, 3.70 ]
Total events: 28 (Fluticasone), 7 (Control)
Heterogeneity: Chi2 = 4.54, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 1.12 (P = 0.26)
5 Fluticasone furoate 200 mcg
Dransfield 2013 23/811 3/273 2.1 % 2.63 [ 0.78, 8.82 ]
Martinez 2013 3/205 1/102 0.6 % 1.50 [ 0.15, 14.60 ]
Martinez 2013 2/203 0/102 0.3 % 2.54 [ 0.12, 53.47 ]
Subtotal (95% CI) 1219 477 3.0 % 2.38 [ 0.87, 6.51 ]
Total events: 28 (Fluticasone), 4 (Control)
Heterogeneity: Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
Total (95% CI) 10983 8521 100.0 % 1.76 [ 1.48, 2.08 ]
Total events: 419 (Fluticasone), 213 (Control)
Heterogeneity: Chi2 = 18.90, df = 26 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 6.49 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.08, df = 4 (P = 0.90), I2 =0.0%
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(1) Control participants split between dose subgroups. Only 1 control event so entered 1 per subgroup (conservative option).
(2) LABA control events would not split evenly across 3 FF susbgroups (8/818). 3 events each were entered.
(3) 3/205 control events split 1/3 and 2/3 in 50 mcg and 100 mcg subgroups respectively. Event ratio maintained.
(4) Fluticasone/vilanterol 100/25 versus vilanterol 25
(5) Fluticasone 100 mcg versus placebo
(6) Fluticasone/vilanterol 100/25 versus vilanterol 25. The vilanterol arm was split between the 100 and 200 subgroups to avoid double counting.
(7) Fluticasone 100 mcg versus placebo. Placebo arm split between 100 and 200 subgroups to avoid double counting.
Analysis 2.2. Comparison 2 Subgroup analyses-fluticasone versus controls, Outcome 2 Duration-Non-fatal,
serious adverse pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 2 Subgroup analyses fluticasone versus controls
Outcome: 2 Duration Non-fatal, serious adverse pneumonia events
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Duration≤ one year
Anzueto 2009 13/394 8/403 3.7 % 1.68 [ 0.69, 4.11 ]
Calverley 2003 TRISTAN 7/358 9/373 4.2 % 0.81 [ 0.30, 2.19 ]
Calverley 2003 TRISTAN 9/375 3/363 1.4 % 2.95 [ 0.79, 10.99 ]
Dransfield 2013 72/2437 8/818 5.7 % 3.08 [ 1.48, 6.43 ]
Ferguson 2008 19/394 10/388 4.7 % 1.92 [ 0.88, 4.17 ]
GSK FLTA3025 2005 (1) 4/434 1/206 0.7 % 1.91 [ 0.21, 17.17 ]
GSK SCO100470 2006 2/518 4/532 1.9 % 0.51 [ 0.09, 2.81 ]
GSK SCO104925 2008 1/42 0/42 0.2 % 3.07 [ 0.12, 77.59 ]
GSK SCO104925 2008 0/39 0/38 Not estimable
GSK SCO30002 2005 1/131 1/125 0.5 % 0.95 [ 0.06, 15.42 ]
Hanania 2003 0/178 1/177 0.7 % 0.33 [ 0.01, 8.15 ]
Hanania 2003 1/183 0/185 0.2 % 3.05 [ 0.12, 75.34 ]
Kardos 2007 13/507 3/487 1.5 % 4.25 [ 1.20, 14.99 ]
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(. . . Continued)
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kerwin 2013 (2) 4/618 4/412 2.3 % 0.66 [ 0.17, 2.67 ]
Mahler 2002 2/165 0/160 0.2 % 4.91 [ 0.23, 103.04 ]
Mahler 2002 2/168 0/181 0.2 % 5.45 [ 0.26, 114.36 ]
Martinez 2013 5/816 2/408 1.3 % 1.25 [ 0.24, 6.48 ]
Verhoeven 2002 0/10 0/13 Not estimable
Subtotal (95% CI) 7767 5311 29.5 % 1.91 [ 1.39, 2.63 ]
Total events: 155 (Fluticasone), 54 (Control)
Heterogeneity: Chi2 = 13.69, df = 15 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 4.01 (P = 0.000060)
2 Duration > one year
Calverley 2007 TORCH 121/1552 69/1545 31.1 % 1.81 [ 1.33, 2.45 ]
Calverley 2007 TORCH 138/1546 82/1542 36.4 % 1.75 [ 1.32, 2.32 ]
GSK SCO40041 2008 5/92 4/94 1.8 % 1.29 [ 0.34, 4.98 ]
Lapperre 2009 0/26 2/29 1.1 % 0.21 [ 0.01, 4.53 ]
Subtotal (95% CI) 3216 3210 70.5 % 1.74 [ 1.42, 2.13 ]
Total events: 264 (Fluticasone), 157 (Control)
Heterogeneity: Chi2 = 2.08, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 5.31 (P < 0.00001)
Total (95% CI) 10983 8521 100.0 % 1.79 [ 1.51, 2.12 ]
Total events: 419 (Fluticasone), 211 (Control)
Heterogeneity: Chi2 = 15.72, df = 19 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 6.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
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Analysis 2.3. Comparison 2 Subgroup analyses-fluticasone versus controls, Outcome 3 % FEV1 predicted
normal-Non-fatal, serious adverse pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 2 Subgroup analyses fluticasone versus controls
Outcome: 3 % FEV1 predicted normal Non-fatal, serious adverse pneumonia events
Study or subgroup Fluticasone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 FEV1 < 50% predicted
Anzueto 2009 13/394 8/403 3.9 % 1.68 [ 0.69, 4.11 ]
Calverley 2003 TRISTAN 7/358 9/373 4.4 % 0.81 [ 0.30, 2.19 ]
Calverley 2003 TRISTAN 9/375 3/363 1.5 % 2.95 [ 0.79, 10.99 ]
Calverley 2007 TORCH 138/1546 82/1542 38.4 % 1.75 [ 1.32, 2.32 ]
Calverley 2007 TORCH 121/1552 69/1545 32.7 % 1.81 [ 1.33, 2.45 ]
Dransfield 2013 72/2437 8/818 6.0 % 3.08 [ 1.48, 6.43 ]
Ferguson 2008 19/394 10/388 4.9 % 1.92 [ 0.88, 4.17 ]
Hanania 2003 1/183 0/185 0.3 % 3.05 [ 0.12, 75.34 ]
Hanania 2003 0/178 1/177 0.8 % 0.33 [ 0.01, 8.15 ]
Kardos 2007 13/507 3/487 1.5 % 4.25 [ 1.20, 14.99 ]
Kerwin 2013 4/618 4/412 2.4 % 0.66 [ 0.17, 2.67 ]
Mahler 2002 2/165 0/160 0.3 % 4.91 [ 0.23, 103.04 ]
Mahler 2002 2/168 0/181 0.2 % 5.45 [ 0.26, 114.36 ]
Martinez 2013 5/816 2/408 1.4 % 1.25 [ 0.24, 6.48 ]
Subtotal (95% CI) 9691 7442 98.8 % 1.84 [ 1.55, 2.20 ]
Total events: 406 (Fluticasone), 199 (Control)
Heterogeneity: Chi2 = 11.26, df = 13 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 6.82 (P < 0.00001)
2 FEV1 ≥ 50% predicted
Lapperre 2009 0/26 2/29 1.2 % 0.21 [ 0.01, 4.53 ]
Verhoeven 2002 0/10 0/13 Not estimable
Subtotal (95% CI) 36 42 1.2 % 0.21 [ 0.01, 4.53 ]
Total events: 0 (Fluticasone), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 9727 7484 100.0 % 1.82 [ 1.53, 2.17 ]
Total events: 406 (Fluticasone), 201 (Control)
Heterogeneity: Chi2 = 13.13, df = 14 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 6.73 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.92, df = 1 (P = 0.17), I2 =48%
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Analysis 3.1. Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 1 Non-fatal,
serious adverse pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 3 Budesonide versus controls (all outcomes by treatment)
Outcome: 1 Non-fatal, serious adverse pneumonia events
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide versus placebo
Yildiz 2004 0/20 0/18 Not estimable
Tashkin 2008 SHINE 3/275 1/300 3.4 % 3.30 [ 0.34, 31.89 ]
Shaker 2009 10/127 3/127 9.9 % 3.53 [ 0.95, 13.15 ]
Subtotal (95% CI) 422 445 13.3 % 3.47 [ 1.11, 10.83 ]
Total events: 13 (Budesonide), 4 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
2 Budesonide/formoterol versus formoterol
Tashkin 2008 SHINE 5/845 1/284 5.3 % 1.68 [ 0.20, 14.48 ]
Rennard 2009 10/988 8/495 37.9 % 0.62 [ 0.24, 1.59 ]
Calverley 2010 7/242 1/239 3.5 % 7.09 [ 0.87, 58.07 ]
Sharafkhaneh 2012 17/815 7/404 32.9 % 1.21 [ 0.50, 2.94 ]
Fukuchi 2013 5/636 2/657 7.0 % 2.60 [ 0.50, 13.42 ]
Subtotal (95% CI) 3526 2079 86.7 % 1.33 [ 0.78, 2.28 ]
Total events: 44 (Budesonide), 19 (Control)
Heterogeneity: Chi2 = 5.69, df = 4 (P = 0.22); I2 =30%
Test for overall effect: Z = 1.05 (P = 0.30)
Total (95% CI) 3948 2524 100.0 % 1.62 [ 1.00, 2.62 ]
Total events: 57 (Budesonide), 23 (Control)
Heterogeneity: Chi2 = 8.36, df = 6 (P = 0.21); I2 =28%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 2.23, df = 1 (P = 0.14), I2 =55%
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Analysis 3.2. Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 2 Mortality,
all-cause.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 3 Budesonide versus controls (all outcomes by treatment)
Outcome: 2 Mortality, all-cause
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide versus placebo
Calverley 2003b 6/257 5/256 6.3 % 1.20 [ 0.36, 3.98 ]
Mirici 2001 1/68 2/69 2.5 % 0.50 [ 0.04, 5.65 ]
Pauwels 1999 8/634 10/643 12.7 % 0.81 [ 0.32, 2.06 ]
Shaker 2009 5/127 5/127 6.2 % 1.00 [ 0.28, 3.54 ]
Szafranski 2003 5/198 9/205 11.2 % 0.56 [ 0.19, 1.71 ]
Tashkin 2008 SHINE 2/275 1/300 1.2 % 2.19 [ 0.20, 24.29 ]
Vestbo 1999 4/145 5/145 6.3 % 0.79 [ 0.21, 3.02 ]
Yildiz 2004 0/20 0/18 Not estimable
Subtotal (95% CI) 1724 1763 46.5 % 0.85 [ 0.52, 1.37 ]
Total events: 31 (Budesonide), 37 (Control)
Heterogeneity: Chi2 = 1.70, df = 6 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
2 Budesonide/formoterol versus formoterol
Calverley 2003b 5/254 13/255 16.5 % 0.37 [ 0.13, 1.06 ]
Calverley 2010 4/242 0/238 0.6 % 9.00 [ 0.48, 168.09 ]
Fukuchi 2013 4/636 5/657 6.3 % 0.83 [ 0.22, 3.09 ]
Rennard 2009 9/988 2/495 3.4 % 2.27 [ 0.49, 10.53 ]
Sharafkhaneh 2012 16/815 10/404 17.0 % 0.79 [ 0.35, 1.75 ]
Szafranski 2003 6/208 6/201 7.7 % 0.97 [ 0.31, 3.04 ]
Tashkin 2008 SHINE 7/845 1/284 1.9 % 2.36 [ 0.29, 19.30 ]
Subtotal (95% CI) 3988 2534 53.5 % 0.94 [ 0.61, 1.46 ]
Total events: 51 (Budesonide), 37 (Control)
Heterogeneity: Chi2 = 7.50, df = 6 (P = 0.28); I2 =20%
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 5712 4297 100.0 % 0.90 [ 0.65, 1.24 ]
Total events: 82 (Budesonide), 74 (Control)
Heterogeneity: Chi2 = 9.17, df = 13 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 3.3. Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 3 Mortality,
due to pneumonia.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 3 Budesonide versus controls (all outcomes by treatment)
Outcome: 3 Mortality, due to pneumonia
Study or subgroup Budesonide Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Budesonide versus placebo
Shaker 2009 0/127 0/127 Not estimable
Yildiz 2004 0/20 0/18 Not estimable
Subtotal (95% CI) 147 145 Not estimable
Total events: 0 (Budesonide), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Budesonide/formoterol versus formoterol
Sharafkhaneh 2012 1/815 0/404 100.0 % 4.46 [ 0.07, 286.99 ]
Subtotal (95% CI) 815 404 100.0 % 4.46 [ 0.07, 286.99 ]
Total events: 1 (Budesonide), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 962 549 100.0 % 4.46 [ 0.07, 286.99 ]
Total events: 1 (Budesonide), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 3.4. Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 4 Non-fatal,
serious adverse events (all).
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 3 Budesonide versus controls (all outcomes by treatment)
Outcome: 4 Non-fatal, serious adverse events (all)
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Budesonide versus placebo
Calverley 2003b 88/257 66/256 8.8 % 1.50 [ 1.02, 2.19 ]
Mirici 2001 4/68 5/69 1.8 % 0.80 [ 0.21, 3.12 ]
Pauwels 1999 70/634 62/643 9.1 % 1.16 [ 0.81, 1.67 ]
Shaker 2009 55/127 39/127 6.9 % 1.72 [ 1.03, 2.89 ]
Szafranski 2003 35/198 37/205 7.0 % 0.97 [ 0.59, 1.62 ]
Tashkin 2008 SHINE 26/275 25/300 6.2 % 1.15 [ 0.65, 2.04 ]
Vestbo 1999 10/145 34/145 4.5 % 0.24 [ 0.11, 0.51 ]
Yildiz 2004 0/20 0/18 Not estimable
Subtotal (95% CI) 1724 1763 44.3 % 1.02 [ 0.69, 1.50 ]
Total events: 288 (Budesonide), 268 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 21.64, df = 6 (P = 0.001); I2 =72%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Budesonide/formoterol versus formoterol
Calverley 2003b 65/254 85/255 8.7 % 0.69 [ 0.47, 1.01 ]
Calverley 2010 19/242 14/238 4.8 % 1.36 [ 0.67, 2.79 ]
Fukuchi 2013 39/636 41/657 7.7 % 0.98 [ 0.62, 1.54 ]
Rennard 2009 144/988 88/495 10.2 % 0.79 [ 0.59, 1.05 ]
Sharafkhaneh 2012 130/815 68/404 9.7 % 0.94 [ 0.68, 1.29 ]
Szafranski 2003 43/208 37/201 7.2 % 1.16 [ 0.71, 1.89 ]
Tashkin 2008 SHINE 87/845 23/284 7.4 % 1.30 [ 0.81, 2.11 ]
Subtotal (95% CI) 3988 2534 55.7 % 0.93 [ 0.78, 1.11 ]
Total events: 527 (Budesonide), 356 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.38, df = 6 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 5712 4297 100.0 % 1.01 [ 0.83, 1.22 ]
Total events: 815 (Budesonide), 624 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 32.06, df = 13 (P = 0.002); I2 =59%
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 3.5. Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 5 All
pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 3 Budesonide versus controls (all outcomes by treatment)
Outcome: 5 All pneumonia events
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide versus placebo
Calverley 2003b 5/257 2/256 2.3 % 2.52 [ 0.48, 13.11 ]
Tashkin 2008 SHINE 5/275 4/300 4.5 % 1.37 [ 0.36, 5.16 ]
Vestbo 1999 16/145 24/145 25.5 % 0.63 [ 0.32, 1.23 ]
Subtotal (95% CI) 677 701 32.3 % 0.87 [ 0.50, 1.50 ]
Total events: 26 (Budesonide), 30 (Control)
Heterogeneity: Chi2 = 2.95, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Budesonide/formoterol versus formoterol
Calverley 2003b 8/254 7/255 8.1 % 1.15 [ 0.41, 3.23 ]
Fukuchi 2013 8/636 7/657 8.1 % 1.18 [ 0.43, 3.28 ]
Rennard 2009 30/988 17/495 26.2 % 0.88 [ 0.48, 1.61 ]
Sharafkhaneh 2012 45/815 11/404 16.6 % 2.09 [ 1.07, 4.08 ]
Tashkin 2008 SHINE 13/845 5/284 8.8 % 0.87 [ 0.31, 2.47 ]
Subtotal (95% CI) 3538 2095 67.7 % 1.24 [ 0.87, 1.77 ]
Total events: 104 (Budesonide), 47 (Control)
Heterogeneity: Chi2 = 4.02, df = 4 (P = 0.40); I2 =1%
Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI) 4215 2796 100.0 % 1.12 [ 0.83, 1.51 ]
Total events: 130 (Budesonide), 77 (Control)
Heterogeneity: Chi2 = 8.01, df = 7 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 1.17, df = 1 (P = 0.28), I2 =14%
0.1 0.2 0.5 1 2 5 10
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Analysis 3.6. Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 6
Withdrawals.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 3 Budesonide versus controls (all outcomes by treatment)
Outcome: 6 Withdrawals
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide versus placebo
Bourbeau 1998 3/39 10/40 0.9 % 0.25 [ 0.06, 0.99 ]
Calverley 2003b 102/257 106/256 6.5 % 0.93 [ 0.65, 1.32 ]
Mirici 2001 12/68 10/69 0.8 % 1.26 [ 0.51, 3.16 ]
Ozol 2005 1/12 3/10 0.3 % 0.21 [ 0.02, 2.47 ]
Pauwels 1999 176/634 189/643 13.8 % 0.92 [ 0.72, 1.18 ]
Renkema 1996 2/21 5/18 0.5 % 0.27 [ 0.05, 1.63 ]
Shaker 2009 55/127 62/127 3.6 % 0.80 [ 0.49, 1.31 ]
Szafranski 2003 62/198 90/205 6.2 % 0.58 [ 0.39, 0.88 ]
Tashkin 2008 SHINE 63/275 77/300 5.8 % 0.86 [ 0.59, 1.26 ]
Vestbo 1999 36/145 51/145 3.9 % 0.61 [ 0.37, 1.01 ]
Yildiz 2004 0/20 2/18 0.3 % 0.16 [ 0.01, 3.59 ]
Subtotal (95% CI) 1796 1831 42.7 % 0.80 [ 0.69, 0.93 ]
Total events: 512 (Budesonide), 605 (Control)
Heterogeneity: Chi2 = 12.85, df = 10 (P = 0.23); I2 =22%
Test for overall effect: Z = 3.02 (P = 0.0025)
2 Budesonide/formoterol versus formoterol
Calverley 2003b 74/254 111/255 8.0 % 0.53 [ 0.37, 0.77 ]
Calverley 2010 30/242 34/239 3.1 % 0.85 [ 0.50, 1.45 ]
Fukuchi 2013 42/636 56/657 5.3 % 0.76 [ 0.50, 1.15 ]
Rennard 2009 277/988 157/495 15.4 % 0.84 [ 0.66, 1.06 ]
Sharafkhaneh 2012 235/815 133/404 12.9 % 0.83 [ 0.64, 1.07 ]
Szafranski 2003 59/208 64/201 4.8 % 0.85 [ 0.56, 1.29 ]
Tashkin 2008 SHINE (1) 125/845 61/284 7.9 % 0.63 [ 0.45, 0.89 ]
Subtotal (95% CI) 3988 2535 57.3 % 0.76 [ 0.67, 0.86 ]
Total events: 842 (Budesonide), 616 (Control)
Heterogeneity: Chi2 = 6.17, df = 6 (P = 0.40); I2 =3%
Test for overall effect: Z = 4.34 (P = 0.000014)
0.005 0.1 1 10 200
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(. . . Continued)
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 5784 4366 100.0 % 0.78 [ 0.71, 0.85 ]
Total events: 1354 (Budesonide), 1221 (Control)
Heterogeneity: Chi2 = 19.41, df = 17 (P = 0.31); I2 =12%
Test for overall effect: Z = 5.25 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
0.005 0.1 1 10 200
Favours budesonide Favours control
(1) 3 combination therapy arms combined
Analysis 4.1. Comparison 4 Subgroup analyses-budesonide versus controls, Outcome 1 Dose - Non-fatal,
serious adverse pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 4 Subgroup analyses budesonide versus controls
Outcome: 1 Dose - Non-fatal, serious adverse pneumonia events
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide 320 mcg (160 mcg bid)
Rennard 2009 5/494 4/248 18.0 % 0.62 [ 0.17, 2.34 ]
Sharafkhaneh 2012 4/408 3/202 13.6 % 0.66 [ 0.15, 2.96 ]
Tashkin 2008 SHINE (1) 2/281 1/142 4.5 % 1.01 [ 0.09, 11.24 ]
Subtotal (95% CI) 1183 592 36.1 % 0.68 [ 0.27, 1.71 ]
Total events: 11 (Budesonide), 8 (Control)
Heterogeneity: Chi2 = 0.12, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Budesonide 640 mcg (320 mcg bid)
Calverley 2010 7/242 1/239 3.3 % 7.09 [ 0.87, 58.07 ]
Fukuchi 2013 5/636 2/657 6.7 % 2.60 [ 0.50, 13.42 ]
Rennard 2009 5/494 4/247 18.0 % 0.62 [ 0.17, 2.33 ]
Shaker 2009 10/127 3/127 9.4 % 3.53 [ 0.95, 13.15 ]
0.02 0.1 1 10 50
Favours budesonide Favours control
pooled estimates were only marginally affected due to the relatively small weight of the study in the analysis, and conclusions did not change..
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(. . . Continued)
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sharafkhaneh 2012 13/407 4/202 17.7 % 1.63 [ 0.53, 5.07 ]
Tashkin 2008 SHINE 3/275 1/300 3.2 % 3.30 [ 0.34, 31.89 ]
Tashkin 2008 SHINE 3/564 1/142 5.4 % 0.75 [ 0.08, 7.30 ]
Subtotal (95% CI) 2745 1914 63.9 % 2.02 [ 1.15, 3.57 ]
Total events: 46 (Budesonide), 16 (Control)
Heterogeneity: Chi2 = 6.24, df = 6 (P = 0.40); I2 =4%
Test for overall effect: Z = 2.43 (P = 0.015)
3 Budesonide 1280 mcg (640 mcg bid)
Yildiz 2004 0/20 0/18 Not estimable
Subtotal (95% CI) 20 18 Not estimable
Total events: 0 (Budesonide), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 3948 2524 100.0 % 1.54 [ 0.96, 2.48 ]
Total events: 57 (Budesonide), 24 (Control)
Heterogeneity: Chi2 = 9.71, df = 9 (P = 0.37); I2 =7%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Chi2 = 3.88, df = 1 (P = 0.05), I2 =74%
0.02 0.1 1 10 50
Favours budesonide Favours control
pooled estimates were only marginally affected due to the relatively small weight of the study in the analysis, and conclusions did not change..
(1) Given that this study makes two comparisons against the same control formoterol monotherapy arm, the control participants have been split between subgroups in
4.1.1 and 4.1.2. Since
137Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.2. Comparison 4 Subgroup analyses-budesonide versus controls, Outcome 2 Duration - Non-
fatal, serious adverse pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 4 Subgroup analyses budesonide versus controls
Outcome: 2 Duration - Non-fatal, serious adverse pneumonia events
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Duration≤ one year
Calverley 2010 7/242 1/238 3.5 % 7.06 [ 0.86, 57.83 ]
Fukuchi 2013 5/636 2/657 7.0 % 2.60 [ 0.50, 13.42 ]
Rennard 2009 10/988 8/495 37.9 % 0.62 [ 0.24, 1.59 ]
Sharafkhaneh 2012 17/815 7/404 32.9 % 1.21 [ 0.50, 2.94 ]
Tashkin 2008 SHINE 5/845 1/284 5.3 % 1.68 [ 0.20, 14.48 ]
Tashkin 2008 SHINE 3/275 1/300 3.4 % 3.30 [ 0.34, 31.89 ]
Yildiz 2004 0/20 0/18 Not estimable
Subtotal (95% CI) 3821 2396 90.1 % 1.41 [ 0.83, 2.37 ]
Total events: 47 (Budesonide), 20 (Control)
Heterogeneity: Chi2 = 6.39, df = 5 (P = 0.27); I2 =22%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Duration > one year
Shaker 2009 10/127 3/127 9.9 % 3.53 [ 0.95, 13.15 ]
Subtotal (95% CI) 127 127 9.9 % 3.53 [ 0.95, 13.15 ]
Total events: 10 (Budesonide), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
Total (95% CI) 3948 2523 100.0 % 1.62 [ 1.00, 2.62 ]
Total events: 57 (Budesonide), 23 (Control)
Heterogeneity: Chi2 = 8.35, df = 6 (P = 0.21); I2 =28%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 1.63, df = 1 (P = 0.20), I2 =39%
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Analysis 4.3. Comparison 4 Subgroup analyses-budesonide versus controls, Outcome 3 % FEV1 predicted
normal - Non-fatal, serious adverse pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 4 Subgroup analyses budesonide versus controls
Outcome: 3 % FEV1 predicted normal - Non-fatal, serious adverse pneumonia events
Study or subgroup Budesonide Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 FEV1 < 50% predicted
Calverley 2010 7/242 1/238 3.5 % 7.06 [ 0.86, 57.83 ]
Fukuchi 2013 5/636 2/657 7.0 % 2.60 [ 0.50, 13.42 ]
Rennard 2009 10/988 8/495 37.7 % 0.62 [ 0.24, 1.59 ]
Sharafkhaneh 2012 17/815 7/404 32.7 % 1.21 [ 0.50, 2.94 ]
Tashkin 2008 SHINE (1) 8/1120 2/584 9.3 % 2.09 [ 0.44, 9.89 ]
Yildiz 2004 0/20 0/18 Not estimable
Subtotal (95% CI) 3821 2396 90.1 % 1.39 [ 0.82, 2.34 ]
Total events: 47 (Budesonide), 20 (Control)
Heterogeneity: Chi2 = 6.04, df = 4 (P = 0.20); I2 =34%
Test for overall effect: Z = 1.23 (P = 0.22)
2 FEV1 ≥ 50% predicted
Shaker 2009 10/127 3/127 9.9 % 3.53 [ 0.95, 13.15 ]
Subtotal (95% CI) 127 127 9.9 % 3.53 [ 0.95, 13.15 ]
Total events: 10 (Budesonide), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
Total (95% CI) 3948 2523 100.0 % 1.60 [ 0.99, 2.59 ]
Total events: 57 (Budesonide), 23 (Control)
Heterogeneity: Chi2 = 8.05, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Chi2 = 1.67, df = 1 (P = 0.20), I2 =40%
0.02 0.1 1 10 50
Favours budesonide Favours control
(1) All bud/form and bud groups merged, and placebo and formoterol merged in the control group
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Analysis 5.1. Comparison 5 Sensitivity analysis-risk of bias, Outcome 1 Non-fatal serious adverse
pneumonia events.
Review: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Comparison: 5 Sensitivity analysis risk of bias
Outcome: 1 Non-fatal serious adverse pneumonia events
Study or subgroup Inhaled steroid Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluticasone versus control
Verhoeven 2002 0/10 0/13 Not estimable
GSK SCO104925 2008 0/39 0/38 Not estimable
Hanania 2003 0/178 1/177 0.8 % 0.33 [ 0.01, 8.15 ]
GSK SCO100470 2006 2/518 4/532 2.2 % 0.51 [ 0.09, 2.81 ]
Kerwin 2013 4/618 4/412 2.7 % 0.66 [ 0.17, 2.67 ]
GSK SCO30002 2005 1/131 1/125 0.6 % 0.95 [ 0.06, 15.42 ]
Martinez 2013 5/816 2/408 1.5 % 1.25 [ 0.24, 6.48 ]
Anzueto 2009 13/394 8/403 4.3 % 1.68 [ 0.69, 4.11 ]
Calverley 2007 TORCH 138/1546 82/1542 42.3 % 1.75 [ 1.32, 2.32 ]
Calverley 2007 TORCH 121/1552 69/1545 36.0 % 1.81 [ 1.33, 2.45 ]
GSK FLTA3025 2005 4/434 1/206 0.8 % 1.91 [ 0.21, 17.17 ]
Hanania 2003 1/183 0/185 0.3 % 3.05 [ 0.12, 75.34 ]
GSK SCO104925 2008 1/42 0/42 0.3 % 3.07 [ 0.12, 77.59 ]
Dransfield 2013 72/2437 8/818 6.6 % 3.08 [ 1.48, 6.43 ]
Kardos 2007 13/507 3/487 1.7 % 4.25 [ 1.20, 14.99 ]
Subtotal (95% CI) 9405 6933 100.0 % 1.82 [ 1.52, 2.19 ]
Total events: 375 (Inhaled steroid), 183 (Control)
Heterogeneity: Chi2 = 9.68, df = 12 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 6.40 (P < 0.00001)
2 Budesonide versus control
Yildiz 2004 0/20 0/18 Not estimable
Tashkin 2008 SHINE 5/845 1/284 27.7 % 1.68 [ 0.20, 14.48 ]
Fukuchi 2013 5/636 2/657 36.4 % 2.60 [ 0.50, 13.42 ]
Tashkin 2008 SHINE 3/275 1/300 17.6 % 3.30 [ 0.34, 31.89 ]
Calverley 2010 7/242 1/238 18.2 % 7.06 [ 0.86, 57.83 ]
Subtotal (95% CI) 2018 1497 100.0 % 3.28 [ 1.22, 8.81 ]
0.005 0.1 1 10 200
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(. . . Continued)
Study or subgroup Inhaled steroid Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 20 (Inhaled steroid), 5 (Control)
Heterogeneity: Chi2 = 0.96, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Chi2 = 1.31, df = 1 (P = 0.25), I2 =24%
0.005 0.1 1 10 200
Favours inhaled steroid Favours control
A D D I T I O N A L T A B L E S
Table 1. Fluticasone-summary of studies and baseline characteristics
Study ID Duration
(m)
N Rand Funder ICS dose
(mcg)
% Male Mean age Pack-years % pred FEV1
Fluticasone versus placebo (n = 18)
Bourbeau
2007
3 41 GSK 1000 78 65 53 57
Burge 2000 36 740 GSK 1000 75 64 44 50
Calverley
2003
TRISTANa
12 763 GSK 1000 73 63 43 45
Calverley
2007
TORCHa
36 3097 GSK 1000 76 65 49 44
Choudhury
2005
12 260 Indep. 1000 52 67 39 54
GSK
FLTA3025
2005
6 640 GSK 500, 1000 69 64 - -
GSK
SCO104925
2008a
3 84 GSK 1000 77 64 - -
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Table 1. Fluticasone-summary of studies and baseline characteristics (Continued)
GSK
SCO30002
2005
12 256 GSK 1000 82 65 - -
Hanania
2003a
6 368 GSK 500 63 64 57 42
Hattotuwa
2002
3 36 GSK 1000 87 65 63 46
Kerwin
2013a,b
6 413 GSK 100 66 62 46 42
Lapperre
2009
30 55 GSK 1000 86 60 43 55
Mahler
2002a
6 349 GSK 1000 66 65 55 41
Martinez
2013a,b
6 612 GSK 100, 200 72 62 43 48
Paggiaro
1998
6 281 - 1000 74 63 - 57
Schermer
2009
36 190 Indep. 1000 71 59 28 64
van
Grunsven
2003
24 48 GSK 500 52 47 9 97
Verhoeven
2002
6 23 GSK 1000 82 55 26 63
WM 22 m 459 - - 72 62 43 54
Fluticasone/LABA combination versus LABA monotherapy (n = 15)
Anzueto
2009
12 797 GSK 500 54 65 57 34
Calverley
2003
TRISTANa
12 731 GSK 1000 73 63 43 45
Calverley
2007
TORCHa
36 3088 GSK 1000 76 65 49 44
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Table 1. Fluticasone-summary of studies and baseline characteristics (Continued)
Dal Negro
2003
12 12 - 500 92 - 42 50
Dransfield
2013b
12 3255 GSK 50, 100, 200 57 64 - 45
Ferguson
2008
12 782 GSK 500 55 65 56 33
GSK
FCO30002
2005
3 140 GSK 1000 66 62 - -
GSK
SCO100470
2006
6 1050 GSK 500 78 64 - -
GSK
SCO104925
2008a
3 77 GSK 1000 77 64 - -
GSK
SCO40041
2008
36 186 GSK 500 61 66 - -
Hanania
2003a
6 355 GSK 500 63 64 57 42
Kardos
2007
10 994 GSK 1000 76 64 37 40
Kerwin
2013a,b
6 617 GSK 100 67 63 46 43
Mahler
2002a
6 325 GSK 1000 66 65 55 41
Martinez
2013a,b
6 610 GSK 100, 200 72 62 43 48
WM 16 m 867 - - 69 64 53 42
aMulti-arm studies making both comparisons of interest (ICS vs placebo and ICS/LABA vs LABA).
bStudies using vilanterol as the LABA combination and monotherapy comparator, with fluticasone furoate.
Dose is given as the total received per day (i.e. 500 signifies 250 morning and evening).
WM = weighted mean.
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Table 2. Budesonide-summary of studies and baseline characteristics
Study ID Duration
(m)
N Rand Funder ICS dose
(mcg)
% Male Mean age Pack-years % pred FEV1
Budesonide versus placebo (n = 13)
Bourbeau
1998
6 79 AZ 640 79 66 51 37
Calverley
2003ba
12 513 GSK 640 76 64 35 36
Laptseva
2002
6 49 NR 640 NR NR NR NR
Mirici 2001 3 50 NR 640 75 53 27 62
Ozol 2005 6 26 NR 640 69 65 45 59
Pauwels
1999
36 1277 AZ 640 73 52 39 77
Renkema
1996
24 39 AZ 1280 100 55 NR 64
Senderovitz
1999
6 26 NR 640 54 61 NR NR
Shaker 2009 36 254 AZ 640 58 64 56 52
Szafranski
2003a
12 403 AZ 640 79 64 45 36
Tashkin
2008
SHINEa
6 575 AZ 640 68 63 41 40
Vestbo 1999 36 290 AZ 640 88 59 NR 87
Yildiz 2004 3 38 ? 1280 100 67 51 46
WM 23 m 278 - - 77 61 43 54
Budesonide/LABA combination versus LABA monotherapy (n = 7)
Calverley
2003ba
12 509 GSK 640 76 64 35 36
Calverley
2010
11 481 Chiesi 640 81 64 39 42
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Table 2. Budesonide-summary of studies and baseline characteristics (Continued)
Fukuchi
2013
3 1293 AZ 640 89 65 44 41
Rennard
2009
12 1483 AZ 320, 640 63 63 NR 39
Sharafkhaneh
2012
12 1219 AZ 320, 640 62 63 44 38
Szafranski
2003a
12 409 AZ 640 79 64 45 36
Tashkin
2008
SHINEa
6 1129 AZ 320, 640 68 63 41 40
WM 9 m 932 - - 75 64 41 39
aMulti-arm studies making both comparisons of interest (ICS vs placebo and ICS/LABA vs LABA).
Dose is given as the total received per day (i.e. 640 signifies 320 morning and evening).
WM = weighted mean.
Table 3. BDP equivalent doses
Drug Daily dose (mcg) BDP equivalent (mcg)
Budesonide 320 320
640 640
1280 1280
Fluticasone 500 (propionate) 1000
1000 (propionate) 2000
50 (furoate) 500
100 (furoate) 1000
200 (furoate) 2000
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Table 4. Control group event rates
Monotherapy comparison-Placebo con-
trol events
Combination comparison-LABA control events
Fluticasone Budesonide Fluticasone Budesonide
Pneumonia-related seri-
ous adverse events
2.5%, 77/310 0.9%, 4/445 2.5%, 134/5420 0.9%, 19/2079
0.5% without TORCH 0.7% without TORCH
All-cause mortality 7.6%, 282/3713 2.1%, 37/1763 5.1%, 254/5489 1.5%, 37/2534
2.4% without TORCH 1.2% without TORCH
All-cause serious adverse
events
25%, 882/3471 15%, 268/1763 21%, 1152/5489 14%, 356/2534
14% without TORCH 14% without TORCH
For the fluticasone control groups with and without the large 3-year TORCH study.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
CENTRAL Quarterly (four issues per year)
PSYCINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
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Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
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11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search terms ClinicalTrials.gov
intervention: fluticasone OR budesonide OR corticosteroid OR steroid
condition: COPD
study type: interventional studies
F E E D B A C K
Response regarding fluticasone furoate, 1 April 2014
Summary
I was very interested to read the recent Cochrane review of inhaled steroids and risk of pneumonia in COPD. This is an important issue
for patient safety and therefore for GSK. We have been looking at all of the data from our own trials, from meta-analyses, systematic
reviews and database studies in great detail. The view we have come to is that many of the previous systematic reviews were flawed
because of inappropriate comparisons. The recently published Cochrane review is a huge improvement on the previous reviews and
deals with many of the issues that we had identified as problems.
There are, however a number of issues, which I would be grateful that you consider:
1. Your recent review analyses fluticasone propionate and fluticasone furoate together. I would like to emphasise that these are distinct
inhaled steroid molecules with completely different potency ratios and I strongly feel that in the review these need to be separated. If
you require any papers on their pharmacology to support this please let me know.
2. The review includes both licensed and unlicensed doses of fluticasone furoate. This means that currently the review is including
doses which are lower than the licensed dose (50 mcg) and higher than the licensed dose (200 mcg). Would you consider analysing the
results for the licensed and unlicensed doses separately?
I would be very interested in your views. As you know GSK has supported the initiative to provide data for meta-analysis and systematic
reviews. If there is any further data that you require, we will do our very best to provide this in order to advance the scientific and
clinical understanding on this important question.
Reply
We thank you for your comments and the papers which we have now referenced. Our responses to the issues you have raised are as
follows.
1) Combining fluticasone furoate with fluticasone propionate
When the review protocol was written (September 2012), we did not foresee the inclusion of fluticasone furoate (FF). As such, we were
faced with the decision to either exclude these studies, or include them in the review alongside fluticasone propionate (FP) evidence.
We chose to include the studies, taking justification for their combination with FP from tests to assess the statistical similarity of their
effects (test for subgroup differences). Analysis 2.1, which has now been adjusted to show each fluticasone furoate dose separately,
showed no significant difference between the effects for the five doses (two FP and three FF; Analysis 2.1; I2=0%, P=0.90), and there
was substantial imprecision in the FF estimates compared with FP. There was no statistical difference when we compared only the
studies which used the licensed dose of FF (100 mcg) to studies using the BDP equivalent dose of FP (250 mcg twice daily) (I2=0%,
P=0.85), and the same was true for FF 200 mcg once daily compared with FP 500 mcg twice daily (I2=0%, P=0.58).
That said, we tried to remain aware of the possible difficulty of combining the two preparations, and attempted to make the reader
aware of this narratively throughout the review. We accept that, as further RCTs of FF are published, this is likely to increase the
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precision of the evidence and hence our confidence in any difference that might exist between FP and FF. This may warrant separating
FF from FP in future updates of this review.
2) Licensing and BDP equivalent doses
Cochrane reviews are intended to be used internationally and hence do not generally exclude studies on the basis of local licenses. As a
result, it would be post-hoc to exclude or isolate particular doses of FF, especially as we did not set out to do so for FP or budesonide.
Both authors searched for information regarding the BDP equivalence of FF to present in Table 3 (BDP equivalent doses). Since the
publication of the review, information fromNICE and the eMChas been published which states that 100 mcg FF daily is approximately
equivalent to twice daily FP 250 mcg (i.e. 1000 mcg BDP) and 200 mcg is equivalent to FP 500 mcg twice daily (i.e. 2000 mcg BDP).
We have added this information to the review to help readers make sense of the evidence and comparability of the two preparations
to each other, and to budesonide. The lowest dose of 50 mcg FF is not mentioned, but since this is roughly equivalent to the lower
included budesonide doses, it does not seem necessary or consistent to re-analyse separately or exclude it entirely.
Contributors
Neil Barnes
Medical Head, Global Respiratory Franchise, GSK
COI statement: I am employed by GSK and submitted these comments on behalf of GSK
WH A T ’ S N E W
Last assessed as up-to-date: 5 September 2013.
Date Event Description
4 December 2014 Amended Typo corrected in analysis 2.1
H I S T O R Y
Protocol first published: Issue 9, 2012
Review first published: Issue 3, 2014
Date Event Description
25 April 2014 Feedback has been incorporated Feedback added to the review along with a response from the review authors
The following changes were made
• Analysis 2.1 Fluticasone dose subgroup analysis amended to separate all
fluticasone furoate doses. Results updated.
• Sentence and references added to ’Why is it important to do this review’
to address differences in ICS molecules.
• BDP equivalence for fluticasone furoate added to Table 3 and text.
• Sentence added to ’Quality of the evidence’ regarding separation or
merging of ICS preparations in future updates.
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C O N T R I B U T I O N S O F A U T H O R S
Alieksei Seniukowich and Kayleigh Kew extracted data. Kayleigh conducted the analysis, interpreted the data and wrote up the results,
with clinical input from Alieksei.
Charlotta Karner, authored the protocol, sifted the search and contributed to data extraction.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• NIHR, UK.
This review is supported by a programme grant from NIHR.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The subgroup analysis stated in the protocol based on diagnostic criteria for pneumonia could not be conducted, as most trials did
not state the definition. We included studies using fluticasone furoate, alone or in combination with the LABA vilanterol; these new
formulations were not anticipated during the writing of the protocol. For reasons explained in the review, we chose not to calculate an
indirect comparison of fluticasone/LABA versus budesonide LABA.
We added the following additional comparisons: fluticasone furoate/vilanterol versus vilanterol; fluticasone/vilanterol versus budesonide/
formoterol.
We added to the methods a section on assessing transitivity.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adrenergic beta-2 Receptor Agonists [administration & dosage; adverse effects]; Androstadienes [admin-
istration & dosage; ∗adverse effects]; Anti-Inflammatory Agents [administration & dosage; ∗adverse effects]; Bronchodilator Agents
[administration & dosage; ∗adverse effects]; Budesonide [administration & dosage; ∗adverse effects]; Drug Therapy, Combination
[methods]; Pneumonia [chemically induced]; Pulmonary Disease, Chronic Obstructive [∗drug therapy]; Randomized Controlled Trials
as Topic
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MeSH check words
Female; Humans; Male; Middle Aged
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